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ii. Abstract 
The work described in this thesis focuses on the development of an 
innovative bioimpedance device for the detection of breast cancer using 
electrical impedance as the detection method. The ability for clinicians to 
detect and treat cancerous lesions as early as possible results in improved 
patient outcomes and can reduce the severity of the treatment the patient 
has to undergo. Therefore, new technology and devices are continually 
required to improve the specificity and sensitivity of the accepted detection 
methods. The gold standard for breast cancer detection is digital x-ray 
mammography but it has some significant downsides associated with it. The 
development of an adjunct technology to aid in the detection of breast 
cancers could represent a significant patient and economic benefit. In this 
project silicon substrates were pattern with two gold microelectrodes that 
allowed electrical impedance measurements to be recorded from intact 
tissue structures. These probes were tested and characterised using a range 
of in vitro and ex vivo experiments. The end application of this novel sensor 
device was in a first-in-human clinical trial. The initial results of this study 
showed that the silicon impedance device was capable of differentiating 
between normal and abnormal (benign and cancerous) breast tissue. The 
mean separation between the two tissue types 4,340 Ω with p < 0.001. The 
cancer type and grade at the site of the probe recordings was confirmed 
histologically and correlated with the electrical impedance measurements to 
determine if the different subtypes of cancer could each be differentiated. 
The results presented in this thesis showed that the novel impedance device 
demonstrated excellent electrochemical recording potential; was 
biocompatible with the growth of cultured cell lines and was capable of 
differentiating between intact biological tissues. The results outlined in this 
thesis demonstrate the potential feasibility of using electrical impedance for 
the differentiation of biological tissue samples. The novelty of this thesis is in 
the development of a new method of tissue determination with an application 
in breast cancer detection. 
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1. General Introduction 
1.1 Thesis Objectives 
The work described in this thesis focuses on the development of an 
innovative bioimpedance device for the detection of breast cancer using 
electrical impedance as the detection method. The ability for clinicians to 
detect and treat cancerous lesions as early as possible results in improved 
patient outcomes and can reduce the severity of the treatment the patient 
has to undergo. Therefore, new technology and devices are continually 
required to improve the specificity and sensitivity of the accepted detection 
methods. The four main objectives of this thesis were: 
1) Design and fabrication of a novel impedance probe 
2) Packaging, characterisation and testing of the fabricated devices 
3) Biocompatibility  and tissue differentiation testing using the impedance 
sensors 
4) A first-in-human clinical trial to differentiate between normal and 
abnormal tissues in ex vivo breast tissue specimens. 
The novelty of this thesis is in the development of a new method of tissue 
determination with an application in breast cancer detection. 
1.2 Thesis Overview 
Chapter 1 provides an introduction to breast cancer as a disease and how it 
is currently detected using x-ray mammography. The chapter also provides 
an overview of previous work undertaken using electrical impedance as a 
cancer detection method in a number of different body tissues.  During the 
course of the Ph.D. project there was a key research question which needed 
to be answered: 
 Can we use electrical impedance to differentiate between healthy and 
cancerous tissues of the breast? 
In an attempt to answer this question it was hoped that a significant body of 
new research in the area of breast cancer detection would be produced as 
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well as a number of new research questions that would require future 
investigation. 
Chapter 2 investigates the design, fabrication and characterisation of both 
stainless steel and silicon prototype devices patterned with gold 
microelectrodes. The fabrication of the stainless steel prototypes was 
unsuccessful at producing probes that were suitable for electrochemical 
recording. However, the silicon probes proved to be effective and reliable 
prototypes and were fully characterised using a suite of techniques including 
imaging and electrochemical measurements.   
Chapter 3 involves the determination of the biocompatibility and tissue 
differentiation ability of the prototype devices. A number of biocompatibility 
tests were performed involving light, fluorescent and electron microscopy as 
well as a resazurin cell viability assay.  The silicon probes were then tested, 
using animal samples, to determine their ability to differentiate between fat 
and muscle tissues. A number of secondary experiments were conducted to 
determine the effect of applied voltage, depth and pressure on the electrical 
impedance detection capability of the silicon devices. 
Chapter 4 describes the first in-human clinical trial that was undertaken to 
demonstrate the ability of the silicon prototypes to differentiate between 
tissue margins and cancerous lesions in ex vivo samples obtained during 
breast surgeries. 
1.3 Microsystems 
Microsystems or a micro-electromechanical system (MEMS) is a term used 
to describe sub-millimetre integrated electro-mechanical systems that 
contain both electrical and mechanical components. Typically, these 
miniaturised devices perform non-electronic functions such as sensing or 
actuation. The integrated components generally range from 1 µm to 1 mm in 
size and are fabricated in a parallel manner through photolithography [1]. 
The use of photolithographic tools for the fabrication of microsystem devices 
results in the ability to produce large quantities of identical devices with an 
extremely low per unit cost. This provides an extremely reliable and 
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repeatable manufacturing process which can be readily optimised for the 
production of novel prototype devices. Silicon substrates are the most widely 
used in the production of microsystem devices because it is a chemically 
inert material compatible with existing semi-conductor fabrication processes 
[1]. The fabrication process for devices in microsystems usually involves the 
deposition of multiple photolithographic layers such as material deposition, 
patterning and pattern transfer which will be further discussed in greater 
detail in Chapter 2 of this thesis. The flexibility of the fabrication processes 
involved with creating new MEMS devices has expanded the capability and 
scope of microsystems and has resulted in many different application areas. 
These can include healthcare, energy management and environmental 
monitoring. In the area of healthcare, MEMS devices are becoming 
increasingly common. These can be used in monitoring patient wellbeing and 
recovery, assessing infection development and diagnosing diseases. This 
requires technological advancements which can be addressed by 
microsystem devices. Within the larger definition of microsystems there 
exists a smaller subsection of the research community involved in the area of 
life science interfaces. This research is focused on exploiting design, 
fabrication and characterisation tools to enable the manipulation, detection 
and characterisation of a wide range of small molecules, nucleic acids, 
proteins and cells. The focus of healthcare and life science interface 
research in the area of microsystem technology has resulted in the 
development of novel devices and hardware platforms to address key 
societal challenges, particularly in the area of new diagnostic and screening 
techniques for the increased sensitivity and specificity of disease detection. A 
significant amount of the research conducted within the life science interface 
community is involved with the development or improvement of biosensor 
devices. 
1.4 Biosensors 
A biosensor is defined as a self-contained integrated device which is capable 
of providing specific quantitative or semi—quantitative analytical information 
using a biological recognition element which is in direct spatial contact with a 
transducer element. This produces a signal which is sent to a processing unit 
General Introduction   Chapter 1 
5 
 
which presents the data in a useable format for the user (Figure 1.1). 
Biosensors have a range of applications covering diverse fields including: 
medicine, pharmaceuticals, food and process control, environmental 
monitoring, defence and security. The primary market for biosensors is in 
medical diagnostics. Self-monitoring of blood glucose is one of the largest 
users of biosensors and this is evident from the market size which was 
estimated be worth $11.1 billion worldwide in 2014 [2]. This is an increasing 
market due to the increasing incidence of diabetes worldwide which is 
estimated to be 366 million people by 2030 [3]. 
 
Figure 1.1: Schematic layout of a biosensor. Figure is Author’s own. 
The current trend towards personalised medicine worldwide will lead to 
significant increases in the utilisation of biosensors for the monitoring of 
routine physiological measurements such as blood pressure, heart rate, 
blood glucose, blood alcohol, activity and exercise tracking [4]. Biosensors 
can also be utilised in the monitoring of chronic conditions, infection control 
and rehabilitation [5]. There are applications for biosensors outside of 
healthcare monitoring which include: detection of bacteria and pesticides in 
air, water, food and detection of chemical and biological weapons. The 
incorporation of multiple biosensors in an integrated device has led to a 
dramatic increase in the usability and functionality of biomedical devices 
across all areas of healthcare and patient monitoring. Biosensors can be 
broadly classified in three distinct types: 
1) Electrical 
2) Mechanical 
3) Electrochemical 
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The biosensors of interest to this particular research are electrical impedance 
sensors. This type of sensor measures the change of electrical properties in 
a system due to the proximity or contact with an analyte or biomarker. The 
use of these biosensors has become widespread and they use a raw 
electrical signal such as current or impedance that can be directly processed 
and analysed by the user. In the area of cancer diagnostics a significant 
number of tests have been developed that incorporate biosensors for the 
rapid detection of cancer cells or biomarkers [6]. Biomarkers are defined as a 
biological molecule found in blood, other body fluids, or tissues that are a 
sign of a normal or abnormal process or of a condition or disease. They are a 
potentially valuable tool in a number of areas including the early detection of 
cancer, pre-treatment staging, determining response to chemotherapy 
treatment and monitoring disease progression. The most commonly 
assessed biomarkers in cancer are outlined in Table 1.1: 
Table 1.1: Selection of the most common cancer biomarkers for 8 common cancer types. 
AFP – Alpha-fetoprotein; BRCA – Breast Cancer; CA – Cancer Antigen; CASA – Cancer-
associated Serum Antigen; CEA – Carcinoembryonic Antigen; EGF – Epidermal Growth 
Factor; ER/PR – Oestrogen/Progesterone Receptor; HCG – Human Chorionic 
Gonadotrophin; HCG – Human Chorionic Gonadotropin; HER2 – Human Epidermal Growth 
Factor Receptor 2; ING-1 – Inhibitor of Growth Family, Member 1; NSE – Neuron Specific 
Enolase, NY-BR-1 – New York Breast 1; NY-ESO-1 – New York Oesophageal Squamous 
Cell Carcinoma 1; p53 – Tumour Protein 53; PSA – Prostate Specific Antigen; TAG – 
Tumour-associated glycoprotein 72. Table was redrawn from reference [7]. 
Type of 
Cancer 
Biomarker 
Breast 
BRCA1, BRCA2, CA 15-3, CA 125, CA 27.29, CEA, NY-
BR-1, ING-1, HER2, ER/PR 
Colon CEA, EGF, p53 
Liver AFP, CEA 
Lung CEA, CA 19-9, NSE, NY-ESO-1 
Melanoma Tyrosinase, NY-ESO-1 
Ovarian 
CA 125, HCG, p53, CEA, CA 549, CASA, CA 19-9, CA 15-
3, TAG72 
Prostate PSA 
Impedance based biosensors can be used to monitor cell morphology, detect 
antibodies, deoxyribonucleic acid (DNA) analysis and growth and motility in 
tissue culture environments which is known as electric cell-substrate 
impedance sensing (ECIS) [8]. In this technique, cells are cultured on 
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electrodes immersed in the tissue culture medium. The cells attach to and 
spread across the electrode surface. An alternating current (AC) at a 
specified frequency is applied between the working and reference electrodes 
and the change impedance measured. Since the current is constant, the 
measured magnitude and phase responses are assumed to be proportional 
to the impedance [8].  At relatively low frequencies (<100 Hz), resistive 
behaviour is predominant, while at higher frequencies (>100 KHz) capacitive 
effects are more dominant. The impedance of the circuit is substantially 
increased by the presence of cells at moderate frequencies [9].  
1.5 Cancer 
Cancer is defined as abnormal and uncontrolled cell growth due to an 
accumulation of specific genetic and epigenetic defects which are 
environmental in origin. Unregulated cell growth leads to the formation of a 
tumour mass that over time becomes independent of normal homeostatic 
checks and balances. Tumour cells, in essence, become resistant to 
programmed cell death, which is known as apoptosis, and other antigrowth 
defences within the body. As the cancer progresses, the tumour begins to 
spread beyond the site of origin and metastasize to other body organs and 
systems [7]. Cancer is a leading cause of death worldwide, accounting for 
8.2 million deaths annually, representing 14% of all deaths [10, 11]. There 
are over 200 distinct forms of cancer including lung, prostate, breast, 
ovarian, hematologic, skin, colon, and leukaemia. The most common cancer 
subtypes diagnosed in men and women in the United States of America 
(USA) each year are outlined in Table 1.2 [12].  
Table 1.2: The top 5 most common cancers in men and women diagnosed in the USA in 
2014. Reference [12]. 
Rank Cancer in Men Cancer in Women 
1 Prostate Breast 
2 Lung and Bronchus Lung and Bronchus 
3 Colon and Rectum Colon and Rectum 
4 Urinary Bladder Uterine Corpus 
5 Melanoma of the Skin Thyroid 
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In 2000, Ireland introduced a national breast cancer screening service, 
BreastCheck. The National Breast Screening Programme, aimed to reduce 
the number of deaths from breast cancer in Ireland amongst women aged 
50-64. By providing an effective screening service of the highest possible 
quality, a significant number of breast cancers can be detected at an earlier 
stage. Following a phased roll-out of mammography-centred screening, the 
numbers of women screened grew from 45,000 in 2000 to over 140,000 in 
2014 [13, 14]. Mammography-based breast cancer detection has a number 
of limitations which provide an imperative to improve both the technology and 
the screening process. 
In the past two decades a significant amount of clinical research has been 
conducted in which electrical impedance was used to differentiate between 
healthy and cancerous tissues including cancers of the breast [15, 16], 
prostate [17, 18], bladder [19-21], kidney [22, 23],  brain [24-26], lung [27, 
28], liver [29], stomach [30], and tongue [31, 32]. The next four sections of 
this chapter will focus on the detection of breast and prostate cancer which 
are the two most commonly occurring malignancies in women and men 
respectively [11].  
1.6 Breast Cancer 
Breast cancer is the most common carcinoma diagnosed in women 
worldwide [12]. It is a genetically and histologically heterogeneous disease 
that can be categorised into many different subtypes. The most broad 
distinction is between in situ and invasive carcinomas with both containing 
many more subtypes. In situ cancer refers to a cancerous growth or tumour 
which is still confined to the site from which it started, and has not spread to 
surrounding tissue or other organs in the body. The classification contains 
both ductal (DCIS) and lobular subgroups [33].  The term invasive is 
described as any cancerous growth which has infiltrated beyond its site of 
origin to the surrounding healthy tissue. The major invasive breast tumour 
types include invasive ductal carcinoma (IDC) and invasive lobular 
carcinoma (ILC) along with other less common subtypes including mucinous 
and tubular [33] (Figure 1.2).  
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Figure 1.2: The histological classification of breast cancer subtypes. HPF – High Powered 
Field. Reference [33]. 
The most common form of breast cancer is IDC accounting for almost 80% 
of all breast cancers [34]. This type of cancer develops initially as an 
abnormal replication of cells which make up the single cell layer of the milk 
ducts. These structures are responsible for transporting milk from the milk-
producing lobules to the nipple during lactation (Figure 1.3).  
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Figure 1.3: Left: The anatomical structure of the breast and chest wall. Right: The steps 
along the way towards the development of invasive ductal carcinoma. Reference [34]. 
The healthy lactiferous or milk duct is composed of a single layer of columnar 
epithelial cells surrounded by an intact basement membrane [35]. Atypical 
ductal hyperplasia results from the cellular proliferation and architectural 
abnormalities within one or more of the milk ducts. As the replication of cells 
within the milk ducts continues the pre-cancerous condition of DCIS 
develops (Section 1.6.1). Once the abnormally replicating cells infiltrate 
beyond the basement membrane IDC begins to develop. These tumours 
excite a pronounced fibroblastic stromal reaction to the invading tumour cells 
resulting in a palpable mass (normally larger than 1.5 cm in diameter) with a 
hard consistency being produced. The tumours show an infiltrative 
attachment to the surrounding structures and may cause dimpling of the skin 
(due to traction on suspensory ligaments) or nipple retraction. The cut 
surface of the tumour appears gritty and shows irregular margins with stellate 
infiltration and foci of yellow, chalky streaks. Histologically, the tumour cells 
are larger in diameter than normal epithelium, and can assume a variety of 
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patterns such as glandular formation, cords of cells, broad sheets of cells or 
a mixture of all these, usually within a dense stroma. The tumours range 
from well differentiated, in which there is glandular formation, to poorly 
differentiated, containing solid sheets of pleomorphic neoplastic cells [36]. 
Breast cancer staging is extremely important in the decision making of the 
clinician when deciding on patient treatments. The classification system most 
commonly used is the American Joint Committee on Cancer (AJCC) Tumour, 
Node and Metastasis (TNM) system. It is used to determine the size of the 
primary tumour (T), involvement of the lymph nodes (N) and the presence of 
metastasis (M). The system uses a combination of these three categories to 
grade and stage each tumour in the following way: 
1) The letter T followed by a number from 0 to 4 describes the size of the 
tumour and if it has spread to the skin or to the chest wall under the 
breast. Higher T numbers mean a larger tumour and/or wider spread 
to tissues near the breast [37]. 
2) The letter N followed by a number from 0 to 3 indicates lymph node 
involvement. The number of lymph nodes involved is important in 
prognosis [37]. 
3) The letter M followed by a 0 or 1 indicates whether the cancer has 
spread to distant organs [37]. 
In addition to this gross classification of breast cancer tumours it is also 
necessary to perform genetic analysis of the cells to determine the presence 
of cell surface receptors which are important in determining the treatment a 
patient receives. This has led to the inclusion of molecular markers in the 
classification of cancer subtypes. These include oestrogen receptor (ER), 
progesterone receptor (PR), ErbB2 (Her2/neu) and p53 which has resulted in 
six specific groups being identified: basal-like, ErbB2+, normal breast like, 
Claudin-low, luminal A and luminal B [33, 38, 39] (Figure 1.4).  
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Figure 1.4: The molecular classification of breast cancers based on the intrinsic molecular 
subtypes of breast cancer identified by micro-array analysis. Reference [33]. 
The identification of cell surface receptors can significantly influence the 
course of treatment undertaken by the patient. The two most commonly 
identified receptors are Her-2 and ER. If these receptors are identified on the 
cell surface then the drugs Herceptin and Tamoxifen can be administered 
respectively. The use of these targeted therapies has been shown to 
significantly improve the overall patient outcome [40, 41]. 
1.6.1 Ductal Carcinoma in situ 
Ductal carcinoma in situ is a disease which is characterised, histologically, by 
the proliferation of malignant-appearing cells which are located in the milk 
ducts of the breast. These cells have not invaded beyond the basement 
membrane into the normal breast parenchyma [42, 43].  The condition 
covers a broad spectrum from low-grade to high-grade DCIS and it can be 
associated with micro-invasion [43]. Micro-invasion is a term used to 
describe a borderline difference between completely contained DCIS and a 
minimally invasive ductal carcinoma. It can also be sub-divided into five 
recognised categories based on architectural features of the tumour which 
gives rise to: Comedo, Cribriform, Micro-papillary, Papillary and Solid [33]. It 
is estimated that DCIS accounts for between 10-20% of all breast 
malignancies detected by screening [44-46]. In 2009, the American Cancer 
Society predicted that over 62,280 new cases of breast carcinoma in situ 
would be diagnosed annually in the USA [47]. By 2014 this figure had 
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increased fractionally to 64,640 [12, 48], demonstrating that the detection 
rate remained constant following a rapid increase in cases during to 1980s 
and 1990s [43, 49]. DCIS is usually detected using high-resolution 
mammography which allows visualisation of the intra-ductal micro-
calcifications that may be suggestive of DCIS [50]. It is a direct precursor to 
IDC, although the condition itself is not life-threatening. The exact time-frame 
over which DCIS may progress to invasive cancer is unclear. It has a 10-year 
survival rate of >95% with treatment [42]. The treatment options for a patient 
with biopsy-confirmed DCIS are similar to that of a patient with IDC although 
chemotherapy is not required. The primary treatment for localised DCIS is 
breast conservation surgery followed by radiation therapy. For more 
widespread DCIS, the definitive treatment is complete mastectomy with or 
without reconstructive surgery [42]. 
1.6.2 Breast Cancer Detection 
It is estimated that breast cancer results in 40,000 deaths (39,210 women, 
410 men) annually in the USA [12]. The method by which breast cancer is 
detected can occur as follows: 
1. Physical Examination for a palpable mass 
a) Patient 
b) Physician 
2. Imaging 
a) Mammography 
b) Ultrasound 
3. Biopsy 
a) Surgical 
b) Fine-needle Aspiration 
c) Core-needle Biopsy  
4. Histologic confirmation 
If a patient has a suspected tumour on a mammographic image they will 
undergo a surgical, fine-needle aspiration or more commonly a core-needle 
biopsy (CNB). This extracts a representative sample of tissue from the breast 
and is usually performed under ultra-sound guidance to aid with needle 
placement to ensure correct sampling of the target lesion. These samples 
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are then processed in the histology laboratory and examined histologically by 
a pathologist to confirm the presence of malignant tumour cells. 
1.6.2.1 X-ray Mammography 
Mammography has over time become the “gold standard” target population 
screening tool for early breast cancer detection. The technique uses low-
levels of ionizing radiation to generate an image of the breast which aids in 
the detection of cancerous masses or characteristic micro-calcifications 
suggestive of DCIS. The introduction of mammography has been proven to 
detect breast cancer at an early stage and, when followed up with 
appropriate diagnosis and treatment, to reduce mortality from breast cancer 
[51]. The average size at which breast cancer tumours can be detected with 
mammographic screening is 7.5 mm compared to 15 mm without screening 
[52]. Prior to the introduction of a national breast screening programme in 
Ireland (1994-1999) the 5-year survival rate for women with breast cancer 
was 74.3%. Women who were diagnosed between 2006 and 2011 had a 
five-year survival rate of  84.7% [53]. This increase in patient survival cannot 
entirely be attributed to the introduction of the mammographic screening 
programme. However, the ability to detect breast cancers at an earlier stage, 
allows a patient to undergo treatment as soon as possible which increases 
the likelihood of survival. 
1.6.2.2 Limitations of Mammography 
Mammography does however have some significant limitations including, 
relatively low sensitivity and specificity (79% and 90% respectively) which 
are both significantly reduced in young patients (less than 40 years old) due 
to the increased breast density [54-56]. There are two major problems 
surrounding mammographic screening. The first of these is radiologically 
occult disease. This manifests as breast cancer tumours which cannot be 
detected using mammography. The second significant issue is the 
interpretation of mammography results which requires highly trained, 
specialist radiologists to systematically review each individual mammogram. 
Misinterpretation of mammography results can alter either the sensitivity 
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(disease is present but not detected) or the specificity (disease is absent but 
interpreted as being present) of the screening test. 
A comprehensive review of clinical trial data relating to screening 
programmes for breast cancer detection determined significant increases in 
the rates of over-diagnosis and over-treatment of up to 30%. In reality this 
figure is hard to quantify and is probably much lower than 30%.  A number of 
drawbacks are associated with breast cancer screening including an 
increase in psychological distress which can include anxiety, worry, 
despondency and sleeping problems [57-60]. The report also suggested that 
the number of mastectomies can increase by up to 20% as a result of 
screening programs [58]. A recent  independent review conducted by a panel 
in the United Kingdom noted that there were significant methodological 
limitations to the Cochrane Review and that the true rate of over-diagnosis is 
likely to be closer to 11% for women invited to attend a screening 
programme and approximately 19% for those who actually attend a 
screening [61]. In a study by Berg et al. (2004), the team assessed the 
specificity and sensitivity of a number of cancer detection modalities 
individually and in combinations. They determined, using 258 proven lesions, 
that mammography on its own had a sensitivity of 67%, specificity of 75% 
and a positive predictive value of 85.7% [55] . They then determined the 
effectiveness of mammography by breast tissue composition (extremely 
dense, heterogeneously dense, minimal scattered fibro-glandular densities 
and predominantly fatty). As before 258 histologically proven lesions were 
used of which mammography was only able to detect 45% (21/47) in 
extremely dense tissue compared with 100% (8/8) in predominantly fatty 
breasts [55]. A limitation of this study was that only a small number of 
patients were analysed. 
The current imaging modalities used to further evaluate mammographically 
suspicious lesions are magnetic resonance imaging (MRI) [56, 62], and 
ultrasound (US) [62]. Computed tomography (CT) and positron emission 
tomography (PET) [62] are not routinely used in clinical practice for 
evaluation of breast lumps or abnormal mammographic findings. The major 
limitation of these technologies is the significant cost of both the hardware 
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and the procedures. PET/CT scanning, as with mammogram, uses low 
doses of ionising radiation during the procedure which is a potential limiting 
factor for its use in cancer patients. It is primarily used in the detection of 
metastatic diseases [62]. MRI on the other hand does not use any radiation 
and instead utilises an intravascular injection of a contrast agent such as 
gadolinium diethylene tri-amine penta-acetic acid (GdDTPA) [63, 64] but MRI 
has limitations with its cost, potential adverse reactions and nephrotoxicity to 
contrast media and an unacceptably high false positive rate [65].  
1.7 Prostate Cancer Detection 
Prostate cancer in men has many similarities to breast cancer in women in 
terms of number of new cases per year, gender affected and confirmation of 
cancer type. The American Cancer Society estimates that 233,000 and 
232,670 new cases of prostate and female breast cancer respectively will be 
diagnosed in the USA in 2014 [12]. This shows that the incidence rate for 
these two cancers is almost identical. Approximately 99% of all breast cancer 
occurs in women while 100% of prostate cancer occurs in men. The current 
method of detecting prostatic malignancy is a histological examination of 
core-needle tissue samples removed during a trans-rectal biopsy. This 
method of using CNB to extract tissues for histological analysis is the same 
as that used to determine the presence of breast cancer. Prior to the CNB 
procedure a patient will likely have had a combination of a digital rectal 
examination (DRE), a prostate specific antigen (PSA) test showing elevated 
levels and a trans-rectal US [66]. There are a number of concerns 
surrounding the ability of both DRE and PSA tests to accurately predict the 
presence of prostate cancer in patients [67-69]. The use of DRE is limited 
due to the inability to palpate the entire prostate gland and is not sufficient in 
the detection of cancers which have not progressed to the prostatic capsule 
[69]. These deficits are compounded by a low sensitivity (53.2%) and 
specificity (83.6%) of the test when used in isolation [68]. PSA testing was 
first developed by Kuriyama et al. in 1980 [70] and has since become one of 
the major tools used in the assessment of prostate cancer.  An abnormal test 
occurs when a serum PSA level of ≥ 4.1 ng/ml, however studies have shown 
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that individuals can present with elevated PSA levels but subsequent biopsy 
revealed no identifiable cancerous lesion [71, 72]. This is due to a naturally 
higher baseline level of PSA. One of the major downsides of PSA usage is 
the lack of sensitivity which has been calculated as part of a recent meta-
analysis to be 72.10% with a specificity of 93.10% [67]. The random 
sampling of the prostate during the procedure may result in a tumour being 
missed and the patient receiving an incorrect diagnosis. The authors of that 
review illustrate a number of potential limitations to the clinical trials on which 
the analysis was based citing a lack of a control group receiving no 
screening or treatment and a lack of biopsy results for all of the involved 
patients. As a result, they state that the figures for sensitivity and specificity 
are potentially biased due to the aggressiveness of the biopsy procedure and 
variations in PSA determination and DRE findings [67]. Another significant 
downside to the use of PSA testing for the determination of prostate cancer 
is the overlap with benign prostate hyperplasia. It has been shown that 
between 21-47% of patients with a pathologically confirmed benign condition 
have serum levels above the cut-off of ≥ 4 ng/ml, while as many as 48% of 
men with prostate cancer have antigen concentrations below the 4 ng/ml 
threshold [67]. A number of novel electrical impedance devices have focused 
on prostate cancer detection and are outlined in later sections.  
1.8 Unmet user needs 
Current CNB needles are passive devices that provide no objective feedback 
as to the needle tip location during advancement or at the time of biopsy 
which is where the requirement for ultra-sound guidance arises. There is an 
unmet user need with regard to the identification of the tissue type into which 
the tip of a biopsy needle and a wire-localisation device are inserted. This 
potential, combined with the ability to distinguish between healthy and 
cancerous tissues in real-time would greatly improve the biopsy procedure 
and sample acquisition. It may also avoid the need for a formal biopsy of 
benign lesions which account for almost 95% of lesions that develop within 
the breast [73]. Current research in this area needs to involve clinicians who 
can identify a technological deficit in their field and can guide the research 
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necessary to test a prototype medical device in a clinical setting. This is an 
area that appears to be ideally suited to the use of electrical bio-impedance. 
1.9 Electrical Impedance 
The flow of direct current through an electrical circuit is impeded only by the 
resistance presented by the circuit. In systems utilizing alternating current, 
which is a sinusoidal signal, the opposition to a current is the impedance, 
which takes into account both the magnitude of the opposition to the applied 
current and the phase shifts between the current and voltage caused by the 
components of the circuit [74, 75] . Electrical impedance (Z), measured in 
Ohms (Ω), is the total opposition to current flow in an alternating circuit and is 
defined in terms of three individual components: resistance (R), inductance 
(L) and capacitance (C). The angular frequency of the current is represented 
by ω, and j is the square root of (-1) [22, 74, 76]. Impedance may be 
expressed as a complex number (Equation 1.1). 
Z = R + j(ωL − 1/ωC)  
Equation 1.1: Equation for the determination of electrical impedance (Z). R – resistance, j – 
square root of -1, ω – angular  frequency, L – inductance and C – capacitance. 
Resistance is a property that opposes current flow and conductance is the 
inverse of resistance. Capacitance is the opposition of a change in voltage or 
electrical potential across an object and acts to store energy. A capacitor 
consists of two conductors; each oppositely charged and separated by a 
dielectric material. Permittivity is a property of the dielectric material and 
reflects the ability of charges in the material to move in response to an 
electric field [77]. Capacitance is a function of the permittivity and the 
physical geometry of the object. The capacitance formula for a two-plate 
capacitor is: 
C = εA/d 
Equation 1.2: Formula for the calculation of value of a two plate capacitor. C – capacitance, 
ε – permittivity, A – area of each plate, d – distance between plates. Reference [77]. 
The modulus of the impedance, |Z|, is the ratio of the magnitudes of the 
voltage and current (V/I). For the purpose of this thesis only the modulus of 
the impedance will be investigated as the study is only interested in 
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assessing the difference in the resistive element of impedance to provide a 
relative measurement capable of differentiating between biological tissue 
types. 
The measurement of electrical impedance has been investigated for breast 
analysis since the early 20th century when Fricke and Morse first described 
altered capacitance values of breast cancer tissue compared to normal 
breast tissue in 1926 [78]. In the last two decades the utility of impedance in 
discrimination between biological samples has been extensively investigated. 
The term bio-impedance is used to describe the response of a living 
organism to an externally applied electric current, and is a measure of the 
opposition to the flow of that electric current through tissues [31, 74]. Each 
cell type in the human body is composed of different chemical and physical 
elements which result in the production of distinctive impedance signals 
generated by each variant [79, 80]. This is also true of diseased, cancerous 
tissues which have been shown to have a lower impedance value when 
compared to healthy cells of the same type [15, 18, 79]. Most benign lesions 
have been shown to exhibit impedance similar to healthy tissues. This finding 
could provide a potential method of differentiating between benign and 
cancerous lesions during screening of breast cancer patients [81-83]. 
The differential electrical properties associated with cancerous tissues result 
from increased cellular water and salt content, amount of extracellular fluid, 
altered membrane permeability, changed packing density and orientation of 
cells [84-87]. Tissues within the human body provide two forms of resistance 
to an applied electrical current. Capacitive R (reactance) results from the lipid 
bilayer cell membrane while resistive R is due to the extra- and intracellular 
fluid present in the tissue of interest [88]. A number of equivalent circuit 
models of biological tissues have been proposed to explain this behaviour. 
The most commonly used simple equivalent circuit arranges intracellular fluid 
R (Ri) and cell membrane capacitance (Cm) in series with extracellular fluid R 
(Re) in parallel in an R(RC) circuit (Figure 1.5) [79, 88].  
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Figure 1.5:  A simple equivalent circuit model of biological tissues. Ri – intracellular 
resistance, Cm – cell membrane capacitance, Re – extracellular resistance. Figure is 
Author’s own. 
Another equivalent circuit model of cell and tissue behaviour can be 
described as an ([(CR)(CR)](CR)) circuit (Figure 1.6). In this system both the 
resistance and capacitance of the extracellular fluid, intracellular fluid and the 
cell membrane are taken into account [79]. 
 
Figure 1.6: An equivalent circuit model of biological cell behaviour. Ri – intracellular 
resistance, Re – extracellular resistance, Rm – cell membrane  resistance, Ci – intracellular 
capacitance, Ce – extracellular capacitance, Cm – cell membrane capacitance. Figure is 
Author’s own. 
At zero (to low) frequency, the applied current does not penetrate the cell 
membrane, which acts as an insulator, and as a result the current is 
transferred exclusively across the extracellular fluid. At very high frequencies 
the cell membrane is charged as a near perfect capacitor which results in the 
dielectric properties of the tissue resulting from the combined impedance of 
the extra- and intracellular fluid [80, 88]. The electrical properties of tissues 
vary according to applied frequency as seen from α-, β- and γ-dispersion [84, 
89, 90]. α- (10 Hertz [Hz] – 10 kHz) and β-dispersions (10 kHz – 10 MHz) are 
of relevance to medical applications as the changes between pathological 
and normal tissue typically occur in these ranges [84, 91]. The α-dispersions 
General Introduction   Chapter 1 
21 
 
are associated with electrical double-layers and surface ionic conduction 
effects at the membrane boundaries [89]. The β-dispersion results from a 
combination of the capacitive shorting-out of membrane resistance and 
rotational relaxations of bio-macromolecules [89]. The γ-dispersion arises 
from the relaxation of bulk water in the tissue [89].  
There are two branches of electrical impedance measurement which have 
evolved gradually in the last number of years: electrical impedance 
tomography (EIT) and invasive impedance detection.  
1.10 Electrical Impedance Tomography  
1.10.1 TransScan TS 2000 
Electrical impedance tomography is an imaging modality that estimates the 
electrical properties of an object from measurements made on its surface 
[92].  The technique has been investigated for the detection of breast cancer. 
The difference between the electrical storage potential of normal and 
pathologically altered tissues allows an image of conductance and 
permittivity to be produced from measurements on the skin surface [93]. A 
number of devices have been developed to test the effectiveness of skin 
surface impedance recordings at visualising a cancerous growth in breast 
tissue. In 1999, the Food and Drug Administration approved the use of the 
TransScan TS 2000 (Siemens Medical, Germany and TransScan, Ramsey, 
NJ, USA) as an adjunct to mammographically equivalent patients to aid 
biopsy recommendation [94]. This system utilised a reference electrode 
placed in the patients hand and an 8 x 8 electrode array contained on a 
hand-held probe that would be placed firmly against the breast to ensure 
adequate skin-electrode contact. Although the initial product introduced by 
TransScan Medical Inc. was granted approval, a subsequent model TS 
2000ED (Mirabel Medical Systems, Inc.) was rejected due to concerns 
relating to device sensitivity, the size and population of the study, number of 
cancers detected in study patients, and risks associated with additional 
screening events [95]. 
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1.10.2 Mammography Electrical Impedance Device 
Another EIT device, which was developed by the Institute of Radio 
Engineering and Electronics in Russia, was designed using a 256-electrode 
array and a hand-held external reference electrode (Figure 1.7). One 
electrode is used to administer a 0.5 mA current at 50 kHz frequency which 
is detected across the skin surface by the other electrodes present on the 
device.  
 
Figure 1.7: The electrical impedance mammography device with the 256-electode design. 
Reference [93]. 
This generates a grey-scale image in which areas of hyper- and hypo-
impedance can be distinguished. In 2001, Cherepenin et al. (2001) 
conducted an initial clinical trial of the mammography electrical impedance 
(MEIK) device which involved 21 women with tumours, between 1.5 and 5 
cm on x-ray mammogram. The imaging scans revealed 14 focal 
abnormalities across the 21 patients studied which accounted for 67% of the 
total tumours. When the team combined these results with 4 images without 
clear abnormalities, they were able to fully or partially diagnose 86% of 
confirmed lesions in the study [96]. The researchers describe a number of 
limitations to the technology including a decrease in scanning area 
associated with increased measurement depth. Poor image resolution at the 
corners of the recording device was due to poor contact between the skin 
and the electrodes [96]. A further study conducted using the MEIK system 
was conducted by Prasad et al. (2008), in which the team examined a group 
of 88 patients with a range of breast abnormalities. These included 
fibrocystic disease, mastitis, cysts, fibroadenoma and carcinoma which were 
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assessed using mammography, ultra-sound and EIT. Of the 88 patients, 59 
were determined to have a suspicious finding using at least one of the 
imaging techniques. Across each of the detectable lesions EIT fared best 
only for the detection of cysts where it correctly identified 21/21 (100% 
specificity) [97]. However, this was matched by ultra-sound which also 
detected all of the lesions successfully, whereas mammography could only 
determine 17 of the 21 cases (81%) [97]. For each of the remaining 
categories being investigated EIT showed a lower sensitivity than either 
mammography or ultra-sound. For the detection of carcinoma, the 
sensitivities were determined to be 100% for mammography and ultra-sound 
but only 75% for EIT [97]. The team noted that further investigation involving 
larger numbers of patients would be required to more accurately determine 
the specificity and sensitivity of the MEIK device and its potential use as an 
adjunct to the currently available diagnostic techniques. 
In a study by Raneta et al. (2012) the team used the device to test a 
population of 808 randomly selected patients (aged 18-94; mean 54 years) 
who presented with abnormalities which had previously been detected by 
mammography and/or sonography [93]. The group determined the sensitivity 
and specificity of the device and compared it to mammography (657 patients) 
and ultrasonography (571 patients) [93]. When used to detect breast cancer 
the MEIK system had a reported sensitivity, specificity and negative 
predictive value (NPV) of 87%, 85% and 96% respectively [93]. When 
combined with traditional mammography these values increased to 96% and 
99% for sensitivity and NPV; the specificity declined slightly to 79% [93]. The 
advantages of this technology include its non-invasive nature, zero exposure 
to ionizing radiation, along with it being portable and relatively inexpensive. 
However, some disadvantages include a limited depth of field and low spatial 
resolution.  
1.10.3 Dartmouth Ag/AgCl Device 
One of the major research groups in the area of electrical impedance 
spectroscopy (EIS) comes from Dartmouth University where the team have 
been investigating devices for the detection of breast cancer for a number of 
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years. Their initial clinical trial was a study of 26 women who underwent both 
mammography and EIS to determine the presence of breast abnormalities. 
The device used in the experiment was a radially translatable circular array 
of 16 silver/silver chloride (Ag/AgCl) electrodes that were placed around the 
patient’s breast while they lay in a prone position [98]. The team divided the 
patients into three groups based on their American College of Radiology 
(ACR) Breast Imaging-Reporting and Data System (BIRADS) score: ACR 1 
(38 patients); ACR 2-5 (13 patients); and the six most serious lesions were 
classified as ACR 4-5. Each group was analysed using the EIS method 
described by the team and the sensitivity of the technique was calculated as 
73%, 83% and 79% for ACR 1, 2-5 and 4-5 respectively [98]. The team also 
investigated a numerical identification method for determining the presence 
breast abnormalities but this resulted in sensitivity values lower than the 
visual interpretation of the EIS images. They did acknowledge that the 
numerical estimation was in its infancy and that significant improvement 
would be required to match the capability of the visual method [98].  
A follow up study conducted by the Dartmouth team was conducted in 2008 
in which the group tested a newly designed EIT device which contained 64 
Ag/AgCl electrodes in a circular arrangement of 16 electrodes across 4 
layers. This allowed the electrodes to adjust to the size of each patient’s 
breasts while maintaining maximum electrode contact on the patient’s skin 
[99]. The clinical trial undertaken by the team involved the EIT imaging of 96 
women in the Dartmouth-Hitchcock Medical Centre. The women were 
divided into 4 groups based on the composition of their breast tissue upon 
mammographic interpretation. The EIT based breast imaging system 
presented in this study provided a novel design concept for this type of 
device. The results of the clinical trial were mainly limited to system 
performance tests. The team reported the results of conductivity tests 
performed on areas of peripheral fatty tissue and centrally located 
fibroglandular tissue. In all cases analysed, the fatty tissue displayed a lower 
conductivity than that of the fibroglandular tissue [100].  
Unfortunately, the use of EIS for breast cancer detection has disadvantages 
that outweigh the advantages. The images produced are not as effective as 
General Introduction   Chapter 1 
25 
 
the currently accepted imaging modalities of mammography and ultra-sound. 
For this reason there have been more recent efforts to develop invasive 
needle electrodes for the measurement of impedance values below the 
surface of the skin.  
1.11 Invasive Breast Cancer Detection 
One of the earliest investigations carried out using invasive bio-impedance 
measurement devices was conducted by Morimoto et al. (1993). They 
utilised a co-axial needle in conjunction with an external plate electrode to 
measure three parameters: Re, Ri and Cm. The team investigated a total of 
111 patients who were admitted to the University of Tokushima, Department 
of Surgery between April 1986 and September 1988. Fifty four of these were 
due to undergo resection of breast tumours and the remaining 57 scheduled 
for thoracotomy (which is an incision into the pleural space of the chest) [79]. 
In each patient, between 3 and 5 frequency sweep impedance recordings 
were conducted in three tissue types in the breast resection cases: fatty 
tissue, mammary tissue and breast tumour. The research group found that 
the Re and Ri were not significantly different between areas of fibroadenoma 
and healthy tissue however there was a significant (p=0.01) difference 
between these two tissues and breast carcinoma [79]. Fatty tissue was 
shown to have the highest recorded Re and Ri values as well as the lowest 
Cm value which were significantly different from cancerous tissues and 
fibroadenoma and normal tissue. The results of this very early trial 
highlighted a potential application for invasive measurement of bio-
impedance in the determination of both benign and malignant breast 
conditions. 
A follow-up study was conducted by Kinouchi et al. in 1998. The aim of the 
research was to show the speed at which in vivo impedance measurements 
of local tissues could be obtained using invasive needle electrodes. The 
team used a similar electrode set-up to the 1993 study with the addition of 3 
extra needle electrodes, while retaining the surface plate reference electrode 
[16]. By utilising this configuration the team were able to obtain extremely 
fast impedance measurements from 0-200 kHz. The 0.5 mm outer diameter 
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of the needle electrode provided a minimally invasive tool for the 
measurement of electrical impedance values in vivo [16]. However the 
placement of four stainless electrodes in to the region of interest detracts 
significantly from this benefit. Therefore it is still necessary to reduce the total 
size of any invasive measurement device to maximise the benefit to the 
patient. 
Another study conducted by Mäki et al. demonstrated a prototype biopsy 
instrument for use in tissues of different origin including breast. The device 
design built on the work of Mishra et al. (Section 1.12.2) to use a functional 
CNB needle and insulate the trocar and the cannula from each other in a 
novel geometry (Figure 1.8). 
 
Figure 1.8: The two geometries used by Mäki et al. to design an electrical impedance biopsy 
needle. Reference [101]. 
By utilising their unique needle geometry the team were able to increase the 
total measurement sensitivity obtained from directly in front of the needle to 
98.3% compared to 4.85% using the previously tested prototype [101]. This 
enabled more spatially accurate measurements, which were more 
representative of the originating sample. Using the prototype bioimpedance 
probe the team showed promising results in differentiating between adipose, 
muscle, liver and kidney tissues in an anesthetized piglet. The future 
development of this prototype device may provide a significant advancement 
in CNB sampling and accuracy. 
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A 2015 article by Kang et al. showed the most advanced research into 
invasive electrical impedance detection of breast cancer. The team describe 
a novel method of patterning gold electrodes on to a 27 gauge needle. They 
utilised a flexible parylene-C photolithography mask to allow deposition of 
interdigitated electrode (IDE) layouts on to the curved needle substrate 
(Figure 1.9) [102]. 
 
Figure 1.9: Images of the IDE electrodes on the curved surface of the needle; (A) IDE 
electrodes on the needle assembled with syringe (B) microscopic image for detailed view, 
and (C) SEM image showing the projected boundaries of the needle. Reference [102]. 
They outlined the initial electrical impedance measurements undertaken 
using the novel EIS-on-a-needle prototype. A range of phosphate-buffered 
saline (PBS) phantoms and slaughtered pork fat, muscle and skin samples 
were used to examine the ability of the probe to differentiate between 
solutions and tissues of varying conductivity [102]. The team showed a 
statistically significant difference (p < 0.001) between each of the pork 
tissues tested (muscle < fat < skin) across a frequency range of 1 MHz – 1 
KHz. The final experiment outlined in the article involves the recording of 
electrical impedance measurements from ex vivo breast tissue samples 
containing cancerous lesions. The research team showed that a statistically 
significant difference existed between the normal and cancerous breast 
tissue measured using their prototype device. The data presented 
demonstrates that for both the resistance and reactance components of the 
measured impedance, the cancer tissue impedance was less than that of the 
normal tissue controls across most of the frequency range from 1 MHz to 1 
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kHz. The future development of this prototype device could be extremely 
promising given the novel deposition method employed in its assembly. By 
allowing the electrodes to be patterned directly on to a hypodermic needle it 
significantly increases the probes usability within a clinical setting. 
1.12 Prostate Cancer Detection 
1.12.1 Dual-needle 
A number of research groups worldwide have investigated invasive probes 
for the detection of prostate cancer for use as an adjunct to current screening 
methods. The team of Lee et al. (1999) designed a minimally invasive 
technique for the localisation of prostate cancer. Two 30 mm long, 1 mm 
diameter stainless steel probes, coated with non-conducting epoxy were 
used. The distal 1 mm remained exposed/un-insulated for impedance 
recording and the probes were secured in an insulated fibreglass cylinder in 
parallel alignment with 1 mm separating the two (Figure 1.10) [17]. The 
recordings were then taken using a range of frequencies (100 kHz – 4 MHz), 
at a depth of 3 mm, across 16 locations in freshly excised prostate sections 
[17]. The injection sites were then stained for histologic examination by a 
pathologist to confirm the presence or absence of cancer at the point of 
injection [17]. The group showed that the observed impedance values of 
cancerous tissue was greater across all electrical current frequencies tested 
[17]. 
 
Figure 1.10: A bio-impedance needle probe constructed from two stainless steel needles, 
each 1 mm in diameter and tapered to a point. Reference [17]. 
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1.12.2 Tip-exposure  
This research group designed a standard stainless steel biopsy needle in 
which the component parts of the needle were electrically insulated from 
each other using polyimide. The tip of both the trocar and the cannula were 
not coated with polyimide and were therefore available for bipolar impedance 
measurement (Figure 1.11) [103].  
 
Figure 1.11: The EIS-Biopsy probe design (a), with polyimide insulation and the exposed tips 
(b). Reference [103]. 
This device was designed to induce a 1 mA current across the two 
electrically isolated components of the needle while concurrently measuring 
the voltage [103]. The research group simulated a standard 12-core biopsy 
procedure by suspending surgically removed prostate samples in a specially 
designed chamber filled with 0.01 S/m saline to mimic the conductivity of the 
pelvic cavity [103]. Results from this set of experiments suggested that the 
device was capable of distinguishing between cancerous and healthy tissues 
within ex vivo prostate samples. The team did stress that the in vivo 
application of such a device may be susceptible to a number of physiological 
parameters such as blood flow, cellular metabolism, higher temperatures and 
cellular hydration status [103]. In a set of follow-up experiments the team 
used their device to determine the optimal frequency at which to measure 
resistivity and reactivity in the ex vivo prostate samples being tested. They 
showed the specificity and sensitivity of their device was fairly modest at 
75.4% and 71.4% respectively [18]. As with the previous study there were a 
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number of limitations associated with the experimental design which may 
have affected the outcome [18]. This device showed potential as a clinically 
useful device but has so far only been tested experimentally in a research 
setting. 
1.13 Impedance in the Brain  
The first evidence of micro-fabrication technologies being employed in the 
area of impedance detection was by a research group from the Centro 
Nacional de Microelectrónica (CNM-IMB) in Barcelona, Spain. This group 
developed and manufactured a novel device which utilises silicon and 
platinum for the needle and electrodes respectively [23]. These materials 
where chosen both for their structural and electrical properties but also 
because they are bio-compatible. There are two major benefits achieved by 
the reduction in both the electrode and device design. The first is that the 
device is minimally destructive to healthy tissue adjacent to the target lesion. 
The second is that the tissue-to-electrode ratio is increased which should 
result in more precise localised impedance measurements [23]. The original 
device produced by the team at CNM-IMB used a four electrode system 
arranged in a paired, linear formation along the length of the silicon shaft 
(Figure 1.12). 
 
Figure 1.12: The probe design in which the platinum electrodes are placed at non-constant 
inter-electrode separation distances. Reference [23].  
Further research at the institute led to the development of a variation of this 
design using a tapered ultra-fine micro-needle body. This was made using 
SU-8 photoresist and a precision machined tip which contained four micro-
electrodes arranged in a diamond formation (Figure 1.13). The final 
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measurements of the device were provided in their 2010 paper (Table 1.3) 
[25]. 
 
Figure 1.13: The design and dimensions of the micro-electrode tip and a scanning electron 
micrograph image of a SU-8 micro-needle tip. Reference [25]. 
The focus of this group’s research was to design a probe for neural 
impedance measurement. However, the initial testing was conducted on 
ischaemic-kidney models in rats [23].  
Table 1.3: The size of each aspect of the micro-needle probe. Reference [25]. 
Unit Parameter Measurement 
Probe (Total) 
Length 2-3 cm 
Thickness 100 µm 
Connection Head 
Width 3.8 mm 
Length 6.4 mm 
Insertion Area 
Width 80 µm 
Length 180 µm 
Thickness 30 µm 
In the later studies by Altuna et al., they tested the SU-8 micro-needles by 
injecting them into Cornu Ammonis 3 (CA3) hippocampal slices and 
obtaining impedance measurements. This group of researchers showed that 
it is possible to manufacture a functional impedance device that is both 
suitable for in vivo human and animal testing and also contains electrodes as 
small as 20 µm in diameter. They also concluded that in order to maximise 
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the functionality of these micro-needle probes obstacles needed to be 
overcome in regards to the fabrication process and signal recording [24, 25]. 
One of the major limitations of this proposed device for use in the detection 
of cancer would be that the materials chosen were designed to be flexible for 
use in neural applications to reduce serious damage to important structures 
within the brain. Most cancer detection would require a more robust device of 
sufficient length that would allow penetration into the deeper structures of the 
body and into the target lesion itself. 
1.14 Device Solutions 
The background research presented in the previous sections has shown that 
it is possible to utilise electrical impedance to differentiate between healthy 
and cancerous tissues in humans. It also provides the basis for the research 
presented in this thesis where it is hoped that a combination of semi-
conductor and MEMS manufacturing processes and electrical impedance 
can be used to produce a novel biomedical device for the detection and 
screening of benign and cancerous breast lesions. The inclusion of gold 
microelectrodes on to a rigid substrate such as a CNB needle would allow 
the impedance device to be inserted directly in to the region of interest with 
minimal damage to the surrounding tissues. This would provide a real-time 
indication of probe advancement and tissue differentiation during a biopsy 
procedure for which no technology is currently approved for clinical use. This 
would provide a significant advancement to the current best practice of US-
guided CNB for tissue extraction. It was envisioned that the novel probe 
device, developed as part of this Ph.D. project, would act as an adjunct 
technology to mammography screening which is currently utilised for breast 
cancer detection (Figure 1.14). This would potentially significantly improve 
the process of obtaining tissue for histological examination as well as 
removing the need for patients with benign breast lesions to undergo 
unnecessary procedures. The design of the proposed device was chosen to 
maximise the expertise within the Tyndall National Institute (TNI) in the 
fabrication, packaging and testing of prototypes using semi-conductor 
manufacturing techniques including photolithography, metal evaporation and 
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deposition. The electrochemical testing facilities and cell culture laboratories 
available in the Institute were also vital to the completion of this project.  
 
Figure 1.14: A schematic overview of the breast cancer detection pathway and the area in 
which the novel probe device fits within the pathway. Figure is Author’s own. 
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2. Impedance Probe Fabrication, Characterisation and Validation 
2.1 Objectives 
The main objective of this chapter is to report the design and fabrication of a 
prototype electrical impedance transducer device, suitable for impedance 
testing of biological tissue samples. It was important to develop a device, 
which would be sufficiently robust to withstand repeated testing and cleaning, 
as well as being biocompatible for future use in human studies. A series of 
experiments were designed to determine the electrical and surface 
characteristics of the new probe (Table 2.1). 
Table 2.1:  The experimental methods that will be used in Chapter 2 and the purpose of 
each of them. 
Surface Characterisation Purpose 
Scanning Electron 
Microscopy 
Imaging of surface to show any deposition 
defects 
Energy-dispersive X-ray Elemental analysis of the deposited layers 
Focused-ion Beam Thickness of the deposited layers 
Atomic Force Microscopy Calculation of the total surface roughness 
Optical Profilometry Calculation of the total surface roughness 
Breakage Strength Force required to cause critical failure 
Short-circuit Testing Gold continuity and presence of shorts 
Electrical 
Characterisation 
Purpose 
Cyclic Voltammetry Determination of cleaning protocol 
effectiveness and electron charge transfer 
Electrical Impedance Determine the sensitivity of the probe to 
changes in layer conductivity. 
2.2 Introduction 
This chapter will discuss the design, fabrication and characterisation of a 
novel impedance probe which will be used to aid in tissue differentiation. The 
development of the probe sought to maximise the technology and 
capabilities available in the TNI including silicon fabrication, 
photolithography, electrical packaging and electrochemical testing. The 
construction of this device involved the utilisation of techniques including 
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photolithography, metal deposition, lift-off and plasma etching to allow the 
deposition of gold on to an insulated substrate [1]. Insulation of the substrate 
material is required to prevent conduction of an electrical current from the 
electrodes through the substrate. The characterisation of the probe involved 
the use of a number a key techniques including SEM, FIB milling, AFM, EDX, 
CV and electrical impedance which will all be discussed further in this 
chapter.  
2.2.1 Impedance Probe Design 
The design and layout of the probe devices was initially undertaken as part 
of a National Access Programme (NAP) grant that was subsequently funded 
by a Technology Innovation Development Award (TIDA) which was operated 
by Science Foundation Ireland (SFI). The concept was formulated by Dr 
Walter Messina and the layout drawings were completed by Mr Richard 
Murphy both of TNI, University College Cork. These designs were used to 
fabricate the photolithography masks required during the metal deposition 
and etching processes involved in the fabrication of both the stainless steel 
and silicon devices. The prototype device which was chosen for development 
during this project consisted of two gold micro-electrodes patterned on to a 
passivated substrate. The fabrication materials chosen for the development 
of the prototype device were required to provide good biocompatibility and 
sustain long-term stimulation and sensing [2]. During the course of this study 
both silicon and stainless steel substrates were tested because of their 
fabrication convenience and conformity with specific requirements of the 
semiconductor processes (ability to withstand heating cycles, a flat substrate 
and a chemically inert surface) [3]. The electrode material chosen for 
microelectrode devices are usually noble metals such as platinum or in the 
case of this study gold. This is due to the specific properties of these metals 
including high resistance to corrosion and low chemical reactivity which 
makes them ideally suited to electrical stimulation and sensing both in vitro 
and in vivo  [3-7]. The use of the two microelectrode design meant that the 
need for an external reference electrode (which is a necessary component of 
many of the devices mentioned in Chapter 1) was removed. The overall 
probe size can be maintained at a cross-sectional area of approximately 144 
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mm2 which could potentially limit tissue damage upon insertion due to its 
small size. The specific dimensions of the electrode layout were chosen to 
allow the electrochemical sensors to be integrated on to a standard stainless 
steel hypodermic needle. This would make it possible to determine the 
electrical impedance of tissues as the needle is advanced within the human 
body in real-time and may allow for tissue discrimination. 
The photolithography mask design drawings were created using CleWin4 
layout design software by Mr Richard Murphy (Figure 2.1-2.4). The image 
files were sent to Compugraphics International Ltd (Fife, United Kingdom) 
and used to manufacture a series of fused silica glass and chrome 
photolithography masks. The design specifications for each probe were 
(Table 2.2): 
Table 2.2: The probe specifications and dimensions used in the design of the 
photolithography masks. 
Probe Specifications Dimensions 
Total Length 39 mm 
Pitch 3.7 mm 
Output Electrode Width 500 µm 
Output Electrode Length 2 mm 
Recording Electrode Width 200 µm 
Recording Electrode Length 1 mm 
Track Width 100 µm 
Track Separation 100 µm 
These masks were used in the fabrication of both the silicon and stainless 
steel prototype devices. A different mask was used in each step of the 
process to produce a specific deposition pattern for each of the materials. 
These masks were reused in multiple fabrication runs for the production of 
both the silicon and stainless steel prototype devices. This meant that during 
the production of these devices the material deposition should produce 
almost identical electrodes across each of the probes created. 
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Figure 2.1: The design pattern for the masks used in the production of the stainless steel 
and silicon probes. The total length of the patterned probes is 39 mm and the pitch between 
probes is 3.7 mm. 
 
Figure 2.2: A close-up of the design pattern for the recording electrodes for the stainless 
steel and silicon probes. The dimensions of the electrode pads and the gold tracks are 
shown. 
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Figure 2.3: A close-up of the design pattern for the connection pads for the stainless steel 
and silicon probes. The dimensions of the output pads are shown. 
 
Figure 2.4: The outline (light blue) of the mask used during the passivation process for both 
the recording and output electrode pads. This area is etched to remove the Si3N4 to expose 
the electrodes and allow electrical signals to be conducted. 
A small section of the gold tracts were left exposed during the passivation 
process (Figure 2.4). As a result, the functional area of the recording 
electrodes on each probe was slightly larger than the rectangular area of the 
patterned electrode pads. The actual dimensions of the recording electrodes 
are outlined in Table 2.3: 
Table 2.3: The total calculated recording surface area of each of the gold electrodes. 
Recording Electrode Area (µm2) Total Area (µm2) 
Rectangular Electrode 1,000 x 200 = 200,000 
250,000 
Gold Tract 500 x 100 = 50,000 
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2.3 Instrumentation and Techniques 
2.3.1 Scanning Electron Microscope 
Scanning Electron Microscopy (SEM) involves the use of an electron gun to 
generate a stream of electrons which are directed at the sample being 
imaged. The electrons are deflected by the sample being imaged and these 
scattered electrons are detected by a back-scattered electron detector. 
Unlike a conventional light microscope which uses glass lens to focus light, 
an SEM uses a series of electromagnetic lenses to focus the electron beam 
[8, 9]. The use of electrons as the illumination source rather than light allows 
significantly higher magnification and resolution images to be obtained [10, 
11]. The primary use of SEM during the course of this work was to provide 
high resolution images of the surface of the gold electrodes on the silicon 
and stainless steel substrates. It was also used to image the growth of 
immortalised cells on the surface of the silicon probe (See Section 3.5.1.5). 
Figure 2.5 shows an FEI Quanta 650 FEG SEM which is used in the Electron 
Microscopy and Analysis Facility (EMAF) in the TNI.  
 
Figure 2.5: An example of an FEI Quanta 650 FEG SEM. Reference [12]. 
2.3.2 Energy-dispersive X-ray Analysis 
Energy-dispersive X-ray analysis (EDX) is an adjunct technique to SEM 
imaging. The primary electron beam, used for image generation, causes an 
increase in the energy states of electrons at the surface of the material [13, 
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14]. This increase in energy moves the electrons to higher energy orbitals 
[13, 14]. Over time these electrons return to their lowest available orbitals. 
The difference in energy between the two states can be emitted in states 
such as heat, visible light, vibration, or x-rays which is the case in EDX [13]. 
The resultant energy emissions are detected by a specialist EDX 
spectrometer. Each element on the periodic table will generate a distinct 
spectra based on the orbitals to which the electrons in each atom can move. 
These spectra can then be analysed to determine the elements present at 
the surface of a material. 
2.3.3 Focused-ion Beam 
The technique of focused-ion beam (FIB) can be used for high resolution 
imaging and/or precision milling and sputtering. In a process similar to SEM 
imaging, FIB uses gallium (Ga+) ions to bombard the surface of the material 
of interest. At a lower primary beam current, FIB machines can achieve 
image resolution up to 5 nm [15, 16]. At higher currents, FIB can be used for 
the precision removal of surface material, a process known as milling [17]. 
For the purpose of this research the high current milling was used. The most 
common application of FIB is for the preparation of cross-sectional samples 
for SEM and transmission electron microscope imaging. For analysis of 
planar samples it is often necessary to deposit a layer of metal such as 
platinum or tungsten on to the area of interest prior to milling [18]. Chemical 
vapour deposition is used to deposit the desired material on the substrate 
being analysed [17, 19]. The addition of a platinum or tungsten layer has two 
functions, the first of which is to protect the material surface from spurious 
sputtering [19]. The second function is to provide layer contrast for the 
discrimination of material layers when the sample is analysed using SEM. 
Following metal deposition, high-energy Ga+ ions are bombarded across the 
surface of the region of interest. This results in the sputtering and 
subsequent removal of the surface molecules through each of the material 
layers. The area of interest is then imaged using conventional SEM. Using 
this combination of FIB milling and SEM imaging it is possible to get 
approximate measurements of each of the layers deposited during the 
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fabrication process. Figure 2.6 shows an FEI Quanta 3D Dual Beam FIB 
which is used in the EMAF in the TNI. 
 
Figure 2.6: An example of an FEI Quanta 3D Dual Beam FIB. Reference [20]. 
2.3.4 Atomic Force Microscopy 
Atomic Force Microscopy (AFM) was developed in the early 1980s by Gerd 
Binnig and Henrich Rohrer. It was designed as a tool to enable precise 
imaging and measurement of ultra-small forces on particles as small as 
single atoms [21]. Images are produced by measuring the strength of force of 
interaction between the sharp tip of a cantilever (Figure 2.7) made of silicon 
or silicon nitride (Si3N4) and the surface atoms of the material [22]. The 
precision of the technique means that the presence of one atom on the 
surface of the material can cause the cantilever to be deflected. 
 
Figure 2.7: An example of an AFM cantilever and tip. Reference [23]. 
The forces that can be measured include mechanical contact, van der 
Waals, capillary, chemical bonding, electrostatic, piezo responses and 
magnetic forces. Many commercial AFM devices use a process of optical 
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beam deflection to measure the response of the cantilever as it is scanned 
across the surface of a material [24]. When the tip is brought into the 
proximity of a sample the interaction with the surface chemistry leads to a 
deflection of the cantilever. A laser diode light source is directed by a prism 
onto the back of the cantilever. The beam is reflected by a mirror towards a 
photodiode detector which is used to determine the vertical deflection 
experienced by the cantilever [24]. AFM instruments obtain measurements in 
three dimensions to produce a 3D image of the surface. The resolution which 
can be obtained in the x and y plane ranges from 0.1 to 1.0 nm and in the z 
direction of 0.01 nm [22]. 
2.3.5 Cyclic Voltammetry 
Cyclic voltammetry (CV) is a type of measurement first described by John 
Randles in 1948 [25]. The technique involves cycling the applied potential 
between two fixed points at a constant rate in an unstirred solution and 
measuring the resulting current [26]. The sweep rate applied can vary from a 
few millivolts per second to a hundred volts per second. It is an effective 
approach for the evaluation of a redox system’s electron transfer in 
reactions, such as provision of data relating to kinetics and formal reduction, 
reversibility, stability and oxidation potentials in a system [27]. A reference 
electrode such as an Ag/AgCl electrode is used to maintain the potential of 
the working electrode being tested. The potential is applied as a linear 
potential scan with a triangular waveform. The voltage increase begins at V1 
until it reaches V2 at which point the scan is reversed until it reaches V1 again 
(Figure 2.8) [28]. The important parameters of CV measurements include the 
magnitude of the peak currents Ipa (anodic peak current) and Ipc (cathodic 
peak current) and the potential at which the peaks occur at Epa and Epc.   
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Figure 2.8: The forward and reverse potentials versus time of a typical cyclic voltammogram. 
Redrawn from reference [28]. 
For reversible electrochemical reactions there are four characteristics which 
must be present [28, 29]: 
1) Voltage separation between peak currents is (Equation 2.1):  
ΔE = E𝑝
𝑎 − Ep
c =
59
n
mV 
Equation 2.1: The relationship between the anodic and cathodic peak currents. n = number 
of electrons transferred.  
2) The positions of peak voltage do not alter as a function of voltage 
scan rate 
 
3) The ratio of peak currents is equal to one (Equation 2.2): 
|
ip
a
ip
c | = 1 
Equation 2.2: The ratio of the peak anodic and cathodic peak current which equals 1 for 
reversible chemical reactions. 
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4) The peak currents are proportional to the square root of the scan rate 
(Figure 2.9): 
 
Figure 2.9: The effect of increasing scan rate on the peak current response of reversible 
electrochemical reaction. Reference [28]. 
The peak current for a reversible system is described by the Randles-Sevcik 
equation for the forward sweep of the first cycle (Equation 2.3) [26, 30].  
ip = (2.69 x 10
5)n3/2AD1/2Cv1/2 
Equation 2.3: The Randles-Sevcik equation for the calculation of peak current in a reversible 
system. 
Ip is the peak current (A), n is electron stoichiometry, A is the electrode area 
(cm2), D is the diffusion coefficient (cm2/s), C is the concentration (mol/cm3) 
and v is the scan rate (V/s). Therefore, Ip increases with v
1/2 and is directly 
proportional to the concentration. For quasi-reversible systems, the current is 
controlled by both the mass transport and charge transfer. The 
voltammograms produced are more extended and exhibit a larger peak 
separation compared to a reversible system [30, 31]. 
An electrochemical cell used during CV typically consists of a three electrode 
set-up: A working electrode composed of inert materials such as carbon, 
gold, platinum or graphite; a counter electrode most commonly a platinum 
wire; and a reference electrode such as Ag/AgCl or a saturated calomel 
electrode. The potentiostat to which the three electrodes are connected 
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applies the desired potential between the working and reference electrodes. 
The current required to sustain the electrolysis at the working electrode is 
provided by the counter electrode (Figure 2.10) [26]. The current measured 
during the process is often normalised to the electrode surface area and is 
referred to as the current density. A cyclic voltammogram is produced by 
plotting the current density at the working electrode surface during the 
voltage sweep against the applied potential [32]. A peak in the measured 
current is seen at the potential that is characteristic of an electrode reaction 
taking place. The peak width and height for a particular process may depend 
on the sweep rate, electrolyte concentration and the electrode material [33]. 
 
Figure 2.10: A simple schematic of a three-electrode electrochemical cell, showing the 
working electrode, reference electrode and counter electrode immersed in solution. The 
electrodes are all connected to a potentiostat so that the potential differences between the 
electrodes can be measured. Figure is Author’s own. 
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2.4 Experimental Details  
2.4.1 Reagents and Materials 
Silicon Dioxide, MicroChem S1805 Imaging Resist, Microposit MF319 
Developer and Microposit R1165 Resist Stripper, Silicon Nitride (Si3N4) (All 
purchased from Shipley Europe Ltd., Coventry, United Kingdom); Stainless 
steel wafers (Mechanical Workshop, Tyndall National Institute); Silicon 
Wafers (Silicon Fabrication Unit, Tyndall National Institute); Gold Powder (Pi-
Kem Ltd., Staffordshire, United Kingdom); Titanium (Umicore N.V., Brussels, 
Belgium); Single-core wire, Multi-core wire and 2-part Araldite Rapid T 
Hardener Epoxy, Kapton® Tape (all from Radionics Ltd., Dublin, Ireland); 
Ablebond 84-1LM1SR4 Silver Epoxy (Farnell Ltd., Leeds, United Kingdom); 
Tetrafluoromethane, Isopropyl alcohol, 20 ml universal collection tube, Petri 
Dish, Carbon Tape, Microscope slides, Potassium Ferricyanide, Potassium 
Chloride, resazurin sodium salt (all from Sigma-Aldrich Ltd., Dublin, Ireland); 
Scalpel (Swann Morton, Sheffield, United Kingdom). 
2.4.2 Instrumentation 
FEI Quanta 650 FEG Scanning Electron Microscope with EDX (FEI UK Ltd., 
Cambridgeshire, United Kingdom), FEI Quanta 3D Dual Beam Focused-Ion 
Beam (FEI UK Ltd., Cambridgeshire, United Kingdom), Asylum Research 
MFP-3D Classic Atomic Force Microscope (Oxford Instruments, Oxfordshire, 
United Kingdom), Palmsens Potentiostat (Palmsens BV, Utrecht, The 
Netherlands), Instron 5960 Dual-column Testing System (Instron, 
Buckinghamshire, United Kingdom), Temescal FC-2000 (Scotech Ltd., 
Renfrewshire, Scotland), STS310 PC Plasma-enhanced Chemical Vapour 
Deposition (SPTS Newport (UK), Newport, United Kingdom), Karl Suss 
MA1006 Mask Aligner (Suss Microtec AG, Garaching, Germany), PICO 
Ashing (CF4), Disco DAD3350 (Disco Hi-Tec U.K. Ltd., West Sussex, United 
Kingdom), Silver Epoxy Oven (Heraeus VT5042EK vacuum oven, Heraeus 
Holding GmbH, Hanau, Germany); Ultrawave QS3 Ultrasonic Water Bath 
(Ultrawave Ltd., Cardiff, United Kingdom), Harrick Plasma PDC-002 
Extended Plasma Cleaner (Harrick Plasma, New York, U.S.A.); Wild M3Z 
Stereo Microscope (Wild Heerbrugg AG, Gais, Switzerland), CHI111 
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Ag/AgCl Reference Electrode and Platinum Wire Counter Electrode (CH 
Instruments Inc., Austin, Texas, USA); Fluke 16 Multimeter (Fluke UK Ltd., 
Norfolk, United Kingdom); Autolab PGSTAT204 with FRA32M module 
(Metrohm UK Ltd, Runcorn, United Kingdom); Zyga NewView 5032 
(ZygoLOT GmbH, Darmstadt, Germany). 
2.5 Procedures 
2.5.1 Fabrication 
2.5.1.1 Silicon Probes 
The silicon probes were fabricated using the Fabrication Facilities in the TNI. 
The 100 mm diameter silicon wafers were obtained from the Silicon 
Fabrication Unit in the TNI. The silicon probes were fabricated using the 
Fabrication Facilities in the TNI by Mr Dan O’Connell. The initial thickness of 
the wafer was 525 µm. A variable-wet-oxide layer was applied to each of the 
wafers. The process was conducted at 1,100°C for 16 min to produce a 
3,000 angstrom (300 nm) oxide layer. Figure 2.11 shows a conceptualised 
drawing of the three layers of the probe which are deposited onto the silicon 
substrate (SiO2, gold/titanium and Si3N4). 
 
Figure 2.11: An expanded view conceptualised drawing of the individual layers deposited 
during the fabrication of the silicon probes. Black – 525µm Silicon Substrate; Green – 300nm 
SiO2; Yellow – 20 nm/220 nm Titanium/Gold; White – 250 nm Si3N4. Figure was produced by 
Dr Walter Messina. 
The silicon wafers were spin-coated with MicroChem LOR3A lift-off resist at 
3,000 rpm and baked on a hot plate for 3 min at 150°C. MicroChem S1805 
imaging photoresist was applied to the entire surface of the wafer at 3,000 
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rpm for 50 seconds and the wafers were baked again for 2 min at 115°C. 
The pre-designed masks were aligned with the wafers in a Karl Suss 
MA1006 mask-aligner. The wafers were exposed to UV light at a dosage of 
40 mW/cm2. The wafers were placed in a Microposit MF319 developer for 1 
min to activate the positive resist in the pattern of the electrodes. Deionised 
water was used to rinse the wafers which were then baked in an oven for 30 
min at 90°C. A layer of titanium and gold (20 nm:220 nm) was then 
evaporated on top of the photoresist layer. The titanium layer was used as 
an adhesive layer to aid in the attachment of the evaporated gold. The metal 
deposition was conducted using e-beam evaporation in a Temescal FC-2000 
(Scotech, Renfrewshire, Scotland) at a pressure of <5 x 10-7 Torr. Excess 
metal and photoresist were removed using Microposit R1165 resist stripper. 
A passivation layer of Si3N4 was applied by plasma-enhanced chemical 
vapour deposition (PECVD) in a STS310 PC system (SPTS, Newport, United 
Kingdom). A photolithography mask was designed to pattern this layer so 
that both the recording electrodes and the connection pads would be 
exposed after the overlying passivation layer was etched in 
tetrafluoromethane (CF4) plasma in a PICO Ashing system.  
Once each of the deposition processes had been completed the wafers were 
then diced into approximately 3.7 mm wide sections, using a Disco DAD3350 
automatic dicing unit (Disco Hi-Tec U.K Ltd., West Sussex, United Kingdom), 
by Mr Paul Tassie to release the individual probes from the wafers. This was 
completed in the Packaging Laboratory in TNI. To permit the insertion of the 
diced probes into tissue, the probe tips were pointed using an electrical 
sander. 
2.5.1.2 Stainless Steel 
The stainless steel probes were fabricated using the Fabrication Facilities in 
the TNI by Mr Dan O’Connell. The substrates used for the probe 
development were 100 mm diameter and 1 mm thick stainless steel wafers 
which were obtained from the Mechanical Workshop in the TNI. The 
deposition process previously described for the silicon prototypes was used 
to pattern the stainless steel substrates. Insulation layers of silicon dioxide 
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ranging from 250 nm to 1 µm were deposited on the surface of the wafers to 
prevent conduction of an electrical current through the steel substrate. Once 
each of the deposition processes had been completed the wafers were then 
diced using a Disco DAD3350 automatic dicing unit (Disco Hi-Tec U.K Ltd., 
West Sussex, United Kingdom), by Mr Paul Tassie to release the individual 
probes from the wafers. This was completed in the Packaging Laboratory in 
TNI. 
2.5.1.3 Probe Packaging 
After the silicon probes had been shaped they were packaged to allow 
electrical recordings to be performed. Both single-core and multi-core wires 
were used in the development of the silicon probes. The insulation coating 
was first removed from the end of the electrical wires using a scalpel to allow 
a direct contact with the connection pads located on the devices. The wires 
were positioned on a glass microscope slide and held in place using Kapton 
® Tape. The silicon probes were then aligned beneath the wires and also 
held in place with Kapton® Tape. The wires were bonded to the gold output 
pads with a conductive silver epoxy which was applied under a light 
microscope. A compressed air supply line was attached to the tube of silver 
epoxy to allow it to be dispensed in a controlled manner. When both wires 
were connected, the probes were placed in an oven at 120°C for 2 hours to 
allow the epoxy to cure (Figure 2.13). Plastic Pasteur pipettes were then cut 
to size using a scalpel to provide a protective covering over the wire bond 
(Figure 2.12). A 2-part epoxy (Araldite Rapid T Hardener, Radionics Ltd., 
Dublin, Ireland) was mixed in equal parts in a plastic weigh-boat before being 
transferred in to an open syringe tube. This was capped and attached to a 
compressed air supply. The epoxy was then used to fill the tubing and 
allowed for harden for 20 minutes until dry. 
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Figure 2.12: A packaged probe showing the plastic tubing filled with hardened 2-part epoxy 
covering the electrical connects. 
 
Figure 2.13: The Heraeus VT5042EK vacuum oven used in the probe packaging process. 
2.5.2 Probe Cleaning 
Each silicon probe was cleaned prior to electrochemical, cell culture or meat 
and human tissue testing. The devices were cleaned using ultrasonic 
isopropyl alcohol (IPA) and deionised water washes as this combination was 
able to remove contaminants without damaging the probe surface [34-36]. 
The devices were placed in a 20 ml tube which was filled with IPA and 
placed in an ultrasonic water-bath (QS3, Ultrawave Ltd., Cardiff, United 
Kingdom) for 10 min at 25 °C (Figure 2.14).  
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Figure 2.14: The Ultrawave QS3 ultrasonic water-bath used during the probe cleaning 
protocol. 
The IPA was removed and discarded according to laboratory protocols. The 
probes were rinsed 3 times using 18.2 MΩ nano-pure water and the waste 
was discarded. The tube was filled with nano-pure water and placed in the 
ultrasonic bath for a further 10 minutes at 25 °C. The water was discarded 
and the probes were rinsed 3 times with nano-pure water. The devices were 
then placed on a sheet of lint-free cleanroom paper in a fume-hood. 
Compressed nitrogen gas was used to remove any remaining water from the 
probe. The devices were placed in an oxygen-plasma cleaner (PDC-002, 
Harrick Plasma, New York, U.S.A.) and the chamber was pumped out using 
the attached vacuum pump (Figure 2.15). The gas inlet valves were then 
opened to allow oxygen into the cleaning chamber which was maintained 
between 800-1000 microns for 20 min to remove any organic contaminants. 
Once completed the plasma cleaner was switched off and the gas values 
were carefully opened to prevent damage of the probes. The devices were 
then placed in a clean petri dish before being used in experiments. 
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Figure 2.15: The Harrick Plasma oxygen-plasma cleaner and vacuum pump used during the 
silicon probe cleaning protocol. 
2.5.3 Continuity Testing 
A handheld multi-meter (Figure 2.16) was used to determine if the diced 
probes were short-circuited by measuring electrical continuity. The 
multimeter was set-up to determine continuity and would alarm at less than 
25 Ω resistance. The positive cable (red) was placed on one of the gold 
output pads. The negative cable (black) was then placed on the recording 
electrode on the same side as the output under a light microscope to ensure 
correct placement. An alarm signalled a continuous circuit along the length of 
the gold tract. The multimeter probes were moved to the other recording and 
output pads to test the continuity of the opposite gold tract. If the alarm 
sounded when the probes were placed on any other point on the device 
outside of the recording and output pads a short circuit was present. If no 
alarm sounded when the multimeter probes were positioned correctly that 
would indicate that the gold track was not continuous along its entire length. 
This technique was used to qualitatively determine the continuity of the gold 
electrodes to assess if each probe was suitable for packaging. 
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Figure 2.16: A Fluke 16 multimeter which was used to determine if a short-circuit existed in 
the stainless steel and silicon probes. 
2.5.4 Material Characterisation 
2.5.4.1 Scanning Electron Microscope 
Two probes were chosen as representative samples of both the silicon and 
stainless steel devices to be imaged by SEM. The probes were attached to 
the chuck of the microscope stage using carbon tape. The SEM chamber 
was then closed and pumped out to create a vacuum inside. A voltage of 20 
kV generated the stream of electrons used for imaging. The probes were 
imaged across a range of magnifications from 140-100,000x and a stage tilt 
of either 0° or 45°. The purpose of this was to obtain high resolution images 
of the electrode layout, probe surface and the gold deposition. 
Representative images will be shown in the results section. All SEM images 
were obtained using a FEI Quanta 650 FEG scanning electron microscope 
(FEI, Cambridge, United Kingdom) by Mr Vince Lodge in the EMAF in the 
TNI. 
2.5.4.2 Energy-dispersive X-ray Analysis 
This technique was used to determine the composition of the electrodes that 
were fabricated as part of the probe manufacture. The electrodes were 
placed in the vacuum chamber of the SEM as previously described. The 
EDX unit was inserted in to the chamber. The recording parameters were 
setup using the software associated with the EDX unit. The left and right 
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electrode of each probe was analysed each time. The EDX analysis was 
performed by Mr Vince Lodge in the EMAF in TNI. 
2.5.4.3 Focused-ion Beam 
The FIB milling associated with this project was performed using an FEI 
Quanta 3D Dual Beam FIB instrument (FEI, Cambridge, United Kingdom) by 
Mr Vince Lodge in the EMAF in TNI. An area of platinum approximately 20 
µm2 (4 x 5 µm) was deposited on the surface of the gold electrode. The FIB 
instrument was then used to mill through each of the deposition layers. Once 
the milling was complete the probe was imaged using the FEI Quanta SEM 
as previously described using the following parameters (Table 2.4): 
Table 2.4: The SEM imaging parameters used after the FIB milling procedure  
Parameter Value 
Magnification 20,000 and 150,000 x 
Tilt 45° 
Electron Charge 30 kV 
2.5.4.4 Atomic Force Microscopy 
Atomic force microscopy imaging was performed by Dr Lynette Keeney using 
an Asylum Research MFP-3D Classic Atomic Force Microscope (Oxford 
Instruments, Oxfordshire, United Kingdom). The silicon probes were imaged 
in AC (intermittent contact) mode using AC240TS silicon cantilevers (Al 
reflex coated, ~70 kHz resonant frequency). The scan parameters used to 
image the silicon probes are shown in Table 2.5.  
Table 2.5: The AFM imaging parameters used in the analysis of the gold electrode surface. 
Scan 
Rate 
Scan 
Angle 
Set 
Point 
Integral 
Gain 
Drive 
Amplitude 
Drive 
Frequency 
Scan 
Points 
1 Hz 90° ~0.2 V 10 ~0.3 V ~72 kHz 256 
 
Five measurement points were selected on each of the two gold electrodes 
on one silicon probe. A forward and reverse scan was performed over an 
area of 25 µm2 (5 µm x 5 µm). The root-mean squared (RMS) values from 
each of the recordings were averaged and a total surface roughness value 
for each of the individual electrodes was determined.  
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2.5.4.5 Break Strength Testing 
The instrument used to test the force applied to the probe to cause a critical 
failure in the silicon was an Instron 5960 Dual column testing system 
(Instron, Buckinghamshire, United Kingdom). The silicon probe was placed 
vertically in a piece of Blu-tack™ on the lower plate of the machine. The 
upper plate was then lowered until it contacted the top of the probe. The 
system was zeroed prior to a force being applied to the probe. The 
instrument was started and an increasing force was applied to the upper 
plate until a breakage in the probe occurred. The maximum applied force in 
Newton (N) required to break the silicon probe was then calculated. 
2.5.4.6 Optical Profilometry 
The Zyga NewView 5032 instrument was used to image the surface 
topography of the bare stainless steel wafer. The wafer was placed on the 
microscope stage and was aligned using the motorised stage control. The 
20x Mirau objective lens was used during the measurement process. Four 
measurement points were selected on one stainless steel wafer. A forward 
and reverse scan was performed over an area of 0.091 mm2 (0.35 mm x 
0.26 mm). The root-mean squared (RMS) values from each of the recordings 
were averaged and a total surface roughness value for the stainless steel 
wafer was determined.  
2.5.5 Electrochemical Characterisation 
2.5.5.1 Potassium Ferri/Ferrocyanide Solution 
A 1M solution of potassium chloride (KCl) was first made up by adding 14.91 
g of KCl salt to 200 ml of deionised water and mixed thoroughly to ensure a 
homogenous mixture. 100 ml of the solution was divided into two separate 
200 ml Duran® bottles.  Potassium Ferricyanide salt, K3[Fe(CN)6], (0.1645 
g), was weighed out and added to one of the Duran® bottles containing KCl 
solution. 0.211 g of Potassium Ferrocyanide (K4[Fe(CN)6) was then weighed 
out and added to the other KCl solution bottle. The two solutions were 
thoroughly mixed to ensure a homogenous mixture. The ferricyanide and 
ferrocyanide solutions were then mixed in a clean 500 ml Duran® bottle and 
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was inverted a number of times to mix the two solutions. This produced a 5 
mM Potassium Ferri/Ferrocyanide solution in 1 M KCl. 
2.5.5.2 Cyclic Voltammetry Setup 
A three-electrode set-up was used during this experiment. One of the gold 
electrodes acted as the working electrode along with a platinum wire counter 
and an Ag/AgCl reference electrode. The measurements were performed 
using a PalmSens potentiostat (Palmsens BV, Utrecht, The Netherlands) 
(Figure 2.17). 
 
Figure 2.17: The equipment setup for the CV measurements using a PalmSens potentiostat 
and a three electrode circuit. 
5 ml of the Potassium Ferri/Ferrocyanide and KCl solution was pipetted into 
a 10 ml glass beaker and placed on a retort stand. The Ag/AgCl reference 
electrode was attached to the reference cable, the platinum wire counter to 
the counter cable and one of the gold electrodes to the working cable which 
were connected to the PalmSens instrument. The electrodes and the silicon 
probe were then suspended from the retort stand in the ferri/ferrocyanide 
solution (Figure 2.18). 
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Figure 2.18: The Ag/AgCl and platinum wire electrodes and a silicon probe in a solution of 
potassium ferri/ferrocyanide and KCl during CV measurement. 
A scan protocol was setup using the PSTrace software associated with the 
PalmSens instrument (Table 2.6): 
Table 2.6: The parameters used for the cyclic voltammetry measurements performed using 
a three-electrode set-up with the silicon probes, a Ag/AgCl reference and a platinum counter 
electrode. 
Parameter Setting 
Equilibration Time 2 sec 
E Initial -0.3 V 
E Vertex 1 -0.3 V 
E Vertex 2 0.6 V 
E Step 0.002 V 
Scan Rate 0.1 V/s 
Number of Scans 2 
The probes were cleaned using the previously described cleaning protocol 
and were tested at a fixed scan rate of 0.1 V/s. The probes were tested again 
after use in meat tissue and were considered unclean. Each of the gold 
electrodes acted as a working electrode so cyclic voltammograms were 
measured independently on the left electrode and then the right electrode 
each time. Variation between the two was identified by overlaying the 
generated plots which will be presented in the results section.  
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In the second set of experiments a selection of 5 probes were cleaned using 
the previously described cleaning protocol and were tested at a fixed scan 
rate 0.1 V/s. Each of the gold electrodes acted as a working electrode so 
cyclic voltammograms were measured independently on the left electrode 
and then the right electrode each time. Variation between the 5 probes was 
identified by overlaying the generated plots from the left electrode of each 
probe which will be presented in the results section. The purpose of this was 
to identify intra-batch variability between the different probes. 
The final set of experiments conducted using CV was to determine the effect 
of a varying scan rate on the current response. The same electrode set-up 
and analyte solution was used as in the previous experiment. The 
parameters of the CV measurement were maintained as previously 
described except for the applied scan rate which was varied between 0.01 
V/s and 0.1 V/s in 0.01 V increments. As in the previous experiments the left 
electrode was tested first and then the right electrode each time. 
2.5.5.3 Electrical Impedance Testing 
400 ml of water, in a glass beaker, was heated to approximately 70°C on a 
hotplate. A total of 56 g of powdered gelatine (Gelatine, Dr Oetker, Leeds, 
United Kingdom) was weighed out and added to the heated water. The 
solution was then stirred to ensure a homogenous mixture. A plastic 
lunchbox was lined with cling-film and the entire gelatine mixture was poured 
into it and placed in a fridge at 4°C and allowed to set until firm. 250 g of 
Frytex Lard (JDS Foods Ltd., Cork, Ireland) was added to a clean 600 ml 
glass beaker and placed on a hotplate at 190°C. The lard was stirred 
continuously and allowed to melt completely. The gelatine was removed from 
the fridge and liquid lard was poured directly on top. The lunchbox was then 
placed in the fridge at 4°C to allow the lard to set firm. The gel and lard slab 
was removed and brought to the Bioanalysis Laboratory to perform the 
electrical impedance measurements. Silicon probes were connected to the 
Autolab potentiostat and fixed frequency measurements were performed at 
4,500 Hz and 10 mV peak amplitude. A total of 60 individual points were 
recorded each time. The probe which was initially placed in the gelatine layer 
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was moved to the lard layer after approximately 30 seconds. After each 
subsequent 30 seconds the probe was moved to the opposite layer. The 
purpose of this experiment was to determine if the silicon probes were 
capable of determining the change in electrical impedance between a 
conductive (gelatine) and an insulating material (lard) over time. 
2.6 Results and Discussion 
2.6.1 Silicon Probes 
2.6.1.1 Wafer Fabrication 
The patterned silicon wafers (Figure 2.19) were produced using the 
previously described semi-conductor fabrication methods. Visually, the 
patterned wafers appeared to be free of defects. The wafers were diced to 
release the individual probes so that they could be packaged. 
.  
Figure 2.19: A silicon wafer after the entire deposition process had been completed. 
The use of silicon wafers as the base substrate for the deposition of the gold 
electrodes was found to result in reproducibility across the fabrication and 
packaging processes. The key reason for this was the uniformity of the 
silicon surface which provided an exceptionally smooth surface on to which 
the fabricated layers were deposited. The result of this was a very high 
percentage of the fabricated devices were able to undergo packaging to 
allow them to be used for the purpose of electrical recordings. The major 
drawback to using a silicon substrate was the overall brittleness of the 
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material which meant that the finished probes were very easily broken during 
the cleaning and testing procedures. For this reason the long term future of 
the prototype will require the substitution of the silicon substrate for a more 
robust and biocompatible alternative.  
2.6.1.2 Silicon Probe Packaging 
As previously described the process of packaging the silicon devices 
involved a number of stages. Figure 2.20 shows three stages of the 
development process. On the left is a diced probe having been removed 
from the wafer, while the middle one is a fully shaped probe. The probe on 
the right was a fully packaged prototype capable of recording electrical 
signals. 
 
Figure 2.20: The stages of the device packaging process including diced, shaped and 
electrically packaged. 
2.6.1.3 Scanning Electron Microscope 
The high resolution SEM images provided an idea of the surface topography 
of the gold electrodes and the surrounding silicon substrate. The 
micrographs of the silicon probes clearly illustrated the deposition of the gold 
across the electrode surface. The first two images in Figure 2.21 (A and B) 
show relatively low magnification SEM images of the gold electrodes and the 
underlying silicon substrate. These images showed the precision with which 
the electrode patterns are created as well as showing the thickness of the 
silicon substrate and the deposited SiO2. The higher magnification images 
(Figure 2.21 C-E) acquired using this method showed a relatively uniform 
layer of gold across the electrode surface. This indicated that the metal 
deposition used during the fabrication of the devices was satisfactory and 
that the devices produced were defect free. This should provide the best 
possible surface to perform the electrochemical and impedance testing for 
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which the devices were created. The use of SEM as a characterisation tool 
was particularly useful in assessing the metal deposition and surface 
topography of the stainless steel and silicon devices. The SEM images 
showed the cleanliness of the probe surface after the cleaning protocol had 
been performed. This was extremely important for future testing involving the 
prototype device in human and meat tissue samples. The results of the SEM 
imaging of the silicon probes were correlated with the results of the AFM 
testing which will be outlined in Section 2.6.1.6. 
  
Impedance Probe Fabrication, Characterisation and Validation Chapter 2 
70 
 
 
Figure 2.21: A) A 140x magnification SEM image of the gold electrode surface and 
underlying silicon substrate. B) A 250x magnification SEM image of the gold electrode 
surface and underlying silicon substrate. C) A 25,000x magnification SEM image of the gold 
electrode surface. D) A 50,000x magnification SEM image of the gold electrode surface.  E) 
A 100,000x magnification SEM image of the gold electrode surface. 
2.6.1.4 Energy-dispersive X-ray Analysis  
The EDX unit was used in conjunction with the SEM to analyse the surface 
material of the electrodes patterned on the silicon substrates. The surface of 
one electrode was measured on two different silicon probes and the spectra 
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produced are shown in Figure 2.22 A and B. The peaks which were 
determined show the presence of gold, silicon and potentially titanium. These 
results were to be expected as gold was the deposition metal used to pattern 
the electrode, titanium was used as an adhesion layer for the gold and silicon 
is the major substrate upon which the probes were created. The spectra 
produced on the different probes were almost identical which was a positive 
result as it proved that the multiple deposition processes used during the 
device fabrication resulted in uniform layers across the surface of both of the 
electrodes.  
 
Figure 2.22: A) The EDX spectrum of the surface of a gold electrode from a silicon probe. B) 
The EDX spectrum from the surface of a gold electrode on a different silicon probe from the 
one analysed in A). 
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2.6.1.5 Focused-ion Beam 
The area that was milled during the FIB procedure was imaged using an 
SEM to obtain the highest resolution image possible. The use of this 
technique allowed for the approximation of the individual layer thickness of 
each of the deposited materials on the silicon substrate. This provided a 
cross-sectional image of each layer of the probe. It was then possible to 
estimate the true thickness of each layer which could then be compared to 
the specified value. Figure 2.23a showed the area which was etched out 
using the FIB instrument. The area of platinum overlaid on the gold electrode 
surface was used to provide contrast during the SEM imaging.   
 
Figure 2.23: A) A 20,000x magnification SEM image of the focused-ion beam milling site on 
the gold electrode. B) A 150,000x magnification SEM image of the hole milled using the FIB 
instrument. The approximate layer thickness of the gold (A), titanium (B) and SiO2 (C) layers 
are also shown. 
The SEM image used for the determination of the layer thickness was taken 
at 150,000x magnification. Figure 2.23b shows the approximate dimensions 
of each of the layers that could be visualised using this technique. The 
topmost layer is the gold electrode which should have been 220 nm thick. 
The approximate thickness of the gold was 239.0 nm. As this value was only 
an approximation of the true value it was possible that the real thickness was 
closer to that of the target 220 nm. The layer immediately below the gold was 
titanium which was used as an adhesion layer for the gold. The approximate 
thickness of this layer was measured as 63.20 nm. The theoretical height of 
this layer was 20 nm. The final layer which could be visualised in this image 
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was the underlying insulation layer of SiO2. The estimated value obtained 
during the SEM measurement is 263.8 nm while the target value was 300 
nm. All of these approximations of layer thickness were close to the specified 
values that were planned in the fabrication protocol at the outset of the 
production process (Table 2.7). This technique provided an insight into the 
accuracy of the metal deposition process and also estimated the real 
dimensions of the material layers. 
Table 2.7: The theoretical and approximate values of the deposition layers observed on the 
silicon probes using SEM imaging. 
Deposition Layer Target Value (nm) SEM Image Value (nm) 
Gold 220 239 
Titanium 20 63 
 Silicon Dioxide 300 263 
2.6.1.6 Atomic Force Microscopy 
The use of AFM in this project was to determine the approximate surface 
roughness of the gold electrodes after fabrication. This provided an indication 
of the relative uniformity of the gold across the probe surface. The major 
benefit of using the AFM was the ability to obtain a quantitative measurement 
of the surface roughness of the gold electrode which could be correlated with 
the surface topography imaging provided by the SEM technique. A total of 20 
measurements across 10 different areas on two electrodes were performed. 
Images were obtained to show the probe location at each of the recording 
sites. Figure 2.24 shows the silicon cantilever at the site of the first recording 
on the gold electrode. 
Impedance Probe Fabrication, Characterisation and Validation Chapter 2 
74 
 
 
Figure 2.24: The position of the AFM cantilever during one of the measurement recordings. 
For each of the recordings performed a two-dimensional grey scale image 
was produced which represented the total deflection encountered by the 
AFM probe tip as it moved across the surface. Figure 2.25 shows a 
representative grey scale image from one of the scans performed across a 
25 µm2 area of the gold electrode. 
 
Figure 2.25: A representative image from one of the AFM scans performed on the gold 
surface of the silicon probe. 
The calculated RMS data obtained from each of the AFM scans was 
averaged for each of the measurement sites and then averaged to produce a 
combined value for each of the electrodes. The RMS roughness is similar to 
the roughness average, with the only difference being the mean squared 
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absolute values of surface roughness profile [37]. These values were then 
graphed as the RMS ± Standard Deviation (S.D.) for each of the individual 
electrodes (Figure 2.26). The mean values for the left and right electrodes 
were 5.0 nm and 4.9 nm respectively. These values correlated well with the 
images obtained from the SEM which showed that the deposition of gold 
across the electrode surface was extremely smooth. The combination of the 
data obtained from both the AFM and SEM showed that fabrication of the 
gold electrodes on the silicon substrates was successful. As a result, the 
electrode surface should be suitable for electrochemical recording as it is 
defect free and should act as a planar electrode during recording. Any 
significant deviation in the surface roughness of the electrode would change 
the total surface area of the electrodes and would impact on the recordings 
obtained using that electrode.  
  
Figure 2.26: The mean RMS roughness of the left and right electrodes 
obtained using AFM. N=1; Mean ± S.D. 
2.6.1.7 Breakage Tests 
The breakage analysis testing was performed using an Instron 5960 dual 
column testing system. Each of the silicon devices were placed upright 
between the two plates of the machine on which the force was applied 
(Figure 2.27).  
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Figure 2.27: A silicon probe held in position between the two plates of the Instron force 
testing instrument. 
The results of a number of probe breakages can be seen in Table 2.8. The 
figures obtained from 5 separate probes showed a mean value of 50.39 N of 
force applied to produce a critical failure in the devices. This was an 
approximation of the true breaking strength of the silicon probes when the 
force was applied directly on the pointed tip in a vertical direction. This setup 
was used to replicate the force which would be applied to the tip of the probe 
when it was inserted in to ex vivo tissues which would be the most likely 
cause of failure in each of the devices. The variability in the results obtained 
may have resulted from the initial set-up of the probes in the testing 
instrument. The devices were placed in the machine by hand and 
approximately vertical to the base plate. Minor variations in the angle of 
applied force may account for the differences in the results presented in 
Table 2.8. 
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Table 2.8: The values of the applied force in Newton obtained during the silicon probe 
breaking force tests. 
Probe Force Applied (N) 
1 47.33 
2 48.66 
3 42.75 
4 58.45 
5 54.74 
Mean 50.39 
Standard Deviation 6.22 
The results obtained for the silicon probe could be compared to future 
prototype devices to demonstrate if the new devices have a higher breakage 
threshold. This would indicate that the device would be more capable of 
being inserted directly in to ex vivo tissues. 
2.6.1.8 Cyclic Voltammetry 
Cyclic voltammetry measurements were performed to determine the effective 
charge transfer at the electrode surface for each of the packaged devices. 
The electrochemical response of the gold electrode devices was analysed 
using the accepted technique of CV [38, 39]. The first set of experiments was 
designed to show the effect of fouling on the surface of the electrode as a 
result of experimental use in the testing of meat tissues and to validate the 
effect of the cleaning protocol applied prior to testing. Voltammograms were 
obtained at a scan rate of 0.1 V/s for each electrode. Two sweeps were 
performed each time and the second one was graphed for each electrode. 
The overlay of the left and right electrodes showed extremely similar scans 
which showed good stability across both (Figure 2.28). 
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Figure 2.28: A cyclic voltammogram of the left and right electrodes of a gold probe prior to 
cleaning and directly after cleaning. The cleaning protocol resulted in an increase in both the 
anodic and cathodic peak currents. 
An increase in both the anodic and cathodic peak currents can clearly be 
seen. The difference in the peak currents was used to determine if 
imperfections or contaminations existed at the electrode surface. The 
theoretical value achievable for single electron transfer reactions, such as in 
the [Fe(CN)6]3-/4- couple, on a perfect gold surface should ΔE = 58 mV [30, 
40]. The differences between the anodic and cathodic peaks are shown in 
Table 2.9. The values for the left and right electrode after cleaning was 0.062 
V (62 mV) and the value for the unclean electrodes was 0.07 V (70 mV). 
Both of the clean electrodes showed an improvement of 8 mV compared to 
the unclean electrodes. This indicated that the cleaning protocol used was 
effective at removing surface contaminants which resulted in an increase in 
electron transfer across the electrode surface. The ΔE obtained for the clean 
electrodes of 62 mV compares favourably with the theoretical value of 58 mV 
which could be achieved for a perfect gold surface. These results indicated 
that the surfaces of the electrodes tested were virtually free of imperfections 
and that cleaning protocol was effective at removing surface contaminants.  
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Table 2.9: The anodic and cathodic peak voltages and peak differences of the clean and 
unclean electrodes measured using cyclic voltammetry. 
Electrode Status Peak Peak Voltage (V) ΔE=ΔEA-ΔEC 
Left Electrode Clean 
Anodic 0.282 
0.062 
Cathodic 0.22 
Left Electrode Unclean 
Anodic 0.286 
0.07 
Cathodic 0.216 
Right Electrode Clean 
Anodic 0.282 
0.062 
Cathodic 0.22 
Right Electrode Unclean 
Anodic 0.286 
0.07 
Cathodic 0.216 
The second experiment was designed to demonstrate the intra-batch 
variability that was present across probes fabricated from the same batch. 
These probes were all packaged at the same time using the previously 
described method. Each of the cleaned probes was scanned in 5 mM 
Ferri/Ferrocyanide in 1 M KCl, as previously described, at a rate of 0.1 V/s. 
The second scan from each of the five probes was overlaid and the results 
are shown in Figure 2.29. 
 
Figure 2.29: The overlaid CV graphs from the left electrode of 5 silicon probes from the 
same batch. 
 
Impedance Probe Fabrication, Characterisation and Validation Chapter 2 
80 
 
The peak potential values for each of the anodic and cathodic peaks were 
calculated and the ΔE was determined (Table 2.10). The maximum peak 
difference observed was probe 3 (0.068 V) while both probe 6 and 8 showed 
a difference of 0.062 V. The difference between the highest and lowest ΔE 
values observed is 0.006 mV which is a percentage difference of 9.7 which 
should not significantly affect the observed values during experimental 
recordings. 
Table 2.10: The peak anodic and cathodic potentials and differences for the five silicon 
probes from the same batch scanned at a rate of 0.1 V/s. 
Probe No. ΔEA ΔEC ΔE=ΔEA-ΔEC % Difference 
2 0.286 0.22 0.066 6.5 
3 0.29 0.222 0.068 9.7 
4 0.29 0.224 0.066 6.5 
6 0.282 0.22 0.062 0 
8 0.282 0.22 0.062 0 
The final set of experiments conducted using CV was to determine the effect 
of varying scan rate on the peak current response of the probe. If the transfer 
of electrons at the electrode surface is diffusion controlled then there will be 
a linear relationship observed between the peak current and the square root 
of the scan rate. The same electrode set-up and analyte solution was used 
as in the previous experiments. The applied scan rate was varied from 0.01 
V/s to 0.1 V/s in 0.01 V increments. A total of two scans were performed at 
each rate and the second scan each time was used to graph the current 
versus potential. The left and right electrodes were graphed in Figure 2.30a 
and 2.31a respectively. It can clearly be seen from each of the graphs that 
the peak current achieved in each of the scans shows a step wise increase 
with respect to increasing scan rate. This was an expected result as an 
increase in scan rate should produce an increase in peak current [28, 41]. As 
in the previous experiment investigating the cleaning protocol and fouling, 
the probes tested showed extremely stable quasi-reversible curves at each 
scan rate analysed. This was a positive result as it showed that the prototype 
devices could obtain stable recordings across the measurement parameters. 
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In order to determine the linearity of the current response to varying scan 
rate the peak current values were graphed versus the square root of the 
scan rate for the left and right electrodes respectively (Figure 2.30b and 
2.31b). By observing the peak currents of the [Fe(CN)6]
3-/4- reaction in figures 
2.30a and 2.31a it is clear to see that the electron transfer at the surface of 
the gold electrodes undergoes a quasi-reversible one-electron redox 
reaction. Both the left and right electrodes which were measured 
independently of each other showed a linear relationship between peak 
current and the square root of the scan rate when varied between 10 mV/s 
and 100 mV/s (Figure 2.30b and 2.31b). 
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Figure 2.30: A) Cyclic voltammograms of a left working electrode displaying an increase in 
peak current with increasing scan rate from 10 mV/s to 100 mV/s. B) A graph of the redox 
peak currents -v- the square root of the scan rate from 10 mV/s to 100 m/Vs. 
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Figure 2.31: A) Cyclic voltammograms of a right working electrode, from the same probe as 
in Figure 2.34, which shows the increase in peak current with increasing scan rate from 10 
mV/s to 100 mV/s. B) A graph of the redox peak currents -v- the square root of the scan rate 
from 10 mV/s to 100 m/Vs. 
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Table 2.11: The linear regression equations for the anodic (Ipa) and cathodic (Ipc) peak 
current -v- square root of the scan rate for the left and right working electrodes for a gold 
probe. The test solution used was 5mM [Fe(CN)6]3-/4- in 1 M potassium chloride (KCl). 
Electrode Linear Regression Equation R2 Value 
Left 
Ipa (µA) = 1.3443x + 0.0483 0.9995 
Ipc (µA) = -1.4768x – 0.0269 0.999 
Right 
Ipa (µA) = 1.3283 + 0.0487 0.9996 
Ipc (µA) = -1.4216x – 0.0373 0.9987 
The results shown here indicated that the electron transfer process was 
diffusion controlled across both the left and right electrodes (Table 2.11). The 
differences in peak heights were 1.013 and 1.016 µA for the left and right 
electrodes respectively. This showed that there was no significant variation 
between the electro-active surface areas of either to the two electrodes. This 
was to be expected as the initial design was the same for both. It also 
indicated that the metal deposition process did not differ significantly 
between the left and right side of the probe. This meant that either of the 
electrodes could be used as the working electrode in a two- or three-
electrode system. 
Cyclic voltammetry was the technique used to assess the viability of the 
prototype probes for use as electrical recording devices. The experiments 
were able to show the effective current transfer across the two electrodes 
which resulted in a complete electrical circuit being created. They were also 
used to demonstrate the effect of the cleaning protocol on electron transfer 
as well as demonstrate the linear relationship between the peak current and 
a variable scan rate. Finally, the CV technique was used to demonstrate the 
intra-batch variability in the probes. When the peak currents obtained were 
compared with the theoretical values for gold electrodes there was only a 6 
mV difference between the two. This shows that the surface of the gold 
electrodes tested was in extremely good condition and the cleaning protocol 
was efficient at removing surface contamination. The use of CV to determine 
the electrochemical characteristics is a widely accepted technique that can 
produce a significant amount of information about each electrode tested. In 
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relation to this project the most significant finding was the comparability 
between the left and right electrodes of each probe which showed little to no 
difference electrochemically. This meant that it did not matter whether the left 
or right electrode was used during an experiment as they would produce 
almost identical results. It was also shown that individual probes from the 
same fabrication batch showed differences in the peak voltage of less than 
10% when measured at the same scan rate after cleaning. This finding in 
combination with the surface characterisation techniques previously 
discussed show that the prototype device fabrication methods produced 
stable and reproducible probes which could be used for the purpose of 
recording electrochemical signals during future experimental testing. 
2.6.1.9 Electrical Impedance Testing 
The final experiment in this section was carried out to determine the 
sensitivity of the silicon probes when moving between layers of different 
conductivity. The materials chosen to create the layers were gelatine and 
lard. These were used because of the significant difference in the expected 
modulus of the impedance between the two materials. The left and right 
electrodes of three probes were tested in triplicate. The average value for 
one probe is shown in Figure 2.33. Figure 2.32 shows a silicon probe 
inserted in to the gelatine layer during the electrical impedance testing 
experiment. The layer of lard (white) can clearly be seen immediately above 
the gelatine layer (orange). 
 
Figure 2.32: A silicon probe inserted in to the gelatine (orange) and lard (white) model during 
the electrical impedance testing. 
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Figure 2.33: The average of the fixed frequency (4,500 Hz) recordings obtained as one of 
the silicon probes was moved between layers of gelatine and lard at 30 second intervals. 
The results displayed here showed that the silicon probe was extremely good 
at detecting the change in the modulus of the impedance at the tip of the 
device immediately after it was moved. This was a positive result as it 
showed that the probes were able to maintain a steady state of recording in a 
homogenous substance while instantly detecting a change upon probe 
movement. It is possible that there was some carry-over of material when the 
device was moved from one layer to the other. However, from the data 
presented this does not appear to have affected the probes ability to detect 
the change the layer impedance. The major obstacle in this experiment was 
the Autolab potentiostat instrument. This apparatus did not allow each of the 
fixed frequency measurements to be taken at set time intervals. This meant 
that the repeated recordings had a different number of data points 
accounting for the 120 second period after the initial recording. In order to 
overcome this problem the recordings were divided into four sections 
according to the corrected time value determined by the Nova 1.10 software 
(Table 2.12). 
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Table 2.12: The corrected time values for each of the gelatine and lard layers tested. 
Layer Corrected Time (s) 
Gelatine (1) 0-30 
Lard (1) 31-60 
Gelatine (2) 61-90 
Lard (2) 91-120 
The corrected time value for each data point was averaged across each of 
the triplicate recordings to provide a uniform value for the graph of the 
average impedance values. For future testing involving the Autolab 
instrument it would be necessary to design a protocol for the fixed frequency 
recordings that would be more suitable for multi-layer testing such as this. A 
period of adjustment after the movement of the probe to the lard layer was 
clearly evident in most of the recordings as the potentiostat adjusted to the 
significant change in the impedance of each layer. This resulted in some 
recordings being as many as 10 seconds apart which would be unacceptable 
in the clinical setting in which we envisage these probes being used. 
2.6.2 Stainless Steel Probes 
The development of a prototype electrical impedance device involved a 
number of different strategies. One of these strategies was to fabricate used 
a stainless steel substrate deposited with gold electrodes. Figure 2.34 shows 
a stainless steel wafer that was patterned with 12 pairs of gold electrodes 
and passivated probe tracts. In the first fabrication run using the stainless 
steel wafers an insulation layer of 250 nm of SiO2 was deposited on to the 
surface. It was discovered after the fabrication process was completed that 
the deposition process had not been successful due to short-circuits present 
in the probes. It was suspected that the insulation layer deposited on to the 
stainless steel was not sufficient to provide to isolate the substrate from the 
electrode metals. It was decided to increase the SiO2 layer thickness to 1µm 
in order to try and produce a usable prototype stainless steel impedance 
probe. The increase in insulation layer thickness did not prevent the short-
circuiting of the probes when tested using a multimeter device which will be 
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described in a later section. Further analysis of the probes surface using 
SEM imaging was undertaken to determine if a cause of the short-circuiting 
could be determined and the results of this will be presented in a later 
section in this chapter. Dicing of the wafer proved to be particularly difficult 
given the hardness of the stainless steel and specialist cutting blades were 
required for this task. It was not possible to shape the recording ends of each 
of the probes which would have aided the insertion of the prototypes into 
tissue samples.  
 
Figure 2.34: A close-up view of a patterned stainless steel wafer with 12 electrode pairs. 
2.6.2.1 Scanning Electron Microscope 
The fabricated stainless steel probes were imaged using the SEM to 
determine the cause of the short-circuiting in the devices. Figures 2.34 and 
2.35 show a selection of the high-resolution micrograph images obtained 
from the patterned stainless steel probes. Figures 2.35 A and B showed the 
electrode surface of a stainless steel probe at 288 and 1,500x magnification. 
A significant defect in the gold electrode surface could clearly be seen and 
was measured as having an approximate diameter of 29.92 µm. This defect 
penetrated through the entire thickness of the gold and possibly the 
underlying titanium layer as well. This type of defect would certainly be 
significant enough to cause a critical short-circuit in the packaged devices.  
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Figure 2.35: A) A 288x magnification SEM image of the recording electrode pads of a 
stainless steel prototype device. B) A 1,500x magnification SEM image of a surface defect 
identified in the left electrode of the stainless steel probe imaged in A). An approximate 
measurement of the width of defect is displayed on the image. 
Figure 2.36 showed a 305x magnification image of the dual gold tracks of a 
stainless steel device. It was clearly evident that the gold was not continuous 
along the entire length of either tract. The insulation layer which was 
deposited over the gold electrode tracts should have protected the gold from 
significant mechanical damage. Therefore, it was possible that either the 
damage occurred during the fabrication process before the insulation layer 
was deposited or that the underlying materials did not provide a suitable 
attachment point for the gold. It was clearly evident from the image that the 
gold tracks were not continuous and would not be capable of conducting an 
electrical signal from the recording electrodes to the output electrodes at the 
opposite end of the probe. 
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Figure 2.36: A 305x magnification SEM image of the insulated gold tracks of a stainless 
steel probe. 
From the SEM micrographs it was clear to see that a number of critical 
defects were present in the devices that were imaged. The images obtained 
of the surface of the stainless steel probes showed significant defects in the 
gold electrode pads and tracts as well as the surrounding substrate. It was 
hypothesised that the cause of the short circuiting of the stainless steel 
probes was as a result of these critical defects distributed across the probe 
surfaces. These defects produce a path of least resistance along which the 
electrical current can flow which prevents the recordings being obtained for 
the recording electrodes. Optical profilometry of the bare stainless steel 
wafers was conducted to investigate this hypothesis and the results are 
presented in Section 2.6.2.4. 
2.6.2.2 Energy-dispersive X-ray Analysis 
An EDX detection unit was used in conjunction with the SEM to analyse the 
materials presents on the surface of a stainless steel probe. A spectrum was 
produced by analysing the surface of one of the gold electrodes deposited on 
the substrate (Figure 2.37). 
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Figure 2.37: An EDX spectrum of a gold electrode on a stainless steel substrate. 
The peaks which were determined showed the presence of gold, silicon, 
chromium, iron, carbon and nitrogen. These results were as expected 
because gold was the deposition metal used to pattern the electrode and 
stainless steel was the major substrate upon which the probes were created. 
The exact composition of stainless steel varies depending on its 
manufactured grade but will certainly include a mixture of iron, carbon and 
chromium. The spectra produced on the different probes analysed were 
almost identical to the one displayed. This was a positive result as it meant 
that the multiple deposition processes were successful in patterning the 
required materials on to the substrate surface.  
2.6.2.3 Continuity Testing 
Using the previously described protocol (Section 2.5.3), the multimeter probe 
was used to test the continuity of the electrical tracks and identify any 
possible short-circuits.  This test was used as a qualitative analysis of the 
electrical conductivity of the stainless steel probes. As a result, quantitative 
data was not collected. Any of the probes which were identified as having an 
issue with continuity were discarded as they were not suitable to be 
packaged for performing electrical recordings. The initial batch of patterned 
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stainless steel wafers contained no functional probes which indicated that 
there was a significant issue with the fabrication process. In order to 
overcome this problem it was decided to increase the thickness of the 
insulation layer deposited during the fabrication process. However, an 
increase in the thickness of the SiO2 insulation layer from 250 nm to 1 µm 
was not sufficient to prevent this problem. It was possible that the thickness 
of the materials deposited on the surface of the stainless steel was not 
sufficient to overcome a very large surface roughness of the stainless steel 
wafer. 
2.6.2.4 Optical Profilometry 
Optical Profilometry was used to quantitatively assess the surface roughness 
of the bare stainless steel wafer used in the fabrication process. The major 
benefit of using the optical profilometer was the ability to obtain a 
measurement of the surface roughness which could not be done using AFM 
as described for the gold electrodes on the silicon probes. A total of 5 
measurements across 4 different areas one stainless steel wafer were 
performed. For each of the recordings performed a two-dimensional colour 
image was produced which represented the combined constructive and 
destructive interference from the light reflected from the surface of the wafer 
and the reference mirror. Figure 2.38 shows a representative image from one 
of the scans performed across a 0.091 mm2 area of the stainless steel 
surface. 
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Figure 2.38: A representative image from one of the optical profilometry scans performed on 
the surface of the bare stainless steel wafer. 
The values obtained from each of the five measurements were averaged to 
show the surface topography profile across the stainless steel wafer. The 
maximum height difference across the recorded areas was 1.01 um. The 
graph showed that the surface of the stainless steel wafer contained many 
significant peaks and crevices which could inhibit the deposition of material 
on to the surface during fabrication (Figure 2.39). 
 
Figure 2.39: A graph of topographical profile of the surface of the bare stainless steel wafer. 
 
Impedance Probe Fabrication, Characterisation and Validation Chapter 2 
94 
 
The calculated RMS data obtained from each of the optical profilometer 
scans was averaged for each of the measurement sites and then averaged 
to produce a combined value for surface of the stainless steel. This value 
was then graphed as the RMS ± S.D. (Figure 2.40). The mean value for the 
stainless steel wafer was 314 nm. This value correlated well with the images 
obtained from the SEM which showed that the deposition of gold across the 
electrode surface was significantly inhibited and may have been as a result 
of the initial surface roughness of the stainless steel wafer.  
 
Figure 2.40: The mean RMS roughness of the surface of the stainless steel wafer obtained 
using optical profilometry. N=1; Mean ± S.D. 
2.6.2.5 Breakage Testing 
It was hoped that breakage strength testing could be performed on the 
stainless steel probes. This was not possible as the application of vertical 
force on to the stainless steel would not result in a critical failure of the 
device. Therefore, it was not possible to conduct this analysis and it was not 
possible to compare the values obtained for the silicon probes to the 
stainless steel ones.  
2.7 Conclusions 
In this chapter a novel microelectrode for use in testing biological tissues was 
fabricated on to silicon and stainless steel substrates using semiconductor 
fabrication techniques including photolithography and etching [1, 42-44]. The 
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configuration included two gold microelectrodes. One of the most significant 
obstacles encountered during the course of this entire project was the issue 
of device construction using stainless steel as the base substrate. The 
original concept was to use metal deposition processes to pattern the dual-
electrode structure on to off-the-shelf hypodermic needles. This would have 
provided a sufficiently strong base material that would also have been 
suitable for use in the clinical environment. The first problem that was 
encountered was that the methods of metal deposition used in 
semiconductor fabrication were only suitable for use with flat substrates. This 
immediately ruled out the use of hypodermic needles for prototype assembly 
as reproducible electrode tracts could not be fabricated on to the curved 
needle shaft. The first alternative to the needles was to use flat stainless 
steel wafers as the substrate for the electrodes. This would remove the 
problem of the curved surface presented by the needles. However, the final 
stainless steel probes were unusable due to an issue with short-circuiting 
that developed following metal deposition. It was hypothesised that the 
reason for this was as a result of the initial surface roughness being too high 
to allow reliable metal deposition. The results of the optical profilometry 
measurements showed that the surface roughness of the stainless steel 
wafer was sufficiently high to significantly impact on the deposition of 
material across the surface of the wafer. Using the profilometry instrument it 
was possible to obtain an approximate surface roughness measurement but 
it was important to note that there were crevices distributed across the wafer 
which may have been as deep as 3 µm or more. The total thickness of the 
deposited materials is approximately 790 nm which was insufficient to 
overcome the issue of the crevices found across the wafer surface.  These 
significant defects in the surface of the stainless steel would be sufficient to 
impede the uniform deposition of materials on to the wafer that was apparent 
using SEM imaging of the patterned devices. Given the time constraints 
associated with this project it was not possible to investigate any potential 
methods of resolving this methodological challenge which meant that it was 
not possible to use the stainless steel probes for the purpose of the electrical 
recordings described in later sections. It was decided to replace the stainless 
steel substrate with a silicon wafer to improve the success rate of the 
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fabrication process and to produce reliable and functional electrochemical 
devices. The main body of work in this chapter focused on the surface and 
electrochemical characterisation of the silicon prototypes. Using a number of 
experimental techniques the probes were shown to be clean, defect free and 
electrochemically stable. The results outlined in this chapter show that by 
utilising the silicon substrate instead of the stainless steel substrate it was 
possible to produce a functional prototype device that was suitable for 
performing electrochemical measurements. 
2.7.1 Future Work 
The future of prototype development in the production of this impedance 
probe must focus heavily on the substitution of silicon as the substrate 
material. Currently accepted biomedical materials such as stainless steel or 
titanium could be investigated as they have been shown to have properties 
applicable to a range of clinical challenges. In particular the tensile strength 
of these materials would far exceed that of silicon which would reduce 
breakage of the devices. This would significantly reduce the number of 
broken packaged devices as well as reduce the potential risk of the device 
failing while under strain in a patient’s body. It is also envisaged that the 
currently used packaging of the device would be evaluated and refined to 
produce a “plug-and-play” device which could be fitted directly into an 
adapter which would contain the electrical contacts [45, 46]. This would 
significantly reduce the handling time for each probe during the production 
phase. It would also reduce the risk of cross-contamination as the probe 
would become a disposable device that could be disconnected and 
discarded after each use. The construction of a very streamlined and easy to 
use device is essential given the niche in the market which this device is 
trying to fill. The device must be functional at the bedside during the breast 
cancer screening process. It must have minimal effect on patient comfort 
while increasing the amount of information available to the doctor at the 
bedside. The final iteration of the impedance probe must be as minimally 
intrusive to the screening timeline while maximally improving the screening 
and detection of breast cancer in patients. It would also be important to 
engage with the manufacturers of the potentiostat instrument to better align 
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the two technologies and to provide a seamless user experience for the 
clinician at the bedside.  
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3. Validation of Biocompatibility and Impedance in Biological Samples 
3.1 Objectives 
The objectives of this experimental chapter are to evaluate the 
biocompatibility of the prototype devices and to determine their ability to 
differentiate between tissue types using ex vivo meat samples. In addition, it 
was planned to evaluate the prototype probes in cell culture media, to 
investigate the electrical impedance of immortalised cell lines. The outcome 
of these experiments would provide the foundation for a first in-human 
clinical trial to differentiate between healthy and cancerous tissue in 
surgically removed breast cancer samples. 
3.2 Introduction 
In this chapter the previously fabricated and characterised silicon and 
stainless steel probes will be assessed for biocompatibility and impedance 
functionality. The experiments were performed in the Cell Culture and 
Bioanalysis facilities in TNI. In recent years there has been a significant 
amount of research conducted using cancer cell lines for the study of early 
cancer diagnosis and the development of novel cancer therapies [1]. In the 
first part of this chapter a number of different immortalised cell lines were 
utilised during the testing process. These included A549 lung cancer [2], HT-
29 colorectal cancer [3] and most significantly Michigan Cancer Foundation 7 
(MCF-7) [4] which is a female breast cancer cell line. These cells were grown 
on the surface of the devices and imaged using three techniques: light, 
fluorescence and SEM. In addition to the imaging of cells on the device 
surface a resazurin assay was performed on fragments of the silicon probes 
to determine the percentage cell viability of the MCF-7 cells grown for 24 hr. 
This provided a quantitative analysis of the biocompatibility of the silicon 
devices and confirmed the qualitative images obtained previously. In order to 
obtain impedance modulus recordings from the seeded MCF-7 cells on the 
packaged silicon prototypes it was necessary to design and fabricate device 
holders that would maintain a defined volume of liquid on the probe surface. 
The holders were produced in the Mechanical Workshop in TNI and used to 
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aid in the culturing of cells on the probe surface and the results of the 
experiments are outlined in this chapter. 
In the second section of this chapter the working silicon prototypes were 
used to record impedance modulus data from a range of meat tissue 
samples including beef, lamb and pork. In each case areas of fat and muscle 
were tested and compared to determine if the probe was capable of 
differentiating between the two tissue types. Experiments were also carried 
out to determine the effect of applying external pressure on the probe during 
testing as well as the effect of penetration depth on the electrical recordings 
obtained. 
3.2.1 Cell Culture 
Cell culture is a term used to describe the method by which primary and 
immortalised cell lines can be grown and maintained in an aseptic 
environment in a laboratory setting. The cell culture facility in the TNI is 
composed of two separate laboratories. One is used for the growth of 
primary cell lines and the other is used for the culture of immortalised cell 
lines. The immortalised cell culture laboratory was used to perform the 
experimental work described in this chapter. The laboratory contains 
specialist instruments including: 
1) SpectraMax Gemini EM Microplate Reader  
2) Airstream Class II Biological Safety Cabinet E-Series  
3) Panasonic MCO-18AC-PE CO2 Incubator  
4) Hettich Universal 320 Centrifuge  
5) Bright-Line™ Haemocytometer 
6) Olympus CKX41 Inverted Microscope  
Each of these components is required to allow the aseptic growth 
environment to be maintained throughout the experimental process. 
Primary cell lines are isolated from tissues of interest and are grown under 
artificial conditions until they reach confluency. Once these cells have been 
subcultured in to a new flask they become a cell line. The number of 
replications these cells can undergo is limited by genetic factors. Eventually, 
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senescence will occur, the cell will fail to replicate and will die [5]. The major 
influencer of cellular senescence is the enzyme telomerase which maintains 
telomere end length during replication. Somatic cells which contain little or no 
telomerase experience successive telomere shortening which eventually 
elicits a senescence checkpoint [6, 7]. Through a process known as 
transformation, finite cell lines can be modified to allow them to replicate 
indefinitely [5]. These are known as immortalised cell lines. The development 
of these cell lines which have almost unlimited replication potential has 
resulted in their use across many research applications. These include cell 
growth and migration; drug toxicity and compound screening; gene 
regulation and biocompatibility testing [8, 9]. The increasing use of cell 
culture to determine drug effect and toxicity has coincided with the worldwide 
push to reduce the number of animals used for screening new compounds 
and products [9]. A number of assays have been developed that utilise cell 
culture techniques to determine the biocompatibility of medical device 
components [10]. One of the most common outcomes of biocompatibility 
assays is to determine cell viability using a quantitative analysis method. The 
resazurin cell viability assay is an example of this type of test. 
3.2.2 Resazurin Assay 
A resazurin cell viability assay, which was performed as part of this research, 
measures the reduction of blue non-fluorescent 1,2,3 Resazurin dye (7-
hydroxy-3H-phenoxazin-3-one10-oxide) to pink fluorescent resorufin by 
metabolically active cells. This is achieved by the action of the mitochondrial 
electron transport chain, and indicates cell viability [11, 12]. Cell health can 
be monitored by numerous methods. Plasma membrane integrity, DNA 
synthesis, DNA content, enzyme activity, presence of adenosine 
triphosphate (ATP) and cellular reducing conditions are known indicators of 
cell viability and cell death. Resazurin assays are used as cell health 
indicators by using the reducing power of living cells to quantitatively 
measure the proliferation of human and animal cell lines, bacteria, plant, and 
fungi. It also allows the establishment of the relative cytotoxicity of agents 
within chemical classes [13]. When cells are alive they maintain a reducing 
environment within the cytosol of the cell. Resazurin is a non-toxic, cell 
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permeable compound that is blue in colour and non-fluorescent. Upon 
entering cells, resazurin is reduced to resorufin, a compound that is red in 
colour and highly fluorescent. Living cells continuously convert resazurin to 
resorufin, increasing the overall fluorescence and colour of the media 
surrounding the cells. The reduction of resazurin correlates with the number 
of live mammalian cells present. The level of reduction was quantified 
through measurements with a spectrophotometer at 445 nm and 590 nm 
emission frequencies [14]. 
3.2.3 Cell Culture Holders 
In order to obtain impedance modulus measurements from immortalised cell 
lines using the silicon probe devices, the design and fabrication of a 2-part 
Perspex holder was necessary. The holder was designed in collaboration 
with Dr Walter Messina, Life Science Interface Group, Tyndall National 
Institute. The purpose of the unit was to provide a suitable volume in which to 
culture the cell lines, while providing a level surface on which to grow the 
cells. This was not previously possible due to the manner in which the 
electrical wires were packaged. This meant that any cell suspension or 
media applied to the probe would dissipate from the surface immediately. 
The holders were fabricated in the Mechanical Workshop, TNI by Mr Donal 
O’Sullivan. The design drawings submitted for the work (Figure 3.1 A-C) 
display the expanded, constructed and side-view profiles of the holder. The 
lower part of the holder contained a recess that matched the width and depth 
of the individual silicon probes. This allowed the surface of each probe to sit 
flush with the surface of the holder. The upper part of the holder contained a 
well that allowed 1 ml of culture media to be maintained above the surface of 
the probe. At the bottom of the well was a hole to allow the transfer of liquid 
and cells on to the silicon device. Immediately below this opening a rubber 
O-ring was inserted which would form a watertight seal between the probe 
surface and the media well. The maximum dimension of this O-ring was 
limited by the width of the silicon probes. This resulted in a very narrow 
opening through which the culture media could pass. The two parts of the 
holder were secured together with four screws inserted at each of the 
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corners. The dimensions for the cell culture holders are outlined in Appendix 
6.7. 
 
Figure 3.1: A) The expanded view of the cell culture probe holder including an O-ring which 
forms a water-tight seal. B) The design drawing of the constructed cell culture holder and 
probe. C) The side-profile view of the cell culture probe holder. 
3.2.4 Pressure Testing 
One of the investigations undertaken during this project was to determine the 
effect of externally applied pressure on the measurement of impedance 
modulus recordings in meat tissue samples. Due to the nature of the tissues 
tested using the prototype silicon probe it was sometimes necessary to make 
an incision into the tissue to allow device placement. These tissues were 
then apposed to the probe surface by pressing them together by hand. This 
could potentially result in a variable pressure being applied to the electrode 
surface during the impedance recordings. In order to determine the effect of 
this pressure on the values obtained, a series of recordings were performed 
with different sources of externally applied pressure. The testing was 
performed using two different probes, which had previously been cleaned; to 
measure beef rib fat and muscle at room temperature. The purpose of this 
experiment was not to determine the pressure which was being applied to 
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the probe surface but to asses if variably and constantly applied pressure 
produced the same impedance modulus values. 
3.2.5 Depth Testing 
In addition to the investigation of the effect of externally applied pressure on 
impedance recordings an experiment was carried out to determine if the 
depth of probe insertion had an effect on the impedance obtained values. 
The design of the silicon probes provided an insulation layer over the length 
of the gold tracts with the exception of the electrodes and output pads which 
were left exposed. This should mean that the depth of insertion does not 
influence the recordings obtained. However, it was necessary to confirm if an 
increase in the depth of recording caused a change in the impedance 
modulus measurements. In order to determine the effect of depth on the 
observed values, a silicon probe was tested at a number of depths in a block 
of gelatine with multiple frequency sweep recordings taken each time.  
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3.3 Experimental Details  
3.3.1 Reagents and Materials 
MCF-7 cells, Minimum Essential Media Eagle (MEME), Trypsin, 
Ethylenediaminetetraacetic acid (EDTA), Foetal Calf Serum, L-Glutamine, 
Non-essential amino acid (NEAA), A549 cells, T75 cell culture flask, 1 ml 
cryogenic vials, 15 ml centrifuge tube, Hank’s balanced salt solution (HBSS), 
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12), 
Penicillin, Streptomycin, HT-29 cells, McCoy’s 5A media, 80% ethanol, 
Propidium iodide (PI), Petri Dish, Plastic Pipette, 6-well plate, poly-L-lysine, 
Primary fixative solution containing glutaraldehyde and paraformaldehyde, 
sodium cacodylate/HCl buffer, osmium tetroxide (OsO4), Acetone, 
Tetramethylsilane (TMS), Double-sided carbon tape, Resazurin sodium salt, 
0.45 nm pore syringe filter, Triton-x (All chemicals and reagents were 
sourced from Sigma-Aldrich Ltd., Dublin, Ireland and were analytical grade); 
Beef, lamb and pork samples (were all sourced from O’Mahony Butchers, 
Cork, Ireland); Powdered gelatine (Vege-gel and Gelatine) (was purchased 
from Dr Oetker, Leeds, United Kingdom). Viton O-rings (were sourced from 
Radionics, Dublin, Ireland).  
3.3.2 Instrumentation 
Quorum Q150T Turbo-pumped Sputter Coating System (Quorum 
Technologies Ltd., East Sussex, United Kingdom); Jeol JSM 5510 Scanning 
Electron Microscope (Jeol (U.K.) Ltd., Herts, United Kingdom); Autolab 
PGSTAT204 with FRA32M module (Metrohm UK Ltd, Runcorn, United 
Kingdom); Data-Therm IR thermometer (Guangxhou Jinxinbao Electronic 
Co. Ltd., Guangzhou, China); SpectraMax Gemini EM Microplate Reader 
(Molecular Devices (UK) Ltd., Berkshire, United Kingdom); Airstream Class II 
Biological Safety Cabinet E-Series (Esco GB Ltd, Yorkshire, United 
Kingdom); Inverted-phase contrast microscope, Weitlaner Tissue Retractor 
(Aesculap Inc., Pennsylvania, USA); MCO-18AC-PE CO2 Incubator 
(Panasonic Biomedical Sales Europe B.V., Leicestershire, United Kingdom); 
Hettich Universal 320 Centrifuge (DJB Labcare Ltd., Buckinghamshire, 
United Kingdom); Bright-Line™ Haemocytometer (Sigma-Aldrich Ltd., 
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Dublin, Ireland); Olympus BX51-P Fluorescent Microscope (Mason 
Technologies Ltd., Dublin, Ireland); Olympus CKX41 Inverted Microscope 
(Mason Technologies Ltd., Dublin, Ireland), Cimarec SP131325Q Ceramic 
Hotplate (Fisher Scientific Ltd., Dublin, Ireland); Grant SUB Aqua 18 Plus 
Waterbath (Grant Instruments (Cambridge) Ltd, Cambridgeshire, United 
Kingdom). 
3.4 Procedures 
3.4.1 Cell Culture 
Three different immortalised cell lines were used during this series of 
experiments. The cell types used were: 
1) A549 – A human alveolar adenocarcinoma basal epithelial cell line 
derived from an explanted tumour of a 58 year old Caucasian male. 
2) HT-29 – A human colorectal adenocarcinoma epithelial cell line 
derived from a 44 year old Caucasian female. 
3) MCF-7 – A human adenocarcinoma epithelial cell line derived from a 
pleural effusion of a metastatic invasive breast ductal carcinoma 
tumour form a 69 year old female. 
Each cell type had specific culture media requirements and subculture 
procedures which will be described in the following sections. The MCF-7 cell 
line was chosen as it is commonly used as a model of breast cancer for in 
vitro testing. The A549 and HT-29 cell lines were used to validate the results 
obtained with the MCF-7 cell line. 
3.4.1.1 MCF-7 Cell Culture Preparation 
The MCF-7 cells used during this project were purchased from Sigma-Aldrich 
Ltd. (Dublin, Ireland) and were stored in liquid nitrogen prior to being 
cultured. All cell culture work was performed in a Class II biological safety 
cabinet (Airstream Class II Biological Safety Cabinet E-Series, Esco GB Ltd, 
Yorkshire, United Kingdom) in a dedicated immortalised cell culture 
laboratory (Figure 3.2).  
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Figure 3.2: The Class II biological safety cabinet in the Tissue Culture Facility in Tyndall 
National Institute. 
To begin growth of the cells they were first removed from liquid nitrogen 
storage and defrosted in a water bath at 37°C (Grant SUB Aqua 18 plus 
Waterbath, Grant Instruments (Cambridge) Ltd, Cambridgeshire, United 
Kingdom). The entire contents (1 ml) of the cryogenic vial were then pipetted 
into a T75 cell culture flask. The MCF-7 cells were cultured in MEME 
complete media (Sigma-Aldrich Ltd., Dublin, Ireland) as per the 
manufacturer’s guidelines (Table 3.1). 30 ml of the complete media was 
added to the flask which was then placed in an incubator at 37C and 5% 
carbon dioxide (CO2) until the cells reached approximately 70% confluency 
[15].  
Table 3.1: MEME complete media composition. 
MEME Complete Media Volume (ml) 
MEME Media 440 
Foetal Calf Serum 50 
L-Glutamine 5 
NEAA  5 
Total 500 
To remove the cells from the flask the culture media was first removed using 
a sterile plastic pipette and the flask was rinsed with 4 ml of pre-warmed 
Trypsin/EDTA. 3ml of trypsin/EDTA was added to the flask which was then 
incubated for 8 min to allow the cells to detach. 7 ml of MEME complete 
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media was then added to inactivate the trypsin/EDTA. The cell suspension 
was removed and placed in a clean 15 ml centrifuge tube and the cells were 
centrifuged for 5 min at 1,000 rpm. The supernatant was removed and the 
cell pellet was re-suspended in 5 ml of fresh complete media. A cell count 
was performed as described in Equation 3.1. 10 μl of the suspension was 
added to 90 μl of complete media.  
  
Figure 3.3: The haemocytometer used during the cell culture counts. 
10 μl of this solution was then pipetted onto a haemocytometer (Figure 3.3) 
and a glass coverslip was placed on top. In total five boxes were counted for 
each sample (Figure 3.4). 
 
Figure 3.4: The layout of a haemocytometer with the 5 large boxes highlighted which are 
counted during a cell count. Modified by Author from Reference [16]. 
The equation was used to estimate the total cell number in suspension 
(Equation 3.1):  
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Cells/ml =
No. of Cells x 10(Dilution Factor) x 104 (Constant)
5 (Boxes Counted)
 
Equation 3.1: Calculation of number of cells per millilitre of cell suspension. 
The total number of cells counted was multiplied by the dilution factor and 
the haemocytometer constant of 104. This value is then divided by 5 which 
was the number of boxes counted in each case. The final value provided an 
approximation of the number of cells per millilitre of cell suspension. To 
continue the growth of the cell line, 1 ml of cell suspension was pipetted in to 
a clean T75 flask and 29 ml of complete media was added. The flask was 
then placed in an incubator at 37°C and 5% CO2 for 48 hours. 
3.4.1.2 A549 Cell Culture Preparation 
The A549 cells used during this project were initially stored in liquid nitrogen 
in the Life Science Interface laboratory, Tyndall National Institute. To begin 
growth of the cells they were first removed from storage and defrosted in a 
water bath at 37°C. The A549 cells were cultured in DMEM/F12 complete 
media (Sigma-Aldrich Ltd., Dublin, Ireland) as per the manufacturer’s 
guidelines (Table 3.2). The entire contents (1 ml) of the cryogenic vial were 
then pipetted into a T75 cell culture flask. 30 ml of the complete media was 
added to the flask which was then placed in an incubator at 37C and 5% 
CO2 until the cells reached approximately 70% confluency [17].  
Table 3.2: DMEM/F12 complete media composition. 
DMEM/F12 Complete Media Volume (ml) 
DMEM/F12 Ham Media 440 
Foetal Calf Serum 50 
L-Glutamine 5 
Penicillin/Streptomycin  5 
Total 500 
To remove the cells from the flask the culture media was first removed using 
a sterile plastic pipette and two washes were performed with pre-warmed 
HBSS (Sigma-Aldrich Ltd., Dublin, Ireland) and 4ml of trypsin/EDTA was 
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added. The flask was then incubated for 5 min to allow the cells to detach. 6 
ml DMEM/F12 complete media was then added to inactivate the 
trypsin/EDTA. The cell suspension was removed and placed in a clean 15 ml 
centrifuge tube and the cells were centrifuged for 5 min at 1,000 rpm. The 
supernatant was removed and the cell pellet was re-suspended in 5 ml of 
fresh complete media after which the cells were then counted using a 
haemocytometer as previously described. To continue the growth of the cell 
line, 1 ml of cell suspension was pipetted in to a clean T75 flask and 29 ml of 
complete media was added. The flask was then placed in an incubator at 
37°C and 5% CO2 for 48 hours. 
3.4.1.3 HT-29 Cell Culture Preparation 
The HT-29 cells used during this project were stored in liquid nitrogen prior to 
being cultured. To begin growth of the cells they were first removed from 
storage and defrosted in a water bath at 37°C. The HT-29 cells were cultured 
in McCoy’s 5A complete media (Sigma-Aldrich Ltd., Dublin, Ireland) as per 
the manufacturer’s guidelines (Table 3.3). The entire contents (1 ml) of the 
cryogenic vial were then pipetted into a T75 cell culture flask. 30 ml of the  
complete media was added to the flask which was then placed in an 
incubator at 37 C and 5% CO2 until the cells reached 70% confluency [18].  
Table 3.3: McCoy’s 5A complete media composition. 
McCoy’s 5A Complete Media Volume (ml) 
McCoy’s 5A Media 450 
Foetal Calf Serum 50 
Total 500 
To remove the cells from the flask the culture media was first removed using 
a sterile plastic pipette and two washes were performed with pre-warmed 
HBSS and 3 ml of trypsin/EDTA was added.  The flask was then incubated 
for 25 min to allow the cells to detach. 7 ml of McCoy’s 5A complete media 
was then added to inactivate the trypsin. The cell suspension was removed 
and placed in a clean 15 ml centrifuge tube and the cells were centrifuged for 
5 min at 1,000 rpm. The supernatant was removed and the cell pellet was re-
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suspended in 5 ml of fresh complete media. A cell count was performed as 
described previously. To continue the growth of the cell line, 1 ml of cell 
suspension was pipetted in to a clean T75 flask and 29 ml of complete media 
was added. The flask was then placed in an incubator at 37°C and 5% CO2 
for 48 hours. 
3.4.1.4 Silicon Biocompatibility 
In order to assess the biocompatibility of the silicon probes, unpackaged 
devices were seeded with cells in a plastic Petri dish. MCF-7 and HT-29 cells 
were seeded at an optimum density of 400,000 cells per silicon. A control 
device containing media only was used each time. The required volume of 
cell suspension was carefully pipetted onto each probe and the Petri dishes 
were placed in the incubator at 37°C and 5% CO2 for 1 hr to allow the cells to 
attach. The final volume in each dish was then made up to 14 ml with the 
appropriate complete media. The devices were placed on the incubator for 
either 24 or 48 hr before being imaged. 
3.4.1.5 Resazurin Assay 
Resazurin sodium salt (Sigma-Aldrich Ltd., Dublin, Ireland) was dissolved in 
HBSS at a final concentration of 440 µM (Equation 3.2). The molecular 
weight of resazurin = 251.17 g/l. 
440 µM = 251.17 g x 440 x 10−6 = 0.110515 g/l 
Equation 3.2: The calculation of the concentration of resazurin in solution. 
Resazurin (440 µM) was sterile filtered using a syringe with 0.45 nm pores 
filters (Sigma-Aldrich Ltd., Dublin, Ireland) prior to use in cell culture. It was 
then diluted in complete media at 10% to provide a final concentration of 44 
µM to be added to cells. 
The resazurin assay was conducted by Ms Michelle Fitzgerald in the Cell 
Culture Laboratory in Tyndall National Institute. The MCF-7 cell line was 
used to demonstrate the biocompatibility of the silicon probe devices. The 
percentage viability of the cells was analysed using a spectrophotometer to 
assess the colour change produced by living cells. The cells were seeded on 
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sections of the silicon probes in a 24-well cell culture plate. The plate layout 
is shown in Table 3.4: 
Table 3.4: The layout used for the resazurin assay experiments. 
Variable Replicate 1 Replicate 2 Replicate 3 
1 Positive Control Positive Control Positive Control 
2 Test Test Test 
3 Negative Control Negative Control Negative Control 
4 Resazurin Blank Resazurin Blank Resazurin Blank 
An optimum density of 500,000 cells was seeded in the positive, test and 
negative wells. Complete media was added to a final volume of 1 ml. The 
negative control wells had 10 µl of Triton-x added with the complete media. 
Triton-x is a laboratory detergent which was used to kill cells in culture. At 24 
hr the complete media was removed and 1 ml of 10% resazurin and 
complete media was added to each of the 12 wells shown in Table 3.4. The 
plate was left for 3 hours to allow the colour change to develop. Each well of 
the plate was then read using a spectrophotometer. The results were 
exported to Excel where they were analysed and graphed. 
3.4.1.6 Scanning Electron Microscope 
MCF-7 cells were cultured for seeding on the silicon devices for imaging 
using an SEM microscope. The cell number was initially optimised by Ms 
Michelle Fitzgerald in the Cell Culture Facility in Tyndall National Institute. 
The cells were grown in T75 cell culture flasks and then seeded at a density 
of 450,000 cells per device as previously described. The probes were 
incubated at 37°C for 24 hours before being fixed for evaluation by SEM. The 
cell media was removed and substituted with a primary fixative solution 
containing glutaraldehyde and paraformaldehyde in 0.1 M sodium 
cacodylate/HCl buffer pH 7.2. After the cells had been immersed in the 
fixative for 90 minutes, they were washed with an SEM buffer for 30 minutes 
before being immersed in OsO4 for 120 minutes (Table 3.5). The OsO4 is 
used as a stain for lipids in membranous structures and vesicles. Following 
this the samples were soaked again in SEM buffer overnight. The 
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dehydration process consisted of several consecutive washes with a solution 
containing an increasing concentration of acetone (Table 3.6). 
Table 3.5: The cell fixation process required for SEM imaging. 
Fixation Day 1 
Primary Fixative 90 min 
Buffer Wash 30 min 
OsO4 120 min 
Buffer Held Overnight 
Table 3.6: The acetone dehydration process required for SEM imaging 
Dehydration Day 2 
25% Acetone 15 min 
50% Acetone 15 min 
75% Acetone 15 min 
100% Acetone 15 min 
100% Acetone 15 min 
100% Acetone 15 min 
100% Acetone 15 min 
Once the Acetone wash sequence was completed, the cells were transferred 
into a TMS solution for 15 minutes and then air-dried in a fume hood. The 
TMS solution has a low boiling point (26.3°C) and is used to allow tissue 
drying while significantly overcoming the deleterious effects of air-drying. 
Samples were then mounted on metal stubs using double-sided carbon tape 
and sputter coated with an approximate 5 nm layer of gold using a Quorum 
Q150T Turbo-pumped Sputter Coating System (Quorum Technologies Ltd., 
East Sussex, United Kingdom). The sputter coating prevents charging of the 
sample which would occur due to the accumulation of static electric fields. It 
also increases the amount of secondary electrons that can be detected from 
the surface of the specimen in the SEM and therefore increases the signal to 
noise ratio. The samples were imaged immediately using a Jeol JSM 5510 
Scanning Electron Microscope (JEOL (U.K.) Ltd, Hertfordshire, United 
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Kingdom). The SEM imaging was performed by Ms Suzanne Crotty in the 
Biosciences Imaging Centre, University College Cork. 
3.4.1.7 O-ring Biocompatibility 
The Viton O-rings used as part of the design of the cell culture probe holder 
were tested to ensure they were biocompatible with cell growth. The MCF-7 
cells were grown and cultured as previously described. They were seeded at 
an optimum density of 100,000 cells per well in 6 wells of a 24 well plate. 
Three of these wells contained the O-rings and 3 wells were seeded with just 
cells and were used as controls for comparison. The cells were incubated for 
24 hr. After this time they were imaged using an Olympus CKX41 Inverted 
Microscope. 
3.4.1.8 Impedance Modulus Measurements 
Figure 3.5 shows each of the components of the Perspex cell culture holder 
and an unpackaged silicon probe prior to assembly. Figure 3.6 shows a top 
and bottom view of the cell culture holder with a silicon probe inserted prior 
to seeding with cells.  
 
Figure 3.5: The individual components of the cell culture probe holder. A) Bottom of holder, 
B) O-ring, C) Top of holder, D) Plastic film cover and screws, E) An unpackaged silicon 
prototype. 
The A549 cells were cultured as previously described and were seeded on 
each of the silicon devices contained in the cell culture holder at densities of 
50,000-200,000 cells per well. This value had previously been optimised to 
ensure a confluent cell layer would be present on each of the electrodes at 
24 hr. The cells were seeded on the devices for 1 hr and left in an incubator 
at 37 °C. The final volume of DMEM/F12 complete media was then added to 
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each well. The cells were placed in the incubator for 24 hr to allow cell 
attachment and growth prior to impedance modulus recordings being 
performed 
 
Figure 3.6: The assembled cell culture probe holder from the top A) and bottom B). 
3.4.1.9 Stainless Steel Biocompatibility 
Three plastic wells were attached to the surface of the wafer with 
biocompatible glue. Two of the wells were seeded with cells and a control 
well containing media only was used each time. A PI nuclear stain was used 
to visualise cell growth on the surface of the wafer. A549 cells were seeded 
at a density of 40- or 80- or 120,000 cells per well. The cells were initially 
grown in DMEM/F12 complete media. The cells were grown for either 24 or 
48 hours at which point they were removed from the incubator to be fixed 
and stained. After each time point, the cells were washed 3 times in 600 µl of 
37C HBSS. The cells were suspended in 500 μl of HBSS. Ice-cold 80% 
ethanol (600 µl) was then added to each well and the device was placed in 
the freezer at -20 °C for 35 min. The ethanol was used as a fixative for the 
cells prior to staining. The ethanol was then removed and 3 x 600 µl of warm 
HBSS was added to each well to rinse the cells and remove any residual 
ethanol. The PI solution (600 µl) was added to each well and incubated for 5 
min at 37 °C. This was removed and 3 further HBSS washes were performed 
and the final wash was left in the well to prevent the samples from drying out. 
The device was then placed in a fridge at 4°C until being imaged using a 
fluorescent microscope. 
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3.4.2 Meat Tissue Recordings 
3.4.2.1 Beef Recordings 
Frequency sweep measurements were performed on beef rib samples in 
regions of fat and muscle tissue. Samples were obtained from O’Mahony 
Butchers (Cork, Ireland) on the day of testing. The samples were left for in 
the Bioanalysis Laboratory for approximately an hour prior to recording. This 
was to allow the tissue to equilibrate to the temperature of the room. The 
frequency range analysed was from 100,000 Hz to 1,000 Hz with an applied 
peak AC voltage of 10, 30 and 50 mV. An Autolab PGSTAT204 with an 
FRA32M module (Metrohm U.K. Ltd., Cheshire, United Kingdom) was used 
to conduct the measurements. A total of 30 values were obtained across the 
frequency range at each site tested.  During the experiment 1 silicon probe 
(No. 13) was used to recorded triplicate values in both fat and muscle tissue 
in random sites across the beef rib sample. Between each tissue type the 
probe was cleaned by dipping it in nano-pure water and wiping it with lint-free 
paper twice. The values obtained for each scan were exported to Excel and 
IBM SPSS Statistics 20 (SPSS) software package where they were analysed 
and graphed. A total of n=9 for the fat and muscle samples was obtained. 
3.4.2.2 Pressure Testing 
To determine the effect of applied pressure on the modulus of the impedance 
of a sample, beef rib fat and muscle tissues (O’Mahony Butchers, Cork, 
Ireland) were tested. Sections of fat and muscle of approximately the same 
thickness were separated from each other and placed on the bench and 
maintained at room temperature. Silicon probes were tested in a number of 
ways which are described in Table 3.7. 
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Table 3.7: The different methods of applying pressure to the beef rib muscle and fat 
samples. 
Pressure Applied Description 
Unsupported Probe inserted into tissue and maintained under own 
weight 
Handheld The tissue was apposed by hand to the probe. 
Clamp Weitlaner tissue retractor (Notch 5) was used to 
appose the tissue to the probe 
Clamp Tight 
(Muscle Only) 
Weitlaner tissue retractor (Notch 4) was used to 
appose the tissue to the probe 
A Weitlaner tissue retractor obtained from the Department of Surgery in CUH 
was used to apply the fixed pressure to the fat and muscle samples (Figure 
3.7). The frequency range analysed was from 100,000 Hz to 1,000 Hz with 
an applied peak AC voltage of 10 mV. An Autolab PGSTAT204 with a 
FRA32M module was used to conduct the measurements. A total of 30 
values were obtained across the frequency range at each site tested. The 
values obtained for each scan were exported to Excel and SPSS where they 
were analysed and graphed. 
 
Figure 3.7: An example of a Weitlaner tissue retractor that was used in the pressure testing 
of the beef rib samples. Reference [19]. 
3.4.2.3 Depth Testing 
500 ml of water was heated to approximately 70°C on a hotplate. A total of 
56 g of powdered gelatine (Vege-Gel, Dr Oetker, Leeds, United Kingdom) 
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was weighed out and added to the heated water. The solution was then 
stirred to ensure a homogenous mixture. A plastic lunchbox was lined with 
cling-film and the entire gelatine mixture was poured into it and placed in a 
fridge at 4°C and allowed to set until firm. The gel was removed and brought 
to the Bioanalysis Laboratory to perform the impedance modulus 
measurements. A ruler, which was used to measure the depth of penetration, 
was placed parallel to the silicon probe and held in place with a retort stand 
(Figure 3.8). The device was connected to the Autolab potentiostat and the 
total probe length was measured (30 mm to bottom of the packaging). The 
probe was then inserted into the gel at increasing increments with triplicate 
measurements taken at each depth (10, 15 and 20 mm). The values 
obtained for each scan were exported to Excel where they were analysed 
and graphed to determine the overall effect of increasing depth on the 
impedance values obtained. 
 
Figure 3.8: The total length of the silicon probe prior to insertion in the gelatine gel. 
3.4.2.4 Parasitic Capacitance Testing 
Frequency sweep measurements were performed using the silicon probes 
immersed in 10 ml of HBSS. The frequency range analysed was from 1 MHz 
- 1 Hz with an applied peak AC voltage of 10 mV. An Autolab PGSTAT204 
with an FRA32M module was used to conduct the measurements. A total of 
50 values were obtained across the frequency range.  During the experiment 
1 silicon probe (No. 13) was used to record five repeat values in the HBSS. 
Between each measurement the probe was cleaned by dipping it in nano-
pure water and wiping it with lint-free paper twice. The values obtained for 
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each scan were exported to Excel where they were analysed and graphed. A 
total of n=1 was obtained. The value recorded for reactance (imaginary 
impedance) was used to calculate the figure for capacitive reactance using 
Equation 3.3. 
𝐶 = −
1
2π𝑓X𝑐
 
 
Equation 3.3: The calculation for capacitance using reactance. f – Applied Frequency, Xc – 
Reactance, C – Capacitance.  
 3.4.2.5 Lamb Recordings 
Frequency sweep measurements were performed on lamb centre loin 
samples in regions of fat and muscle tissue. Samples were obtained from 
O’Mahony Butchers (Cork, Ireland) on the day of testing. The samples were 
left for in the Bioanalysis Laboratory for approximately an hour prior to 
recording. This was to allow the tissue to equilibrate to the temperature of the 
room. The frequency range analysed was from 100,000 Hz to 1,000 Hz with 
an applied peak AC voltage of 10, 30 and 50 mV. An Autolab PGSTAT204 
with an FRA32M module was used to conduct the measurements. A total of 
30 values were obtained across the frequency range at each site tested.  
During the experiment 1 silicon probe (No. 14) was used to recorded 
triplicate values in both fat and muscle tissue in random sites across the 
lamb centre loin sample. Between each tissue type the probe was cleaned 
by dipping it in nano-pure water and wiping it with lint-free paper twice. The 
values obtained for each scan were exported to Excel and SPSS where they 
were analysed and graphed. A total of n=9 for the fat and muscle samples 
was obtained. 
3.4.2.6 Pork Recordings 
Frequency sweep measurements were performed on pork centre loin 
samples in regions of fat and muscle tissue. Samples were obtained from 
O’Mahony Butchers (Cork, Ireland) on the day of testing. The samples were 
left for in the Bioanalysis Laboratory for approximately an hour prior to 
recording. This was to allow the tissue to equilibrate to the temperature of the 
room. The frequency range analysed was from 100,000 Hz to 1,000 Hz with 
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an applied peak AC voltage of 10, 30 and 50 mV. An Autolab PGSTAT204 
with a FRA32M module was used to conduct the measurements. A total of 
30 values were obtained across the frequency range at each site tested.  
During the experiment 1 silicon probe (No. 13) was used to recorded 
triplicate values in both fat and muscle tissue in random sites across the pork 
centre loin sample. Between each tissue type the probe was cleaned by 
dipping it in nano-pure water and wiping it with lint-free paper twice. The 
values obtained for each scan were exported to Excel and SPSS where they 
were analysed and graphed. A total of n=9 for the fat and muscle samples 
was obtained. 
3.4.3 Statistical Analysis 
For the analysis of the fat and muscle tissues a paired-sample T test was 
performed to determine if a statistical significance existed between the tissue 
types. A paired T test is used when there is one measurement variable 
(frequency) and two nominal variables (fat and muscle). This test was 
chosen to see if the means of these two normally distributed interval 
variables differed from one another. The combined values of skewness and 
Kurtosis were used to test the normality of the data. This was performed on 
each of the data sets following analysis with the paired-samples T test. This 
was used to determine if the data was normally distributed which was 
necessary when performing a parametric statistical analysis. Values of < 2 
and < 9 for skewness and Kurtosis have previously been described as being 
suitable for parametric analysis using a paired-samples T test [20]. The 
paired-samples T test was also used to optimise the measurement frequency 
at which fixed frequency measurements could be performed. The triplicate 
measurements in each tissue were averaged each time and the nine repeats 
were combined in the paired-samples T test with a confidence interval of 
95%. A p value of <0.05 would be indicative of a statistical significance 
between the two tissue types. 
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3.5 Results 
3.5.1 Cell Culture 
3.5.1.1 Silicon Biocompatibility 
The MCF-7 and HT-29 cell lines were both grown on the surface of the 
silicon probes to demonstrate the overall biocompatibility of the devices. The 
experiment was repeated a number of times at both the 24 and 48 hour time 
point. A selection of the images taken using the bright-field setting on the 
microscope during this study can be seen in Figures 3.9 and 3.10. Figure 3.9 
shows images taken of the silicon probes seeded with 400,000 HT-29 cells 
at 24 and 48 hours (B and C). A control probe, which contained only media 
and incubated for 24 hours, showed no cell growth as expected (Figure 3.9 
A). A confluent cell layer was clearly evident at each of the time points 
analysed. This demonstrated that the entire surface of the silicon probes was 
compatible with the growth of HT-29 cells. 
 
Figure 3.9: Micrographic images of the tip of the silicon probe seeded with control (no cells; 
A) and HT-29 cells (400,000 cells per device) for 24 hr (B) and 48 hr (C). 
MCF-7 cells were also seeded on the silicon probes to show the 
biocompatibility and to compare with the findings of the HT-29 cells 
previously shown. They were seeded at an optimum density of 400,000 cells 
per device along with a control which contained no cells (Figure 3.10 A and 
B). Under the light microscope the cells were clearly visible across the entire 
probe surface including the gold electrodes. In order to quantitatively assess 
the biocompatibility of the silicon devices a resazurin cell viability assay was 
performed and the results are shown in the Section 3.5.1.2. 
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Figure 3.10: Micrographic images of the tip of the silicon probe seeded with control (no cells; 
A) and MCF-7 cells (400,000 cells per device) for 24 hr (B). 
The significant amount of cell growth observed with each cell line was a 
positive result. It demonstrated that the silicon substrate probes did not 
adversely affect the growth of either cell line over a period 48 hours. This 
indicated that the fabricated devices were biocompatible. This result meant 
that silicon could be put forward as a potential alternative to stainless steel 
for ex vivo tissue measurement because of the reduced stress applied to the 
probes when measuring excised tissue samples. The initial investigations 
performed to test the biocompatibility of the silicon probes involved the 
growth of both the MCF-7 and HT-29 cells lines on the surface of the device. 
Light microscopy was used to confirm that a confluent cell layer was present 
on each of the probes that were seeded with cells. Further investigation in to 
the biocompatibility of the silicon probes was undertaken as they were the 
most promising prototype developed as part of this research project and the 
results are outlined in Sections 3.5.1.2 and 3.5.1.3. 
3.5.1.2 Resazurin Cell Viability Assay 
The resazurin cell viability assay was used to provide a quantitative 
measurement of the viability of the MCF-7 cells grown on the surface of the 
silicon devices. The results obtained showed that the percentage viability of 
cells grown on the silicon probe fragments was 98.7% compared to the 
positive control of cells seeded on the surface of the 24-well plate (Table 
3.8). Figure 3.11 shows a bar chart displaying the mean ± S.D. for the 
positive control, test and negative control wells that were analysed in each of 
the plates (N=4).This showed that the materials and fabrication processes 
used to produce the silicon probes were biocompatible and did not 
significantly inhibit cell growth. The assay results confirmed the results 
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obtained during the light microscopy and SEM investigations which showed a 
confluent MCF-7 cell layer present at 24 hr after seeding. 
Table 3.8: The averaged results of each replication of the resazurin assay and the standard 
deviation. 
Resazurin Assay Positive Control Test Negative Control 
Plate 1 100 104.433 1.108 
Plate 2 100 90.399 1.527 
Plate 3 100 103.795 0.943 
Plate 4 100 96.180 1.222 
Average 100 98.700 1.200 
Standard Deviation 0 6.686 0.246 
 
 
Figure 3.11: The result of the resazurin assay which shows the cell viability of MCF-7 cells 
grown on the silicon devices compared to both positive and negative controls. N=4 and each 
sample was tested in triplicate. Data shown is the average of the % viability value ± S.D. 
The resazurin cell viability assay was used to provide a quantitative analysis 
of the viability of the MCF-7 cells grown on the silicon devices [21]. The 
results of the experiment showed that the presence of fragments of the 
prototype silicon probes did not significantly reduce the percentage cell 
viability when compared with the positive control (Figure 3.11). This was to 
be expected given the preliminary findings from the light microscopy images 
and the known biocompatibility of the materials used in the fabrication 
process [22, 23]. The results also compared extremely well to a recently 
published study by Srinivasaraghavan et al. (2015) who showed that the 
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MCF-10A breast cell line displayed a 98.8 ± 0.2% viability when grown on 
silicon [24]. 
3.5.1.3 Scanning Electron Microscopy 
The final biocompatibility experiment that was conducted with the silicon 
probes involved the SEM imaging of MCF-7 cells seeded at a density of 
450,000 and cultured for 24 hours. The SEM images of the silicon probes 
and gold electrodes seeded with cells were taken using a Jeol JSM 5510 
SEM in the Bioscience Imaging Centre, University College Cork. These high 
resolution images provided an insight in to the growth and distribution of the 
MCF-7 cells cultured across the electrode surface and the surrounding 
silicon substrate. The images clearly illustrated that the cells grew in a 
confluent layer across the entire electrode surface (Figure 3.12 A-D). At the 
lower kV values (A and B) it was not possible to see the gold electrode tracks 
as the electron beam was only focused across the surface of the cells. At the 
higher kV values (C and D) the depth of penetration of the electrons was 
significantly higher and the gold electrodes could be seen more clearly. The 
SEM images of MCF-7 cells seeded on to the silicon probe devices were 
used to visualise the three dimensional growth of the cells across the surface 
of the device. It was evident from these SEM images that the growth of cells 
was not impeded by any part of the surface of the silicon probe. This 
indicated that the fabricated devices and materials were biocompatible. The 
result presented here was in agreement with the findings of the resazurin 
and light microscopy experiments which showed no significant reduction in 
cell viability of MCF-7 cells grown on the prototype devices. The experiments 
performed to test the biocompatibility of stainless steel and silicon devices 
showed that cell growth and viability were not adversely affected by the 
prototype probes. This was an important milestone in the fabrication of the 
novel impedance probe because it indicated that the probe may be safe to 
use in a clinical setting without causing an adverse immune response in the 
patient. This result allowed the project to progress to the next experimental 
section which was the investigation of the impedance modulus 
measurements in meat tissues. 
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Figure 3.12: 35x magnification SEM images of a silicon probe seeded with MCF-7 cells at 
increasing voltage from a) 5, b) 10, c) 20 and d) 30 kV. 
3.5.1.4 O-ring Biocompatibility 
An inverted-phase contrast microscope was used to image the cells grown 
as part of the O-ring biocompatibility study. The representative images 
obtained during the study are shown in Figure 3.13 A-C. The images 
presented showed a layer of confluent cells was present in each of the wells. 
The presence of the O-ring in each of the three test wells did not inhibit the 
growth of cells in the surrounding area (Figure 3.13 A and B). A confluent cell 
layer was present in each of the control wells. This was expected as the 
necessary growth conditions were available (Figure 3.13 C). The result of 
this experiment showed that the O-rings chosen as part of the probe holder 
set-up were suitable for use during the experiment and would not impede the 
growth of cells across the silicon devices. This would allow a confluent layer 
of cells to form across the surface of the probe while also providing a water-
tight seal to maintain the volume of media within the cell culture well. 
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Figure 3.13: The images taken of the O-ring biocompatibility study. A) The outer edge of the 
O-ring in black with cells grown to confluence adjacent to it. B) An image taken from the 
same well as A) which shows growth across the entire well. C) An image of one of the 
control wells used in the experiment in which a confluent cell layer was present. 
3.5.1.5 Culture of Cells on Silicon Probes 
The silicon probes were inserted in the previously described cell culture 
holders and seeded with A549 cells. A rubber O-ring was used to provide a 
watertight seal between the probe and the holder. The A549 cells were 
initially grown on the devices to allow optimisation of the cell numbers and 
liquid volume necessary for confluent growth over a 24 hr period. After the 
cells were seeded for a day they were imaged using a light microscope 
(Figure 3.14 A-C). The representative images shown here displayed no 
significant growth at either 100,000 or 200,000 cell seeding density. The 
control showed no growth as expected. Multiple repeats of this experiment 
were unsuccessful in optimising the growth of a confluent cell layer on the 
silicon probes. During the imaging process it was necessary to remove the 
upper part of the probe holder. It was noticed on a number of occasions that 
the cell culture media was not in contact with the probe surface. This was 
most likely due to surface tension created by the opening in the O-ring being 
too small to allow sufficient transfer of the cell suspension onto the device. 
As a result it was not possible to get cell growth across the electrode surface 
on the silicon probe. 
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Figure 3.14: A) 10x magnification image of a silicon probe seeded with 100,000 A549 cells. 
B) 2.5x magnification image of a silicon probe seeded with 200,000 A549 cells. C) 10x 
magnification image of a silicon probe seeded with no cells as a control. 
Due to time and resource constraints associated with this project it was not 
possible to re-design and manufacture new probe holders that would allow 
sufficient cell and media transfer. The width of the diced and packaged 
silicon probes was a limiting factor in the design of the cell culture holder and 
the size of O-ring used. In order to obtain impedance modulus recordings 
from cells cultured on to silicon devices it would have been necessary to 
completely redesign the silicon probes as well as the cell culture holder. The 
electrical packaging of the silicon probes meant that it was not possible for 
the probes to lie flat on the bottom of a cell culture dish. This meant that the 
culture media and cell suspension could not be maintained on the probe 
surface to allow optimum cell growth. The cell culture holder was designed to 
keep the probes level which provided a flat growth surface. However, the 
width at which the silicon probes were diced limited the maximum diameter 
of the O-ring that could be used to maintain the liquid seal around the 
electrode area. High surface tension across the opening of the O-ring did not 
allow the cell suspension and culture media to contact the probe surface. As 
a result, there was no cell adhesion or growth on the electrode surface. In 
order to increase the width of the O-ring opening it would have been 
necessary to increase the pitch between the patterned probes on the wafer 
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during fabrication. This would have required a complete redesign of the 
photolithography masks used to pattern the probe structures. This was not 
feasible given the time and resource constraints of the project. Ultimately, it 
was not possible to obtain in vitro impedance modulus recordings of the 
immortalised cancer cell lines. The principal reason for this was that the 
silicon probes were designed to obtain ex vivo tissue recordings rather than 
being used as cell culture impedance sensors. If it had been possible to 
obtain these recordings it would have proven that the silicon probes were 
capable of differentiating between cell lines of different origins using the 
modulus of the impedance. This would have provided a baseline 
measurement on which the future studies could have been developed. The 
lack of impedance data collected from this experimental section did not 
present a significant obstacle to the overall project progression as the 
primary research outcome was always to assess the ability of the probe to 
measure impedance in whole tissue samples. For measurement of cells in 
culture an ECIS set-up would be significantly more suitable and has 
previously been shown to effective in a range of screening assays [25-27].  
3.5.1.6 Stainless Steel Biocompatibility  
Previously described results outlined that the stainless steel probes were 
unsuitable for conducting electrochemical recordings. However, a preliminary 
assessment of the biocompatibility of the stainless steel wafers was 
conducted in order to identify if the patterned structures were suitable for 
maintaining cell growth. This would provide an indication as to whether the 
stainless steel probes could be used for in vivo testing should the issue with 
the metal deposition be overcome in the future. A number of repetitions of 
biocompatibility testing of the stainless steel wafers were performed and the 
results obtained were as expected. The method of determining cell growth 
across the surface of the stainless steel wafer was the presence of PI 
nuclear stain. Propidium iodide is a florigenic compound that binds 
stoichiometrically to nucleic acids [28-30] which emits fluorescence 
proportional to the amount of DNA in the cell [31]. Using a fluorescent 
microscope it was confirmed that there was nuclear staining present and a 
corresponding absence in the control sample (Figure 3.15). The materials 
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used during the development were chosen because of the likely 
biocompatibility. The ability of cells to grow on the surface of the device was 
a positive step forward as it meant that not only the materials but also the 
processes were suitable for use in the assembly of the novel biomedical 
technology. Figure 3.15 shows A549 cells seeded at 80,000 (A) and 120,000 
(B) on the surface of the stainless steel wafer. The cells were stained with PI 
and imaged using a fluorescent microscope. The outline of the recording 
electrodes could be seen in both images. This demonstrated that the cells 
were growing across the entire electrode surface and the surrounding 
substrate.  
 
Figure 3.15: A549 cells seeded at 80,000 (A) and 120,000 (B) cells per well for a period of 
24 hours on the stainless steel wafer with plastic cell culture wells attached. The cells are 
stained with propidium iodide (500nM) nuclear stain. 
In this section, biocompatibility testing was carried out on the patterned 
stainless steel wafers. The tests involved the growth of A549 cells on the 
surface of a patterned stainless steel wafer to which wells had been 
attached. Propidium Iodide was previously shown to be effective in staining 
A549 cells, which was used to allow visualisation of the cells seeded on the 
surface of the material [32-34]. Confluent cell growth was shown at both 24 
and 48 hr after seeding. There was an absence of cells in the control well 
which was to be expected as no cells were added. The result of this 
experiment showed that the stainless steel wafer which had been patterned 
with gold electrodes was biocompatible with cell growth. This was to be 
expected as the materials used during the fabrication process should not 
cause adverse reactions when in contact with cells. In particular, stainless 
steel and gold are commonly used materials for medical purposes [35-38] 
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and do not result in cell death in vivo. This initial experiment showed that the 
use of a stainless steel wafer in conjunction with silicon fabrication 
techniques is a potentially viable method of creating a prototype of this novel 
electrical impedance sensor. 
3.5.2 Meat Tissue Results 
3.5.2.1 Beef Impedance Recordings 
One of the silicon probes (Number 13) was tested in fat and muscle samples 
of beef rib (Figure 3.16 A and B).  
 
Figure 3.16: A) A silicon probe in the fat of a beef rib sample. B) A close up image of a 
silicon probe in a section of fat in a beef rib sample. 
As part of the experiment to determine the prototype probes ability to 
differentiate between fat and muscle tissues, the effect of applied voltage 
was investigated. A series of three peak voltages 10, 30 and 50 mV were 
applied in triplicate at each of the measurement sites recorded. The graph 
shows the average values obtained at each of the applied voltages in one of 
the meat samples (Figure 3.17). The results showed that a negligible 
difference existed between the recordings obtained using each of the applied 
voltages. Therefore, it was decided to analyse the values obtained using the 
10 mV peak amplitude as this was the lowest applied voltage which elicited a 
response.  
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Figure 3.17: The triplicate impedance modulus values for beef fat and muscle obtained using 
3 applied voltages (10, 30 and 50 mV peak voltage) across a frequency sweep from 
100,000-1,000 Hz. 
 
Figure 3.18: The Bode plot of the averaged values for beef rib fat and muscle frequency 
sweep recordings at 10 mV peak voltage. N=9. 
The graph shows the averaged Bode plots of the beef samples across the 
frequency range at 10 mV peak amplitude (Figure 3.18). The results 
obtained showed that there was excellent separation between the fat and 
muscle tissues across the majority of the frequencies measured. A paired-
samples T test was performed to determine the significance of the separation 
between the means of the fat and muscle impedance modulus results. For 
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each of the frequencies recorded below 38 kHz the observed p-value was 
≤0.05. Therefore, it was possible to use any of these frequencies as the 
optimum. Normality testing was performed using the 9 pairs of averaged data 
obtained from each of the meat samples at a frequency of 3 kHz. Table 3.9 
shows the skewness and Kurtosis values generated from the beef fat and 
muscle averages for all the samples tested. For both tissue types the values 
for Kurtosis were below the upper limit of 9.  The value for skewness for fat 
was below the threshold of 2 however the value for muscle was not. By 
combining the observed skewness Kurtosis values it was possible to assume 
data normality. Therefore, this data set was suitable for analysis using the 
paired-samples T test.  
Table 3.9: The data output for the normality testing performed on average beef fat and 
muscle recordings at a frequency of 3 kHz. N=9. 
Normality Test Beef Fat Beef Muscle 
Skewness 0.946 2.393 
Kurtosis -0.179 5.866 
Using the results from the paired-samples T test, it was decided that 3 kHz 
would be chosen for all future fixed frequency recordings. The mean 
separation between the two tissue types at 3 kHz (3,039 Hz) was 35,607 Ω 
(p < 0.001) (Appendix 6.8.1).  Figure 3.19 shows the mean ± S.D. for the 
beef fat and muscle samples obtained at 3 kHz (N=9). It was evident from 
the graph that significantly larger variability existed in the fat tissue compared 
to the muscle. Regardless of this, it was still possible to choose a frequency 
that was suitable for fixed frequency recordings that could differentiate 
between all fat and muscles samples of bovine origin. 
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Figure 3.19: The result of the paired-samples T test to compare the means of the beef rib fat 
and muscle impedance modulus recordings at 3 kHz. Mean ± S.D., N=9, p < 0.001. 
The results outlined in this section showed that the prototype silicon probe 
was capable of differentiating between fat and muscle tissues of bovine 
origin. This provided the first confirmation of the devices ability to 
differentiate between ex vivo fat and muscle tissues. The optimum fixed 
frequency value chosen was 3 kHz. This value provided a statistically 
significant separation between the two tissue types and the data was shown 
to be suitable as demonstrated by the normality tests. Therefore, the effects 
observed are less likely to be either entirely resistive or capacitive. This 
result provided the basis for the clinical study that aimed to use electrical 
impedance to differentiate between healthy and cancerous breast tissue 
removed during surgery. 
3.5.2.2 Pressure Testing 
This experiment was conducted to determine the effect of applying pressure 
on tissues during electrical impedance recordings. Figure 3.20 shows the 
results of the pressure testing performed on the beef muscle samples. The 
results showed that for each of the pressures applied, there was very little 
variation between the observed impedance modulus values. There was a 
lack of variability between the clamp and clamp tight recordings which did not 
differ significantly from each other despite the increase in pressure applied 
by the Weitlaner tissue retractor. This suggested that for the purpose of 
0
10
20
30
40
50
60
Fat Muscle
M
o
d
u
lu
s
 o
f 
Im
p
e
d
a
n
c
e
 (
k
O
h
m
) 
Validation of Biocompatibility and Impedance in Biological Samples Chapter 3 
137 
 
recording muscle tissue samples the effect of externally applied pressure 
does not appear to have an effect on the electrical impedance value 
obtained. 
 
Figure 3.20: The average values for the test of pressure on the modulus of the electrical 
recordings obtained in a beef rib muscle sample. The averages of the triplicate recordings 
for each variable are shown. 
The results for the fat measurements showed significant variability across the 
different experimental parameters (Figure 3.21). The clamped sample 
displayed higher impedance than the other two recordings. This indicated 
that the increase in externally applied pressure resulted in an increase in 
electrical impedance compared to the unsupported and handheld recordings. 
Due to the variability observed between the different fat recordings it is 
necessary to ensure that the type of pressure applied is the same for all 
recordings and is constant throughout the recording procedure. 
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Figure 3.21: The average values for the test of pressure on the modulus of the electrical 
recordings obtained in a beef rib fat sample. Average of triplicate recordings for each 
variable. 
The effect of externally applied pressure on electrical impedance values was 
investigated using the silicon prototype to measure beef rib fat and muscle 
samples. The results obtained showed that the effect of pressure was 
negligible during recording of muscle samples but that the electrical 
impedance of fat was variable according to pressure applied. A study by 
González-Correa et al. demonstrated that increased pressure applied to the 
electrical impedance probe could produce an increase in the recordings 
observed. However, the team noted that the effect of pressure was 
significantly less than the observed difference between the tissues of interest 
[20]. They suggested that the increase in impedance resulting from 
increased pressure may be caused by squeezing of the intracellular fluid with 
simultaneous reduction of extracellular spaces within the tissues [20]. An 
important observation of this study was the possibility that the recorded 
impedance values in vitro may not reflect the in vivo situation. This was due 
to the pressure distribution beneath the tissues being different because of a 
lack of support by a firm surface in vivo [20]. This point is particularly relevant 
to the future development of the current silicon prototype utilised in this 
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project. It will have to be able to penetrate tissue structures of the breast 
effectively without damaging the surrounding tissues and without externally 
applied pressure to ensure tissue contact with the electrode surface. The 
concern relating to the differences between in vivo and ex vivo samples is 
expanded on by Keshtkar and Keshtkar in their 2008 paper. They suggest 
that by applying an external pressure to tissues in vivo, it is possible to 
interrupt the blood supply and cause an increase in impedance by reducing 
the volume of fluid in the tissues [21]. Therefore it can be expected that 
higher impedance can be obtained from in vivo tissues compared to ex vivo 
tissue when the same external pressure is applied [21]. Both research 
groups propose that the primary loss of fluid in compressed tissues comes 
from the extracellular fluid compartments. Dodde et al. suggested that when 
soft tissues were compressed fluid loss must be seen as being composed of 
both intra- and extra-cellular fluid [22]. The most significant aspect of the 
research into the effect of pressure on electrical impedance recordings is that 
in both ex vivo and in vivo settings the same force must be applied to the 
probe during all measurements. 
3.5.2.3 Depth Testing 
This experiment was conducted using one of the silicon probes to determine 
if the depth at which a recording is taken has an effect on the measured 
impedance. Triplicate frequency sweep measurements were taken at three 
different depths 10, 15 and 20 mm from the surface of the gel (Figure 3.22 A-
C). The probe was able to support itself in the gel and no external pressure 
was applied during the measurement phase. 
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Figure 3.22: The probe and ruler used to measure the depth of penetration during 
experimentation at 10 mm (A), 15 mm (B) and 20 mm (C). 
The results obtained during this experiment are shown in Figure 3.23. The 
graph shows the average of the triplicate recordings taken at each depth and 
overlaid on each other. It can clearly be seen that there was almost no 
separation between the lines. However, the maximum separation which 
occurs at 1,000 Hz is only 8.5 % of the total value in Ohms recorded. 
 
Figure 3.23:  The results of the depth of penetration experiments at three depths 10, 15 and 
20 mm. Values shown are averages of triplicate recordings at each depth. 
 
The results obtained during the experiment were positive as it showed that 
for all frequencies tested there was almost no difference across the 
penetration depths. This was an expected result due to the design of the 
Validation of Biocompatibility and Impedance in Biological Samples Chapter 3 
141 
 
probe which provided an insulation layer along the entire length the gold 
tracts. This prevented the detection of electrical impedance outside of the 
dual microelectrodes at the recording end of the device. This was important 
to note for future studies as ex vivo and in vivo measurements cannot always 
be taken at the same depth due to the nature of the sample and the tissue 
type of interest.  
3.5.2.4 Parasitic Capacitance Testing 
In order to assess whether parasitic capacitance was present across the 
frequency range being analysed using the silicon probe it was necessary to 
test the device in a standard buffered solution. The solution that was chosen 
was HBSS which had previously been used as part of the cell culture testing. 
The frequency range of interest was from 1,000 – 100,000 Hz at the optimum 
peak voltage of 10 mV. The left electrode of each silicon probe was tested a 
total of 5 times when placed in 10 ml of HBSS. The average capacitive 
reactance plot from one of the silicon probes is shown in Figure 3.24. The 
results show no evidence of parasitic capacitance across the frequency 
range of interest. This indicates that it is possible to use any of the 
frequencies within this range for the purpose of fixed frequency recordings. 
 
Figure 3.24: The average plot of the capacitive reactance response of a silicon probe in 
HBSS buffer. N=1. 
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3.5.2.5 Lamb Impedance Recordings 
One of the silicon probes (Number 14) was tested in fat and muscle samples 
of lamb centre loin (Figure 3.25 A and B).  
 
Figure 3.25: A) A silicon probe placed in an area of fat in a lamb centre loin sample. B) A 
close up of the probe in the fat tissue (right). 
As with the beef rib samples, the effect of applied voltage was investigated 
using the lamb centre loin samples. A series of three voltages 10, 30 and 50 
mV peak voltage was applied in triplicate at each of the measurement sites 
recorded. The graph shows the average values obtained at each of the 
applied voltages in one of the meat samples (Figure 3.26). 
 
Figure 3.26: The triplicate electrical impedance modulus values for lamb fat and muscle 
obtained using 3 applied peak voltages (10, 30 and 50 mV) across a frequency sweep from 
100,000-1,000 Hz. 
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The results showed that a negligible difference existed between the 
recordings obtained using each of the applied voltages. Therefore, it was 
decided to analyse the values obtained using the 10 mV peak amplitude as 
this was the lowest applied voltage which elicited a response. 
 
Figure 3.27: The Bode plot of the averaged values for lamb centre loin fat and muscle 
frequency sweep recordings at 10 mV peak amplitude. N=9. 
The graph shows the averaged Bode plots of the lamb centre loin samples 
across the frequency range at 10 mV peak amplitude (Figure 3.27). The 
results obtained showed that there was excellent separation between the fat 
and muscle tissues across all of the frequencies below 52 kHz. A paired-
samples T test was performed to determine the significance of the separation 
between the means of the fat and muscle impedance modulus results. 
Across each of the frequencies recorded below 52 kHz the observed p-value 
was <0.05. Therefore it was possible to use any of the recorded frequencies 
as the optimum. Normality testing was performed using the 9 pairs of 
averaged data obtained from each of the lamb samples at a frequency of 3 
kHz. Table 3.10 shows the skewness and Kurtosis values generated from 
the lamb fat and muscle averages obtained from each of the meat samples. 
For both tissue types the values were below the upper limit of 2 and 9 for 
skewness and Kurtosis respectively. Therefore, this data set was suitable for 
analysis using the paired-samples T test.  
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Table 3.10: The data output for the normality testing performed on average lamb fat and 
muscle recordings at a frequency of 3 kHz. N=9. 
Normality Test Lamb Fat Lamb Muscle 
Skewness 0.634 1.325 
Kurtosis -1.003 1.819 
As with the beef recordings it was decided that 3 kHz would be chosen for all 
future fixed frequency recordings. The mean difference between the two 
tissue types at 3 KHz (3,039 Hz) was 58,816 Ω (p < 0.001) (Appendix 6.8.1). 
The graph shows the mean ± S.D. at 3 KHz and 10 mV peak voltage for the 
lamb centre loin fat and muscle samples (N=9) (Figure 3.28). It was evident 
from the graph that a larger variability existed in the fat tissue compared to 
the muscle however this was much less than was observed in either the beef 
or pork fat tissue.  
 
Figure 3.28: The result of the paired-samples T test to compare the means of the lamb 
centre loin fat and muscle impedance recordings at 3 kHz. Mean ± S.D., N=9, p < 0.001. 
The results outlined in this section showed that the prototype silicon probe 
was capable of differentiating between fat and muscle tissues of ovine origin. 
This provided additional confirmation of the devices ability to differentiate 
between ex vivo fat and muscle tissues. This result in combination with the 
previously described beef results provided the basis for the future clinical 
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study that aims to use electrical impedance to differentiate between healthy 
and cancerous breast tissue removed during surgery. 
3.5.2.6 Pork Impedance Recordings 
One of the silicon probes (Number 13) was tested in fat and muscle samples 
of pork centre loin (Figure 3.29). As with the beef and lamb samples, the 
effect of applied peak voltage was also investigated using the pork samples. 
A series of three peak voltages (10, 30 and 50 mV) were applied in triplicate 
at each of the recorded measurement sites. The graph shows the average 
values obtained for each of the applied voltages in one of the meat samples 
(Figure 3.30). 
 
Figure 3.29: A) A silicon probe in a region of fat in a pork centre loin sample. B) A close up 
of the probe in the fat tissue (right). 
  
Validation of Biocompatibility and Impedance in Biological Samples Chapter 3 
146 
 
 
Figure 3.30: The triplicate electrical impedance values for pork fat and muscle obtained 
using 3 applied voltages (10, 30 and 50 mV peak voltage) across a frequency sweep from 
100,000-1,000 Hz. 
The results showed that a negligible difference existed between the 
recordings obtained using each of the applied voltages. Therefore, it was 
decided to analyse the values obtained using the 10 mV peak amplitude as it 
was the lowest applied voltage which elicited a response. The graph shows 
the averaged Bode plots of the pork centre loin samples across the 
frequency range at 10 mV peak amplitude (Figure 3.31). The results 
obtained showed that there was excellent separation between the fat and 
muscle tissues across all of the frequencies measured. 
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Figure 3.31: The Bode plot of the averaged values for pork centre loin fat and muscle 
frequency sweep recordings at 10 mV peak voltage. N=9. 
A paired-samples T test was performed to determine the significance of the 
separation between the means of the fat and muscle impedance results. For 
all frequencies recorded except 100 kHz the observed p-value was <0.05. 
Normality testing was performed using the 9 pairs of averaged data obtained 
from each of the pork samples at a frequency of 3 kHz. Table 3.11 shows the 
skewness and Kurtosis values generated from the pork fat and muscle 
averages obtained from each of the meat samples. For both tissue types the 
values were below the upper limit of 2 and 9 for skewness and Kurtosis 
respectively. Therefore, this data set was suitable for analysis using the 
paired-samples T test.  
Table 3.11: The data output for the normality testing performed on average pork fat and 
muscle recordings at a frequency of 3 kHz. N=9. 
Normality Test Pork Fat Pork Muscle 
Skewness 0.050 -0.042 
Kurtosis -0.169 -0.110 
It was decided that 3 kHz would be chosen for all future fixed frequency 
recordings as this would be in line with the optimum chosen for the beef and 
lamb samples while maintaining a significance of below 0.05. The mean 
separation between the two tissue types at 3 KHz (3,039 Hz) was 30,537 Ω 
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(p < 0.001) (Appendix 6.8.1). The graph shows the mean ± S.D. at 3 KHz 
and 10 mV peak amplitude for the pork fat and muscle samples (N=9) 
(Figure 3.32). It was evident from the graph that the pork fat displayed the 
largest variability of any of the recorded tissues in this study. It was clear at 
the time of recording that the pork fat was significantly less solid than either 
the beef or lamb fat tissues. This made the recording of the electrical 
impedance values more difficult and the variable composition of the fat at 
room temperature may have influenced the recorded values. Regardless of 
this it was still possible to choose a frequency that was suitable for fixed 
frequency recordings that could differentiate between all fat and muscles 
samples of porcine origin. 
 
Figure 3.32: The result of the paired-samples T test to compare the means of the pork 
centre loin fat and muscle impedance recordings at 3 kHz. Mean ± S.D., N=9, p = 0.001. 
In order to determine if the silicon impedance probes were functioning in a 
stable manner across each of the recordings performed it was necessary to 
plot the individual phase angle data points for each of the pork 
measurements using a modified Bland-Altman plot. The mean ± 1.96 S.D 
were calculated for pork fat and muscle separately and displayed in Figure 
3.33 and 3.34. 
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Figure 3.33: A modified Bland-Altman plot of the phase angle for each of the pork fat 
recordings. The mean ± 1.96 S.D have been plotted on the graph. 
 
Figure 3.34: A modified Bland-Altman plot of the phase angle for each of the pork muscle 
recordings. The mean ± 1.96 S.D have been plotted on the graph. 
The results show that for both the fat and muscle recordings the phase angle 
associated with the impedance modulus recordings are within 1.96 S.D of 
the mean phase value. This indicated that the recorded phase values did not 
deviate significantly from the mean across any of the tissue recordings. It 
was evident from the graphs that pork fat recordings displayed a larger 
spread of phase angle compared to the muscle tissue but each of the 
average phase values still fell within the 1.96 S.D range. The results 
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demonstrated that the phase angle response observed when recording the 
biological tissue samples were stable enough for a comparison to be made 
between each of repeated experimental measurements. In particular, the 
measured phase angle for the muscle tissues showed a narrow range which 
was centred on the mean phase angle value for the combined muscle 
tissues. This finding is in keeping with the observed impedance modulus 
recordings which showed significantly less variability in the muscle 
recordings compared to the associated fat tissues. 
The results outlined in this section showed that the prototype silicon probe 
was capable of differentiating between fat and muscle tissues of porcine 
origin. This provided further confirmation of the devices ability to differentiate 
between ex vivo tissues including fat and muscle. This result in combination 
with the previously described beef and lamb results provided the basis for 
the future clinical study that would aim to use electrical impedance to 
differentiate between healthy and cancerous breast tissue removed during 
surgery. 
3.5.2.7 All Tissues Combined 
In order to confirm if the origin of the tissue impacted on the ability of the 
silicon probe to differentiate between fat and muscle a paired-samples T test 
was performed on the combined data from all of the beef, lamb and pork 
samples. At the optimum frequency of 3 kHz it was shown that the combined 
data had a mean separation of 41,653 Ω (p < 0.001) (Figure 3.35). The 
results shown here demonstrated that when all of the tissues were combined 
it was possible to obtain a significant separation between the fat and muscle 
tissues. This showed that at the optimum frequency of 3 kHz, the silicon 
probe was capable of differentiating between fat and muscle tissue for each 
of the different animal sources. 
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Figure 3.35: The result of the paired-samples T test to compare the combined beef, lamb 
and pork fat and muscle impedance recordings at 3 kHz. Mean ± S.D., N=27, p < 0.001. 
The results of the ex vivo measurements of meat tissues showed positive 
results. The prototype probe was proven to be capable of differentiating 
between fat and muscle tissue from three different animal sources which 
included cow, sheep and pig. The use of frequency sweep electrical 
impedance measurements at a fixed voltage showed that at all of the 
frequencies tested there was separation between the values obtained for fat 
and muscle. In each of the tissue samples tested there was increased 
separation as the frequency decreased.  One of the most interesting findings 
observed was the level of variability encountered when measuring the fat 
tissues compared to muscle of same origin. This variation may be due to the 
difference in water content throughout the fat tissues and the variable 
increase in the temperature of the cells as they reach room temperature can 
potentially alter the recorded impedance value. The lower water content in fat 
tissues decreases the conductivity of the electrical current and therefore 
increases the electrical impedance [39, 40]. There was significantly less 
variation across each of the muscle samples which were analysed but this 
was to be expected due to significantly higher water content in each of the 
cells [39]. This resulted in increased conductivity which decreased the 
electrical impedance compared to the surrounding fat tissues. 
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3.6 Conclusions 
The results outlined in this chapter demonstrate the biocompatibility and 
electrical impedance ability of the silicon probe prototypes. In the opening 
section it was shown that the devices were biocompatible with immortalised 
cell growth. This was proven using a number of techniques including light, 
fluorescence and SEM and a resazurin cell viability assay. By quantitatively 
measuring the number of living cells grown on the surface of the silicon 
probe fragments it was possible to determine the biocompatibility of the 
individual devices. It is not possible for resazurin to be reduced to resorufin 
by dead cells and therefore only cells which are alive at the time of analysis 
are measured when assessing cell viability. The results of this assay are 
compared with the light and scanning electron microscopy images to gain a 
complete understanding of the biocompatibility of the silicon probes. This 
was a positive result as it demonstrated that both the materials and 
fabrication procedures used in the production of these devices did not 
significantly inhibit cell growth and therefore it was determined that the silicon 
probes were biocompatible. Unfortunately it was not possible to complete the 
intended investigation of the electrical impedance of cultured cells on the 
silicon devices. This was due to a number of design constraints which 
inhibited the packaged probes use in a cell culture environment. In the 
second section of the chapter, the ability of the silicon probes to differentiate 
between fat and muscle tissues was shown. Samples of fat and muscle from 
beef, lamb and pork were repeatedly tested and it was demonstrated that the 
probes were capable of differentiating between the two tissue types. The 
tissues of three different origins were tested to validate the probes ability to 
differentiate between fat and muscle tissue and to ascertain if a significant 
difference existed between the different meats. It was shown that the beef 
and pork samples were similar in terms of mean impedance modulus values 
and fat variability. The lamb showed a higher mean impedance modulus 
value compared to either the beef or pork and displayed less variability in the 
fat recordings. By testing tissues from a number of different animal origins it 
was possible to show that the silicon probe could differentiate between fat 
and muscle tissue of very different cellular composition. This was a 
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significant milestone in this project as it definitively showed that the silicon 
probes were able to differentiate between tissue types in an ex vivo setting. 
3.6.1 Future Work 
The future work associated with this aspect of the research project would 
involve the measurement of a selection of biological tissues recorded at both 
room and physiological temperatures. This could create a database of 
healthy tissue electrical impedance recordings. These values could then be 
used to identify meat tissue samples as well as being used as a comparison 
to pathological tissues including cancerous tissue samples. Future iterations 
of this device may potentially be used in the detection and diagnosis of 
animal diseases but this would require specific research in this area and 
include trials using live animal models. This could open a new market for this 
sensor in the area of the animal health and veterinary medicine for the 
detection of pathological conditions. A significant redesign of the cell culture 
holders would allow for measurements to be obtained from seeded cells on 
the silicon probes. This would allow both primary and immortalised cells to 
be monitored during each stage of the cell growth, differentiation and death 
cycle using electrical impedance as the detection method. This would 
provide real-time analysis of changes in cell morphology and survival and 
would allow for testing of therapeutic substances on the cell cultures with 
feedback provided by impedance detection. However, this probe was 
designed for the purpose of recording electrical impedance measurements in 
ex vivo and in vivo tissues of animal and human origin. Therefore, the most 
appropriate future investigations would focus on differentiation of intact tissue 
structures with a focus on differential disease diagnosis.  
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4. Human Breast Tissue Clinical Trial 
4.1 Objectives 
The objective of this chapter is to give a comprehensive overview of the work 
undertaken in the first-in-human clinical study using the silicon probe. The 
aim of the clinical study was to determine the efficacy of the silicon prototype 
probes at differentiating between tissue types in excised breast tissue after 
surgical removal. The electrical impedance of macroscopically normal and 
macroscopically abnormal (cancerous and benign breast lesions) were 
recorded. The impedance data produced was subsequently correlated with 
histological findings. 
4.2 Introduction 
This chapter will outline research undertaken in a clinical trial conducted in 
Cork University Hospital (CUH), Cork, Ireland from March 2015 - March 
2016. The purpose of this trial was to determine the ability of the silicon 
probe devices to differentiate between normal breast tissue, cancerous and 
benign lesions in breast specimens excised at surgery. These samples were 
obtained from patients who underwent surgery as part of their breast cancer 
or benign breast lesion treatment. The innovative silicon probes were used to 
measure electrical impedance in freshly excised tissue samples in the 
Histopathology department in CUH. This process was performed in parallel 
with the routine tissue processing involved in preparing excised samples for 
microscopic analysis. The ability to perform continuous, real-time tissue 
analytics in a label free and non-destructive manner is a major potential 
advantage of using bioimpedance in evaluation of breast lesions [1]. 
4.2.1 Ethical Approval 
Ethical approval was sought from the Clinical Research Ethics Committee of 
the Cork Teaching Hospitals (CREC). This organisation is responsible for 
processing submissions prior to the commencement of clinical trials within 
any of the four teaching hospitals in Cork, Ireland. As part of this application 
a number of documents were generated: 
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1) Application Form 
2) Clinical Trial Protocol (Section 4.2.2) 
3) Summary of C.V. for Chief Investigator (Appendix 6.3) 
4) Research Participate Information Sheet (Appendix 6.1) 
5) Research Participate Consent Form (Appendix 6.2) 
The clinical trial protocol is outlined in section 4.2.2 and the remainder of the 
ethical approval documents are presented in the appendices (Section 6.1-
6.3). In a letter dated 21 May 2014 the CREC committee decided to grant full 
approval for the study subject to receipt of a number of revised documents 
and clarifications including: 
1) Clarify the rationale for the study  
2) Clarify who discusses the study with the patient 
3) Revised Patient Information Sheet – Patients need to be informed that 
extra tissue will not need to be taken 
In a letter dated 23 June 2014 the necessary clarifications were outlined to 
the committee and a revised copy (Version 1.4) of the patient information 
leaflet was submitted for the approval of the committee. By satisfying the 
concerns outlined by the CREC committee full approval for conducting the 
clinical trial was received. 
4.2.2 Clinical Trial Protocol 
The clinical trial protocol is a standardised procedure by which the electrical 
impedance recordings of human tissue samples (obtained from CUH) were 
carried out. It was designed to ensure optimal sample recording while 
minimising the risk of a misdiagnosis of the patient’s sample by the histology 
team. The initial ethical approval application specified that 100 patients 
would be recruited to the trial and that the clinical data would be reviewed 
after every 25 patients. Each patient took part in the trial on a voluntary basis 
and was free to withdraw their consent at any time at which point their data 
would be removed from the analytical process. The following section 
(4.2.2.1) shows a copy of the clinical trial protocol that was completed for 
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each recruited patient. The purpose of the protocol document was to 
standardise the collection of biographical and specimen data relating to each 
sample recorded as part of the clinical trial. This would ensure that a 
complete data set was obtained for each patient and would enable each 
sample to be tracked once it had been stained and analysed by the 
consultant pathologist.  
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4.2.2.1 Clinical Trial Protocol Sample 
Protocol for Sampling Fresh Breast Cancer Tissue for Research 
Purposes 
Version 3.6 09 Mar. 15 
1. Consent 
Informed consent is to be obtained from the patient before surgery on admission to 
the hospital on the morning of the surgery. 
2. Preparation prior to surgery 
i. Contact the Department of Pathology, Cork University Hospital the morning of 
the surgery to finalise arrangements for sample processing. The resection 
specimen must NOT be placed in formalin fixative after removal but transported 
fresh WITHOUT DELAY to the Department of Pathology, Cork University 
Hospital. 
ii. Histopathology Lab, CUH: Prepare supplies for the collection procedure: 
A. Disposable sterile surgical gloves 
B. Clean laboratory coat 
C. Digital thermometer 
D. Plastic container for tissue samples 
E. Permanent Marker 
F. Digital Camera  
G. Nano-pure Water (20ml) 
H. Lint-free Tissue 
LSI Lab Tyndall: Prior to use of each prototype the surface of the 
probes will be cleaned 1 times with isopropyl alcohol (IPA) and 1 times 
with nano-pure water (18.2 MΩ) in an ultrasonic water-bath for 20 min @ 
20°C each. The probes are then oxygen plasma treated for 20 min @ 
50W. 
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3. Tissue Collection 
i. Decide that the specimen is suitable for sampling. The surgeon will only 
consent patients whose tumours/specimens are likely to be of sufficient size to 
permit tumour testing. The final suitability of a specimen for testing will be 
determined by the pathology laboratory staff to avoid compromising clinical 
care. 
ii. Tumour tissue will be surgically excised by the surgical team according to 
Standard Operating Procedures and in keeping with the surgical care required 
by the patient. 
iii. NOTE: Samples are NOT to be placed in formalin fixative prior to impedance 
testing. They will be transported immediately dry in plastic medical specimen 
containers. 
iv. The medical scientist in breast cut-up will be notified prior to the sample being 
removed so that to ensure minimal delay prior to impedance recordings. 
4. Impedance Testing and Processing 
iii. Samples will be immediately transferred to the Department of Pathology 
laboratory, CUH. 
iv. The fresh tissue samples will be oriented and macroscopically described by a 
medical scientist in the cut-up laboratory. 
v. The prototype probe device will be attached to the Autolab PGSTAT204 
potentiostat and laptop computer which will be calibrated before use. 
vi. The whole tissue sample will then be dissected into a number of sections by the 
medical scientist as per current routine protocol. 
vii. Note: Recording of healthy tissue will be done before cancerous tissue to avoid 
cross-contamination. 
viii. The probe will be inserted to a depth of approximately 2 mm into the regions of 
interest (both within the cancerous lesion and the surrounding healthy tissue) 
that will be visually identified by the medical scientist prior to probe insertion 
and impedance recordings will be taken at 2 sites (1 cancerous; 1 healthy) over 
a frequency range of 1000 Hz – 100000 Hz and at the optimal fixed frequency 
over a period of 5-10 minutes. A digital thermometer will be inserted adjacent to 
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the probe to investigate the tissue temperature at the time of recording. Probe 
will be cleaned using nano-pure water and lint-free tissue between each 
measurement. 
ix. Representative photographic images will be acquired of the probe in situ to 
ensure precise probe placement and this will be confirmed by the medical 
scientist at the time the image is taken. 
x. The area immediately surrounding the needle tip will be inked and submitted for 
processing and slide preparation and the individual slide and block number will 
be recorded in the pathology notes and the data sheet attached. 
xi. Each section will be stained using Haematoxylin and Eosin in accordance with 
the Standard Operating Procedures currently in place in the department of 
pathology. This will enable the diagnosis and also microscopic characterisation 
of the area surrounding the probe insertion point. 
xii. After impedance analysis the samples will be placed in formalin for routine 
tissue processing by the pathology department according to the Standard 
Operating Procedures in place in the department. 
xiii. After staining the samples will be imaged using a light microscope and will then 
be analysed by the medical scientist to confirm the presence or absence of 
cancerous tissue surrounding each probe insertion point. This information will 
then be correlated with the impedance data generated during recording. 
xiv. After imaging, each of the samples will be archived in accordance with the 
current department of pathology guidelines. 
5. Specimen Tracking 
Following tissue sampling, the data below should be recorded and stored in a 
logbook. 
A. Name of the surgeon and medical scientist 
B. Date of surgery and procedure type 
C. Corresponding pathology number of the resected specimen 
D. Slide and block number of specimen into which the probe was inserted 
E. Types of tissue collected (tumour or normal) and anatomical location of each 
F. Storage location of each sample 
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6. Further Information 
The data collected are to be solely used for research purposes as part of a Ph.D. 
project. All specimens are to be stored in the Department of Pathology, CUH under 
standard protocols 
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Breast Tissue Sampling Protocol Checklist 
1. Before Surgery 
Item Required Yes No 
Disposable Surgical Gloves   
Laboratory Coat   
Digital Thermometer (Tissue)   
Tissue Containers   
Permanent Marker   
70% Ethanol   
Digital Camera   
Nano-pure Water (20 ml)   
Lint-free Tissue   
Probes x2 (Cleaned)   
 
Signed Consent Form Yes No 
If No, experimental recordings cannot be taken from the sample 
2. Patient Information  
Patient Name  
Date of Birth  
MRN  
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3. During surgery 
Item Yes No 
Sample Removal  Yes No Time (hh:mm) 
X-ray (Theatre) Yes No Time (hh:mm) 
X-ray (Radiology) Yes No Time (hh:mm) 
Samples Labelled   
Notify Medical Scientist   
4. Specimen Tracking 
 
  
Surgical Team 
1) 
2) 
3) 
Date  
Surgical Procedure  
Breast Left Right 
Tissue Collected (Healthy/Cancerous)  
Sample Weight (g)  
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5. Pathology Lab  
Item Yes No 
Disinfect Autolab Instrument   
Probe Set-up    
Instrument Calibration   
Medical Scientist Name  
Medical Scientist description   
Sample Temperature Yes No Temperature (°C) 
Tissue Hand-Over   
Time of First Measurement  
Total Number of Recordings  
Types of Recordings Healthy: Cancer: 
Specimen Pathology Number  
Slide Number(s)   
Block Number(s)   
 
__________________________   ____________________ 
Niall Savage      Date 
 
___________________________   ____________________ 
Medical Scientist     Date 
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4.3 Experimental 
4.3.1 Materials 
Latex gloves, disposable lab coat, dry specimen container, scalpel and 
formalin (all sourced from the Histopathology Department, CUH), 18.2MΩ 
nano-pure water (Life Science Interface Laboratory, Tyndall National 
Institute) and lint-free tissue. 
4.3.2 Instrumentation 
Autolab PGSTAT204 with FRA32M module (Metrohm UK Ltd, Runcorn, 
United Kingdom), Data-Therm IR thermometer (Guangxhou Jinxinbao 
Electronic Co. Ltd., Guangzhou, China, Ultrawave QS3 Ultrasonic Water 
Bath (Ultrawave Ltd., Cardiff, United Kingdom), Harrick Plasma PDC-002 
Extended Plasma Cleaner (Harrick Plasma, New York, U.S.A.) and silicon 
probes. 
4.4 Procedures 
4.4.1 Device Cleaning 
The silicon probes used throughout the duration of the clinical trial were 
cleaned each time prior to analysing each patients’ tissue sample. The 
previously mentioned IPA and nano-pure water cleaning protocol was used 
to remove any contaminants from the electrode surface (Section 2.5.2). The 
devices were then oxygen-plasma treated for 20 min before use. The 
cleaned probes were stored in a clean 20 ml tube for transport to the hospital 
laboratory. 
4.4.2 Before Surgery 
In accordance with the clinical trial protocol outlined, electrical impedance 
recordings of ex vivo human tissue samples were conducted in CUH over the 
course of a number of months. Prior to the commencement of each surgery, 
patients who fulfilled the inclusion criteria were invited to participate in the 
study. Tumour size was one of the major exclusion criteria. Patients with 
tumours less than 1.5 cm in diameter as determined during the pre-operative 
assessment were not included in the trial, as these tumours were too small to 
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be reliably identified macroscopically in the histopathology laboratory. Each 
potential study participant was informed of the procedure involved and made 
aware of the potential risks associated which their sample being analysed. 
Once patients agreed to participate in the study, formal written consent was 
obtained. Two copies of the most recent version of the clinical trial consent 
form were signed in the presence of Niall Savage. One copy was placed in 
the patients’ medical file and the other was stored with the other clinical trial 
documentation in the office of Dr Brian O’Donnell in CUH. After consent was 
obtained, the medical scientists in the histopathology department were 
informed and a clean, dry specimen container was brought to the surgical 
theatre. 
4.4.3 During Surgery 
During the surgical procedure the relevant information relating to the breast 
specimen was documented according to the Protocol for Sampling Fresh 
Breast Cancer Tissue which has previously been described (Section 4.2.2.1). 
Of particular importance were the sample removal time and the specimen 
tracking information. For breast conserving surgery samples the standard 
operating procedure states that the sample is x-rayed twice i.e. specimen 
mammography. The first time is in theatre and then in the main radiology 
department in the hospital. Mastectomy samples do not require specimen 
mammography. All samples were then placed in a dry specimen container 
without formalin to ensure the sample was not fixed prior to recording. The 
surgical nursing team were responsible for sample labelling and cross-
checking before the specimens could leave the theatre and be brought to the 
Histopathology laboratory.  
4.4.4 Histopathology Laboratory 
Once the breast tissue specimens were received in the histopathology 
laboratory the medical scientists were required to check-in the samples and 
assign an accession number to each case. The accession number was 
logged in the clinical sampling record at the time of processing. The medical 
scientists then performed an initial tissue description in accordance with the 
standard operating procedure in the breast cut-up area of the histopathology 
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laboratory. This involves anatomical orientation of the tissue, tumour 
localisation and marking of the relevant tissue margins with ink prior to 
dissection. In the case of the majority of the specimens tested the tissues 
were only partially inked prior to the recordings being taken. The rest of the 
inking was done after the tissues had been formalin fixed. Six different 
coloured inks are used to mark each of the margins as follows: Lateral – 
Yellow; Medial – Orange; Inferior – Green; Posterior – Black; Anterior – Blue; 
Superior – Red. For each specimen the area of cancer-free tissue was 
analysed before the cancerous lesion to prevent contamination. An area of 
macroscopically normal, cancer free breast tissue was then identified away 
from the cancerous lesion on the margin of the specimen. An incision was 
made to allow the insertion of the probe in to the tissue of interest. Once the 
location of the tumour had been identified a scalpel was used to make an 
incision to expose the inside of the tumour. This allowed the accurate 
placement of the silicon probe on to the cut face of the tumour. The Autolab 
PGSTAT instrument was set-up on the dissection bench. A calibration 
protocol was run each time to ensure the potentiostat was functioning 
correctly. The electrodes were attached to the calibration box in the “C” 
configuration and the “Test FRA” method was used to record 50 
measurements across a range of frequencies. Once the calibration scan was 
completed the electrodes were then connected in a two-electrode system. 
The left electrode of the silicon probe was attached to the sense connector 
each time. The right electrode of the probe was connected to the reference 
electrode each time. The device was then inserted into the incision site and 
the tissue was apposed to the electrode surface by hand (Figure 4.1). 
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Figure 4.1: The placement of a packaged probe in a cancerous lesion in a wide-local 
excision sample obtained from Study Participant 05. 
Frequency sweep measurements were performed on each of the patient 
samples. The reason for this was because no previous recordings had been 
performed on breast tissue using this probe. Therefore, it was necessary to 
obtain impedance recordings across a range of frequencies. This data was 
then statistically analysed to determine an optimum frequency at which all 
future recordings could be performed. Triplicate recordings were obtained at 
each location across 30 frequencies from 100,000-1,000 Hz at 10 mV peak 
amplitude. An infra-red thermometer was used to measure the temperature 
of the tissue surface prior to taking the first recording. The probes were 
cleaned twice using 18.2 MΩ nano-pure water and lint-free tissue between 
the healthy and cancerous recordings. The data was then exported to SPSS 
for analysis. 
4.4.5 After Recording 
Once the final bioimpedance recording was taken, the sample was returned 
to the medical scientist. The sample was covered with formalin and 
processed routinely the following day. Six different coloured inks were 
applied to each of the relevant tissue margins (superior, inferior, superficial, 
deep, medial and lateral), as per departmental protocols. The entire 
specimen was then sectioned in to approximately 1 mm thick slices. Each 
area relevant to the pathological diagnosis was placed in a separate tissue 
cassette. Each section was then paraffin embedded to allow them to be 
sectioned and stained. Once the fixation process was completed the paraffin-
embedded tissue was sectioned using a microtome. The sections were then 
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floated to remove wrinkles. A selection of the microtome sections were 
placed on glass slides for haematoxylin and eosin staining. A consultant 
pathologist microscopically analysed the samples and provided a pathologic 
description of the cells present in each. As part of the bioimpedance clinical 
study, the site of each probe recording was individually analysed to 
microscopically confirm the tissue type. The histological findings were 
aligned with the electrical impedance recordings, thereby facilitating a 
correlation of bioimpedance and histologic data. From the pathologists report 
it was possible to determine both the tumour type and grade present in each 
of the study participant’s tissue samples and how this correlated to the 
impedance values obtained. 
4.4.6 Statistical Analysis 
A statistical analysis was performed on the data obtained during the clinical 
trial. The first test conducted was an inter-rater reliability (IRR) analysis. This 
was used to determine the correlation between the repeated measurements 
taken at each of the healthy and cancerous locations. The triplicate data sets 
for each patient were assessed individually using the SPSS software 
package. Each of the tissue margin and cancerous values were arranged in 
individual columns and a reliability analysis was performed using a two-way 
random model to determine the intra-class correlation coefficient with a 95% 
confidence interval. The value of correlation was measured from 0 to 1, with 
1 being the highest degree of correlation between the data sets. The IRR 
analysis was also performed on the complete healthy, cancerous and 
fibroadenoma data sets to determine the total cohort IRR values. 
The second statistical analysis performed was a paired-samples T test. This 
was used to determine if the difference between the means of the healthy 
and cancerous recordings was significant at a specific frequency. The data 
was arranged in descending order according to frequency (100,000-1,000Hz) 
and sequentially by patient number (Patient 02, 03, 04…). A paired-samples 
T test was used to analyse the data sets as there was one measurement 
variable (frequency) and two nominal variables (normal and abnormal 
tissue). This test was chosen to see if the means of these two normally 
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distributed interval variables differed from one another. The combined values 
of skewness and Kurtosis were used to test the normality of the data. This 
was performed on each of the data sets following analysis with the paired-
samples T test. This was used to determine if the data was normally 
distributed which was necessary when performing a parametric statistical 
analysis. Values of < 2 and < 9 for skewness and Kurtosis have previously 
been described as being suitable for parametric analysis using a paired-
samples T test [2]. The paired-samples T test was also used to optimise the 
measurement frequency at which fixed frequency measurements could be 
performed. The triplicate measurements in each tissue were averaged each 
time and the repeats were combined in the paired-samples T test with a 
confidence interval of 95 %. A p value of <0.05 would be indicative of a 
statistical significance between the two tissue types. 
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4.5 Results and Discussion 
4.5.1 Consented Patients 
A total of 33 patients were consented to the electrical impedance clinical trial 
over the course of the project. Of these patients, 10 were lost to follow-up as 
the surgical samples obtained were not suitable for electrical impedance 
recordings to be taken. Reasons for sample removal from the study for each 
of the patients were as follows: 
1) Tumour size too small and too close to deep margin 
2) Tumour size too small and differential diagnosis only available 
microscopically 
3) No solid tumour mass present; only areas of calcifications 
4) Tumour size too small and wire-guide in situ prevented dissection of 
fibroadenoma 
5) No solid tumour mass and differential diagnosis only available 
microscopically 
6) Tumour size too small and neoadjuvant chemotherapy may have 
decreased tumour size prior to surgery 
7) Tumour too deep in specimen and guide-wire was in situ 
8) Tumour too deep in specimen and guide-wire was in situ 
9) Patient presented with DCIS which was required to be mapped in its 
entirety and therefore could not be cut in to. 
10) Tumour size too small and 2 guide-wires were in situ 
All of the information obtained relating to these patients was confidentially 
maintained and stored securely in accordance with the ethical approval 
application. A total of 23 patients’ surgical samples were suitable for 
electrical impedance recordings to be performed. These included tissue 
obtained during mastectomy, central and wide-local excision surgeries. 
Figure 4.2 shows the specimen obtained from Study Participant 05 that was 
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removed by wide-local excision. The tumour present was approximately 3 cm 
in diameter but is not visible in the image. The short superior (right) and long 
lateral (left) orientation sutures are readily identifiable in Figure 4.2. 
 
Figure 4.2: A wide-local excision sample obtained from Study Participant 05 which contained 
a tumour of approximately 3 cm diameter. The orientation sutures can clearly be seen at two 
locations on the sample. 
Each of the patients consented to the trial and the procedure they underwent 
is documented in Table 4.1. 
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Table 4.1: The details of the participants recruited to the breast cancer 
clinical study 
Participant No. Procedure Side Recordings 
1 Mastectomy Bilateral No 
2 Wide-local Excision Right Yes 
3 Mastectomy Right Yes 
4 Wide-local Excision Left No 
5 Wide-local Excision Left Yes 
6 Wide-local Excision Left No 
7 Central Excision Left Yes 
8 Wide-local Excision Left Yes 
9 Mastectomy Right Yes 
10 Mastectomy Right Yes 
11 Wide-local Excision Left Yes 
12 Mastectomy Bilateral (Left) Yes 
13 Mastectomy Right Yes 
14 Mastectomy Left Yes 
15 Central Excision Right Yes 
16 Wide-local Excision Right No 
17 Wide-local Excision Left Yes 
18 Mastectomy Bilateral (Right) Yes 
19 Wide-local Excision Left Yes 
20 Wide-local Excision Left Yes 
21 Chest Resection Left No 
22 Mastectomy Left No 
23 Wide-local Excision Left No 
24 Wide-local Excision Left No 
25 Mastectomy Right No 
26 Wide-local Excision Left Yes 
27 Wide-local Excision Right Yes 
28 Mastectomy Left Yes 
29 Wide-local Excision Left No 
30 Mastectomy Right Yes 
31 Mastectomy Left Yes 
32 Wide-local Excision Right Yes 
33 Wide-local Excision Left Yes 
4.5.2 Impedance Modulus Recordings 
The medical scientists were responsible for macroscopically identifying the 
area of interest with regard to the cancerous lesion and the surrounding 
healthy tissue. Figure 4.3 shows the partially inked specimen obtained from 
Study Participant 11 into which an incision had been made to reveal the 
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tumour surface. There were three areas identified by the medical scientist 
that were visible in the Figure 4.3: 
1) Red – Cancerous tumour 
2) Green – Fat Necrosis from previous CNB. This area was not analysed 
as part of the study 
3) Blue – Area of macroscopically normal breast tissue 
 
Figure 4.3:  The areas of interest in the wide-local excision sample of study participant 11. 
The areas are the cancerous lesion (Red), fat necrosis (Green) and normal tissue (Blue). 
Of the 33 patients consented to the study 2 patients presented for surgery 
with a breast fibroadenoma. Figure 4.4 shows US wire-guided diagnostic 
excision biopsy sample obtained from Study Participant 08. The white area in 
the centre of the image shows the point of incision into the fibroadenoma. 
This type of tumour is normally benign and may potentially produce different 
impedance values to either the cancerous or normal breast tissue. This may 
be useful in diagnosing the type of tumour present at the point of insertion. 
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Figure 4.4: A partially inked ultrasound wire-guided diagnostic excisional biopsy specimen 
with an incision made in to an area of fibroadenoma shown in white from study participant 
08. 
4.5.3 Pathology Findings 
Microscopic images were taken of each of the slides containing the tissue at 
the site of each electrode recording. Figure 4.5a shows the microscopic 
image from the site of the tissue margin impedance modulus recordings from 
Study Participant 02. The image contains two features associated with 
normal breast tissue. The red square highlights an area of normal peri-
lobular adipose tissue which is evident across the majority of the section. 
The black square highlights a normal breast lobule. The lobules of the 
human breast are formed by ductules containing three cell types: basal cells, 
luminal cells, and myoepithelial cells which are all present in the area 
highlighted [3]. Figure 4.3b displays evidence of hyperchromatic staining, 
pleomorphic cells and dense fibrotic tissue which is indicative of cancerous 
invasion [3]. The microscopic images correlated with the macroscopic probe 
placement in each of the 17 cases analysed by the consultant pathologist to 
date (See Appendix 6.6.2). This was to be expected as the majority of the 
patients consented to the clinical trial had large well-circumscribed tumours 
that were readily identifiable by the medical scientists and pathologists in the 
department. 
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Figure 4.5: The microscopic images obtained from the healthy tissue margin (A) and the 
cancerous lesion (B) of study participant 02 as confirmed by a consultant pathologist. 
The tissue type confirmation at the recording electrode placement site was 
necessary to ensure that the electrical impedance recordings obtained were 
being interpreted correctly (Table 4.2).  
Table 4.2: The patient age, type and grade of the tumour samples analysed during the 
study. 
Participant 
No. 
Age Tumour Type Grade 
2 58 Invasive Ductal Carcinoma 2 
3 65 Invasive Lobular Carcinoma 2 
5 83 Metastatic Squamous Cell Carcinoma N/A 
7 50 Invasive Ductal Carcinoma 3 
8 21 Fibroadenoma N/A 
9 62 Invasive Ductal Carcinoma 2 
10 63 Invasive Ductal Carcinoma 3 
11 65 Invasive Ductal Carcinoma 3 
12 34 Invasive Ductal Carcinoma 3 
13 72 Invasive Ductal Carcinoma 3 
14 78 Invasive Ductal Carcinoma 3 
15 70 Invasive Ductal Carcinoma 2 
17 64 Mixed Invasive Ductal and Lobular Carcinoma 2 
18 50 Invasive Ductal Carcinoma 2 
19 50 Fibroadenoma N/A 
20 88 Invasive Mucinous Carcinoma 2 
26 51 Invasive Ductal Carcinoma 3 
27 79 Mixed Invasive Ductal and Lobular Carcinoma 2 
28 81 Invasive Ductal Carcinoma 3 
30 60 Invasive Ductal Carcinoma 3 
31 52 Mixed Invasive Ductal and Lobular Carcinoma 2 
32 59 Invasive Ductal Carcinoma 3 
33 58 Invasive Ductal Carcinoma 2 
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4.5.4 Inter-rater Reliability Analysis 
The first statistical test performed was an IRR analysis. This was used to 
identify discrepancies between the triplicate recordings obtained in each of 
the tissue locations. Each patient’s data sets were tested separately both 
with and without any data thought to be an outlier compared to the other 
recordings. If the intra-class correlation improved to above 0.900 then the 
outlying data would be omitted from the final analysis. During the analysis, 
three sets of patient’s data were found to contain outlying data. 
Table 4.3: The IRR analysis of the cancerous recordings obtained from study participant 05 
including 3 healthy recordings including the outlying values. 
 Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.616 .419 .776 5.804 29 58 .000 
Average 
Measures 
.828 .684 .912 5.804 29 58 .000 
Table 4.4: The IRR analysis of the cancerous recordings obtained from study participant 03 
including 2 cancerous recordings excluding the outlying values. 
 Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
.997 .994 .999 745.124 29 29 .000 
Average 
Measures 
.999 .997 .999 745.124 29 29 .000 
 
The results in Tables 4.3 and 4.4 shows the data output from the IRR 
analysis with and without one of the repeated values. After removing one of 
the triplicate repeat values the intra-class correlation coefficient increased 
from 0.828 to 0.999. This showed that the value obtained for one of the 
repeat recordings was significantly different from the other impedance values 
from that location. This set of data was therefore omitted as it did not provide 
a representative repeat value that could be averaged appropriately. The 
cancerous recordings for patient 07 were shown to contain an outlying data 
set which was not included in the future statistical analysis (Table 4.5)  
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Table 4.5: The average measures output from the IRR analysis of study participant 07 
before and after data set 01 was removed. 
 Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
Avg Measures 
Before 
.117 -.619 .550 1.133 29 58 .336 
Avg Measures 
After 
.877 .742 .941 8.133 29 29 .000 
 
Although the intra-class correlation value did not increase above the 0.90 
threshold, the removal of the outlying data set did significantly improve the 
overall correlation. The upper bound of the 95% confidence interval does 
however go beyond the required threshold and therefore it was decided to 
omit the outlying data set from any future statistical analysis. The IRR data 
output for Study Participant 09 was found to contain an outlying data set 
which was subsequently removed from the future analysis (Table 4.6). 
Table 4.6: The average measures output from the IRR analysis of study participant 09 
before and after data set 01 was removed. 
 Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower Bound Upper Bound Value df1 df2 Sig 
AvgMeasures 
Before 
.064 -.634 .511 1.069 29 87 .393 
AvgMeasures 
After 
.958 .924 .979 24.039 29 58 .000 
 
As with the analysis of the two previous patients, the results of the IRR 
analysis of patient 09 showed an improvement in both intra-class correlations 
(0.064 – 0.958) and p value significance (p = 0.393 – p < 0.001). It was 
therefore decided to omit the outlying data set. The IRR analysis was 
repeated for all of the data sets obtained to determine the reliability of the 
values from the whole cohort. The first data set analysed was the entire 
tissue margin samples obtained from each patient (Table 4.7). The data 
output shows that the intra-class correlation across of the recorded values 
was 0.984 (p <0.001) which is a positive result. This suggests that the 
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repeated measurements obtained correlated well across all of the patients 
analysed. 
Table 4.7: The IRR analysis for the entire tissue margin recordings obtained from the total 
patient cohort. 
 Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower Bound Upper 
Bound 
Value df1 df2 Sig 
Avg Measures .984 .975 .991 63.894 28 1820 .000 
The next data set that was analysed was all of the cancer recordings which 
did not include the two patients with fibroadenomata, which are benign. The 
statistical output of the IRR analysis is displayed in Table 4.8 which shows 
the intra-class correlation for all the cancer recordings performed to be .997 
(p < 0.001). As with the tissue margin recordings, there was a positive 
correlation between all of the data sets obtained for the patients with breast 
cancer. 
Table 4.8: The IRR analysis for all of the cancer recordings obtained during the clinical 
study. 
 Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower Bound Upper 
Bound 
Value df1 df2 Sig 
Avg Measures .984 .975 .991 62.50 29 1769 .000 
The final IRR analysis performed was on the data obtained for the 
fibroadenoma recordings. Table 4.9 shows the data obtained for the 
reliability analysis of the electrical impedance recordings taken from the two 
fibroadenoma specimens. The intra-class correlation obtained was .999 (p < 
0.001) which was a positive result and there was almost a perfect correlation 
across the recorded values. 
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Table 4.9: The IRR analysis for all of the fibroadenoma recordings obtained from two 
patients. 
 Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower Bound Upper 
Bound 
Value df1 df2 Sig 
Avg Measures .999 .999 1.000 1655.9 29 145 .000 
4.5.5 Paired-samples T Test Analysis 
4.5.5.1 Optimum Frequency Selection 
In order to determine the optimum frequency at which to record fixed 
frequency impedance modulus recordings it was necessary to assess each 
of the individual paired-samples T Test analyses that were performed. It was 
then possible to choose a frequency which would provide the most 
statistically significant separation between the mean impedance modulus 
values for the normal and abnormal breast tissue. In choosing the optimum it 
was necessary to exclude frequencies at either end of the recorded 
spectrum. This was to avoid choosing frequencies that would only contain 
either resistive or capacitive elements as this would not provide a true 
reflection of the difference in impedance modulus between the two tissue 
types despite potentially having a larger mean separation. The optimum 
frequency outputs for each of the paired-samples T test analyses are shown 
in Appendix 6.8.2. 
4.5.5.2 All Study Participants 
Normality testing was performed using the 23 pairs of averaged data 
obtained from each of the patients at a frequency of 20,434 Hz. Table 4.10 
shows the skewness and Kurtosis values generated from the tissue margin 
and lesion averages for the entire patient cohort. For both sample types the 
values were below the upper limit of 2 and 9 for skewness and Kurtosis 
respectively (Table 4.10). Therefore, this data set was suitable for analysis 
using the paired-samples T test. 
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Table 4.10: The data output for the normality testing performed on average tissue margin 
and lesion recordings for each patient. N=17. 
Normality Test Tissue Margin All Lesions 
Skewness .252 1.942 
Kurtosis -1.446 4.960 
A paired-samples T test was used to determine the level of significance 
between the averaged values for the tissue margin and lesion recordings 
from all of the study participants. This provided an overall indication of the 
probes ability to differentiate between tissue margins and both benign and 
cancerous breast lesions. The data obtained from the paired-sample T test 
indicated that the optimum frequency for recording of the combined tissue 
margin and lesions was 20,434 Hz. The mean difference between the tissue 
margin and lesion recordings was 4,340 Ω with p < 0.001. This demonstrated 
that for the combined averages across all of the study participants the 
separation of the means between the tissue margins and lesions was 
significantly different. The triplicate average values for each patient recorded 
were combined and an average value for the healthy and non-healthy 
recordings was graphed (Figure 4.6). 
 
Figure 4.6: The Bode plot of the average impedance values for the tissue margin and lesion. 
N=23. 
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The graph of the electrical impedance tissue results showed separation 
across all of the frequencies tested. This correlates with the results of the T 
test analysis previously shown. The statistical analysis of all 23 study 
participants combined showed that in all cases the silicon probe was able to 
differentiate between the healthy tissue margin and the area of the breast 
lesion in the case of both benign and cancerous lesions at a frequency of 
20,434 Hz and a peak voltage of 10 mV. This finding demonstrated that the 
probe could measure impedance in excised breast tissue. The impedance 
values obtained were sufficiently different to suggest the utility of the probe in 
tissue type identification. 
4.5.5.3 All Cancers 
In order to determine the silicon probes effectiveness at determining the 
difference between only cancerous and normal tissues the values obtained 
for benign fibroadenoma lesions were removed and the paired-sample T test 
analysis was repeated. The skewness and Kurtosis normality tests were 
repeated with the fibroadenoma values removed and the results are 
displayed in Table 4.11. The values obtained were all below the acceptable 
limits for parametric testing. 
Table 4.11: The data output for the normality testing performed on average tissue margin 
and cancer recordings for each patient. N=21. 
Normality Test Tissue Margin All Cancer 
Skewness .337 1.802 
Kurtosis -1.553 4.284 
The statistical analysis of the 21 patient samples showed that at the optimum 
frequency of 20,434 Hz the mean separation between the tissue margins and 
the cancerous lesions was 4,187 Ω (p < 0.001). The Bode plot of the average 
cancer and tissue margin impedance values showed a separation across all 
of the frequencies measured each time (Figure 4.7). The results 
demonstrated that for the combined cancer and tissue margin recordings the 
prototype device was capable of differentiating between the two tissue types. 
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Figure 4.7: The Bode plot of the average impedance values for the tissue margin and cancer 
tumours. N=21. 
4.5.5.4 All Primary Breast Cancers 
A further series of paired-sample T tests were performed to determine if the 
types of lesions being analysed affected the probes ability to differentiate 
between normal and abnormal breast tissue. For this analysis only primary 
breast tumours were included which meant that the metastatic squamous cell 
carcinoma was excluded. Normality testing was performed on the data sets 
obtained at a frequency of 20,434 Hz (Table 4.12). The values generated 
from the normality testing allowed the paired-samples T test to be used to 
statistically analyse the primary breast cancer data. 
Table 4.12: The data output for the normality testing performed on average tissue margin 
and cancer recordings for each patient. N=20. 
Normality Test Tissue Margin All Cancer 
Skewness .434 1.743 
Kurtosis -1.427 4.073 
The paired-sample T test showed that the mean separation between the 
breast cancer tumours and the healthy tissue margins was 3,845Ω (p < 
0.001). The combined analysis of all of the primary breast tumours and the 
associated tissue margins showed that across all of the frequencies tested 
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there was a significant separation between the two tissue types as illustrated 
in the Bode plot in Figure 4.8.  
 
Figure 4.8: The average impedance values for the tissue margin and tumour for primary 
breast cancers. N=20. 
4.5.5.5 All Invasive Ductal Cancers 
The final combined grouping of cancer recordings to be analysed  was the 
IDCs. These accounted for 15 of the 23 study participant samples that were 
recorded. This group of samples was composed of 11 patients who 
presented with IDC grade 3 and 4 samples were confirmed as being IDC 
grade 2. As with the previous data sets the normality of the distribution was 
assessed. The values of skewness and Kurtosis were deemed to be within 
the acceptable range for use with parametric statistics (Table 4.13). 
Table 4.13: The data output for the normality testing performed on average tissue margin 
and cancer recordings for each patient. N=15. 
Normality Test Tissue Margin All Cancer 
Skewness .477 .819 
Kurtosis -1.620 1.165 
The Bode plot of the averaged electrical impedance values obtained from all 
of the IDC samples showed that an excellent separation existed between the 
tissue margins and the cancerous lesions (Figure 4.9). 
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Figure 4.9: The average impedance values for the tissue margin and tumour for primary 
breast cancers. N=15. 
The results of the paired-samples T test demonstrated that a statistically 
significant difference existed between the mean impedance modulus values 
for the combined IDC and the associated tissue margins (4,102 Ω; p = 
0.002). 
4.5.5.6 Differentiation by Cancer Type 
In order to determine if the electrical impedance response produced by the 
tissues was affected by the type of cancer and grade, the study participants 
were subdivided based on their pathological report findings and the analysis 
of the sections obtained from the site of recording. In total the tissues were 
separated into 7 categories and each subtype was statistically analysed 
individually: 
1) Invasive ductal carcinoma – Grade 3 
2) Invasive ductal carcinoma – Grade 2 
3) Mixed invasive ductal and lobular carcinoma – Grade 2 
4) Invasive lobular carcinoma – Grade 2 
5) Invasive mucinous carcinoma (IMC) – Grade 2 
6) Metastatic squamous cell carcinoma (MSCC) 
7) Fibroadenoma 
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4.5.5.6.1 Invasive Ductal Carcinoma Grade 3 
The most common cancer type observed during the study was IDC grade 3 
with a total of 11 patients presenting with it (Figure 4.10). This was to be 
expected as the tumours of interest to the study needed to be 1.5 cm or 
larger in diameter.  Large tumour mass is commonly associated with an 
advanced grade of cancer [4]. The normality of the data distribution was 
assessed for each of the 11 patients who presented with IDC grade 3. The 
values obtained for skewness and Kurtosis are displayed in Table 4.14. 
These values were acceptable to allow the IDC grade 3 data to be analysed 
with the paired-samples T test. 
Table 4.14: The data output for the normality testing performed on average tissue margin 
and cancer recordings for each patient. N=11. 
Normality Test Tissue Margin All Cancer 
Skewness -.088 .972 
Kurtosis -2.035 1.938 
The results displayed here show that a separation exists between the cancer 
and tissue margin recordings across all of the frequencies measured. This 
indicated that it was possible to differentiate between tissue types in patients 
who presented with IDC grade 3. A paired-samples T test was used to 
determine if a statistically significant difference existed between the tissue 
margin and the cancerous tumour (5,111 Ω). A value of p = 0.004 obtained 
by the analysis showed that the difference between the mean impedance 
values at the optimum frequency of 20,434 Hz was statistically significant. 
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Figure 4.10: The Bode plot of the averaged electrical impedance results of the invasive 
ductal carcinoma grade 3 samples recorded during the clinical trial. N=11. 
The group of patients consented to the trial with IDC Grade 3 constituted the 
largest sample population in the study.  In order to assess whether a 
statistical similarity existed across the 11 patients the interclass correlation 
coefficient was determined using an inter-rater reliability test across the 
entire frequency range tested.  The results are presented in Table 4.15. 
Table 4.15: The IRR analysis for all of the IDC Grade 3 tissue margin and cancer recordings 
obtained during the clinical study. 
 Intra-class 
Correlation 
95% Confidence Interval F Test with True Value 0 
Lower Bound Upper 
Bound 
Value df1 df2 Sig 
Avg Measures 
Tissue Margin 
.934 .872 .964 15.103 29 290 .000 
Avg Measures 
IDC Grade 3 
.881 .806 .935 8.383 29 290 .000 
The results presented show that despite the variability observed between 
each of the individual patient samples and environmental factors 
encountered during impedance modulus recordings there is statistical 
evidence to support a correlation between each of the IDC Grade 3 samples. 
The intra-class correlation results for the tissue margin and cancer 
recordings were 0.934 and 0.881 respectively. Although the value for the 
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cancer recordings is below the threshold of 0.9 the upper bound of the 95% 
confidence interval does cross this threshold. 
4.5.5.6.2 Invasive Ductal Carcinoma Grade 2 
The second most common cancer in the study was IDC Grade 2 which was 
determined to be present in 4 of the patients samples recorded as part of the 
study. As with the previous data sets the normality of the distribution was 
assessed. The values of skewness and Kurtosis were deemed to be within 
the acceptable range for use with parametric statistics (Table 4.16).  
Table 4.16: The data output for the normality testing performed on average tissue margin 
and cancer recordings for each patient. N=4. 
Normality Test Tissue Margin All Cancer 
Skewness -.173 .428 
Kurtosis -.660 -.027 
The graph showed that a difference existed between the tissue margins and 
the tumour of patients who presented with IDC grade 2 across all of the 
measured frequencies (Figure 4.11). A paired-samples T test was used to 
determine if the result obtained showed a statistically significant difference 
between the tissue margin and the cancerous tumour. At the optimum 
frequency of 20,434 Hz a mean separation of 1,329 Ω with an associated p-
value of 0.027 was observed. 
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Figure 4.11: The Bode plots of the averaged electrical impedance results of the invasive 
ductal carcinoma grade 2 patients consented to the clinical trial. N=4. 
4.5.5.6.3 Mixed Invasive Ductal and Lobular Carcinoma Grade 2 
Of the 23 patients consented to the clinical study only 3 were determined to 
have a mixed invasive cancer composed of both ductal and lobular 
carcinoma cell types. It was not possible to assess the normality of the data 
distribution as the sample size was too small. The results displayed here 
show that a separation exists between the cancer and tissue margin 
recordings across all of the frequencies measured. This indicated that it was 
possible to differentiate between tissue types in patients who presented with 
mixed IDC and ILC grade 2 tumours. A paired-samples T test was used to 
determine if a statistically significant difference existed between the tissue 
margin and the cancerous tumour 
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Figure 4.12: The electrical impedance results from the mixed invasive ductal and lobular 
carcinoma grade 2 sample. N=3. 
At the optimum frequency of 20,434 Hz a mean separation of 2,278 Ω with 
an associated p-value of 0.426 was observed. The analysis showed that the 
difference between the mean impedance modulus values at the optimum 
frequency was not statistically significant. However, the sample size for 
mixed carcinomas was very small and would need more patient samples to 
draw appropriate conclusions. 
4.5.5.6.4 Invasive Lobular Carcinoma Grade 2 
The second most common cancerous lesion subtype within the breast is ILC. 
During this study 1 patient was consented to the trial with this cancer type 
(Figure 4.13). The Bode plot shows the average of the triplicate recordings 
obtained at the two recording sites. There was separation observed across 
all of the frequencies measured which was a positive result. 
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Figure 4.13: The averaged electrical impedance result of the invasive lobular carcinoma 
(ILC) grade 2 patient consented to the clinical trial. N=1. 
The result outlined here indicated that the probe was capable of 
differentiating between the tissue margins and the tumour of a patient who 
presented with ILC grade 2 across each of the frequencies tested. A paired-
samples T test was not able to be performed on the data without at least one 
more specimen of the same category. However, the mean values for the 
recordings obtained at the optimum frequency of 20,434 Hz showed a 
separation of 7,610 Ω (Figure 4.14). This indicates that the probe was 
capable of differentiating between a tumour and normal breast tissue in a 
patient with ILC Grade 2. In order to assess the statistical difference between 
the mean impedance modulus values it will be necessary to obtain many 
more patient samples with this particular cancer type and grade. 
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Figure 4.14: The mean values of the tissue margin and lesion recordings obtained at a 
frequency of 20 kHz from the tissue margins and cancer from the ILC Grade 2 specimen. 
N=1. 
4.5.5.6.5 Invasive Mucinous Carcinoma Grade 2 
One patient who was consented to the study was found to have an invasive 
mucinous carcinoma grade 2 upon pathological assessment. The Bode plot 
of the recorded impedance values showed that a clear separation was 
present across all 30 data points obtained (Figure 4.15). 
 
Figure 4.15: The electrical impedance results of the invasive mucinous carcinoma (IMC) 
grade 2 patients consented to the clinical trial. N=1. 
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The data outlined here showed a separation of 918 Ω between the tissue 
margins and the tumour of the patient who was determined to have IMC 
grade 2. It was not possible to perform either a paired-samples T test or a 
normality of distribution test on the data obtained from the IMC sample as 
only one sample was obtained. However, the data provided from the Bode 
plot shows a separation between the two tissue types. The mean separation 
observed at the optimum frequency of 20,434 Hz showed separation also 
(Figure 4.16). 
 
Figure 4.16: The mean values of the tissue margin and lesion recordings obtained at a 
frequency of 20 kHz from the tissue margins and cancer from the IMC Grade 2 sample. N=1. 
4.5.5.6.6 Metastatic Squamous Cell Carcinoma 
One patient consented to the trial presented with a secondary breast tumour. 
This was confirmed pathologically to be a metastatic squamous cell 
carcinoma. The histological analysis of this specimen showed evidence that 
the tumour had developed as a lymph node metastasis. Although this sample 
was not a case of primary breast cancer it was included as part of the study 
to demonstrate the probes ability to differentiate between tumours that 
originated outside of the breast and the surrounding healthy breast tissue 
margin (Figure 4.17). 
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Figure 4.17: The Bode plot of the electrical impedance recordings taken from the metastatic 
squamous cell carcinoma (MSCC) specimen. N=1. 
The Bode plots displayed showed that separation existed between the 
cancer and tissue margin recordings across all of the frequencies measured. 
This indicated that it was possible to differentiate between tissue types in 
patients who presented with MSCC tumours in the breast. It was not possible 
to perform a paired-samples T test as only one set of patient data was 
obtained for this cancer subtype. However, the mean values for the 
recordings obtained at the optimum frequency of 20,434 Hz showed a large 
separation (Figure 4.18). 
 
Figure 4.18: The mean values of the tissue margin and lesion recordings obtained at a 
frequency of 20 kHz from the tissue margins and cancer from the metastatic squamous cell 
carcinoma patient. N=1. 
 
Human Breast Tissue Clinical Trial  Chapter 4 
198 
 
4.5.5.6.7 Fibroadenoma 
A fibroadenoma is tumour formed of mixed fibrous and glandular tissue, 
typically occurring as a benign growth in the breast. Two patients who 
consented to the trial presented with a benign lesion within the breast. These 
were confirmed pathologically to be fibroadenomas. Although these samples 
were not technically cases of breast cancer they were included as part of the 
study to demonstrate the probes ability to differentiate between healthy and 
benign breast tissues specimens (Figure 4.19). The Bode plot displayed 
indicated that the probe was capable of differentiating between the tissue 
margins and the benign lesion of the patients who presented with a 
fibroadenoma across all 30 of the frequency points. A paired-samples T test 
was used to determine if the result obtained at the optimum frequency of 
20,434 Hz showed a statistically significant difference between the tissue 
margin and the benign lesion (5,947 Ω; p = 0.029) (Figure 4.20). 
 
Figure 4.19: The Bode plot of the averaged electrical impedance results of the fibroadenoma 
patients consented to the clinical trial. N=2. 
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Figure 4.20: The mean ± S.D. of the tissue margin and fibroadenoma recordings obtained at 
a frequency of 20 kHz from the tissue margins and benign lesions from the fibroadenoma 
patients. N=2; mean ± S.D.; p = 0.029. 
4.6 Discussion 
It was determined from the statistical analysis performed in this chapter that 
the silicon prototype was capable of differentiating between healthy tissue 
margins and both benign and cancerous breast lesions. However, given the 
heterogeneous nature of breast cancer as a disease it has not yet been 
possible to differentiate between the many different subtypes that can be 
detected.  The definitive sub-classification of breast cancer in to distinct 
groups is complicated by the very nature of the disease itself. The World 
Health Organisation published guidelines on the histological classification of 
breast tumours. There were eight tumour origins based on cell type with 
nearly 100 additional subtypes [5]: 
1) Epithelial – 55 subtypes 
2) Myoepithelial – 4 subtypes 
3) Mesenchymal – 18 subtypes 
4) Fibroepithelial – 6 subtypes 
5) Tumours of the nipple – 3 subtypes 
6) Malignant Lymphoma – 4 subtypes 
7) Metastatic Tumours 
8) Tumours of the male breast – 3 subtypes 
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In addition to the histology of the breast cancers it is also possible to classify 
each breast lesion based on molecular classification with six distinct 
categories: basal-like, ErbB2+, normal breast like, Claudin-low, luminal A and 
luminal B [6-8]. As part of the current study it was possible to analyse 6 
histological subtypes of cancer with only one sample in most of the 
categories. Given the number of different breast cancer subtypes it would not 
be feasible to obtain representative sample cohorts for each of histological 
groupings without a very large multi-centre clinical trial conducted over many 
years. This is well beyond the scope of this current study as it would require 
significant resources, manpower and time.  
The most important finding from the work presented in this chapter was the 
confirmation of the prototype silicon probes ability to differentiate between all 
of the cancer types combined and the associated healthy tissue margins.  
This demonstrates that the device is fit for purpose in the recording of ex vivo 
electrical impedance measurements from breast tissue samples. As the 
number of patients consented to the clinical trial continues to increase it 
should be possible to ascertain the true power of the probe in differentiating 
not only between healthy and cancerous lesions but also between cancerous 
and benign lesions which is one of the expected future uses of this device. 
Currently the sample sizes for the cancer sub-types are too low to draw 
appropriate conclusions about the probes true sensitivity and specificity in 
differentiating between breast cancer subtypes. It was possible to assess 
show a correlation between each of the 11 IDC Grade 3 study participants 
that indicated that there was a statistical similarity across all the patient 
samples recorded. This would suggest that it may be possible in the future to 
categorise cancer tumours based on electrical impedance but this study is 
too preliminary to be able to definitively conclude this. However, the real 
clinical benefit of this probe is in the differentiation of normal and abnormal 
tissues within the breast. The ability to distinguish between different sub-
types of cancer may not ever be feasible using electrical impedance. The 
results outlined in this chapter showed that mean difference between the 
normal and abnormal tissues across each of the cancer sub-types was not 
sufficiently different from each other. This means that it would not be 
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possible to readily identify the individual cancer sub-type based solely on the 
electrical impedance. Any patient who is diagnosed as having breast cancer 
will undergo pathological investigation and molecular screening to determine 
the exact cancer type present within the breast as well as the cell surface 
receptors located on each cell. This diagnosis will then determine the 
treatment each individual patient receives. This cellular and molecular 
classification of cancer is far superior to anything that can be achieved by 
electrical impedance alone. Therefore, it is not necessary for the silicon 
probe device to be able to differentiate between cancer sub-types, only 
between cancer and non-cancer which was shown in this chapter to be 
possible.   
The large variability observed between the electrical impedance readings 
obtained from the different patient samples may result from a number of 
different sources: 
1) Probe contact and apposition 
2) Cancer pathology 
3) Extracellular fluids 
4) Heterogeneous nature of breast cancer 
The apposition of the recording electrodes to the exposed surface of the 
tissues of interest is extremely important to obtaining an accurate electrical 
impedance measurement. The current silicon prototype was not able to 
directly penetrate in to the tissues being recorded. Therefore, it was 
necessary to make an incision in to the tumour and tissue margins to access 
the recording sites. The variable firmness of the tumours and tissue margins 
meant that apposition of the electrodes to the tissue surface was often quite 
difficult but ultimately achievable. Cancerous lesions can develop as 
extremely heterogeneous masses with many different structures present 
within the tumour. In case of IDC lesions the histological presentation can 
include [5]: 
1) Tumour cells that can be arranged in cords, clusters and trabeculae 
whilst some tumours are characterized by a predominantly solid or 
syncytial infiltrative pattern with little associated stroma 
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2) In a proportion of cases glandular differentiation may be apparent as 
tubular structures with central lumina in tumour cell groups 
3) The cytoplasm is often abundant and eosinophilic 
4) Nuclei may be regular, uniform or highly pleomorphic with prominent, 
often multiple, nucleoli, mitotic activity may be virtually absent or 
extensive 
5) There may be highly cellular fibroblastic proliferation, a scanty 
connective tissue element or marked hyalisation 
6) Focal necrosis may be present and is occasionally extensive 
7) Up to 80 % will contain foci of associated DCIS 
8) In a minority of cases a distinct lymphoplasmacytoid infiltrate can be 
identified 
In the introduction of this thesis the term bio-impedance was described as 
the response of a living organism to an externally applied electric current, 
and is a measure of the opposition to the flow of that electric current through 
tissues [9, 10]. This opposition the current experiences when passing 
through these tissues is determined by a number of factors including the 
extracellular fluid, cell membrane, intracellular fluid and sub-cellular 
structures. The extremely variable nature of cancerous tumours has resulted 
in tissues which appear to effectively conduct an electrical current and 
thereby results in a low impedance modulus value being observed during 
experimental measurement in previously described literature [11-13]. This 
finding is in keeping with the results presented in this chapter.  
Finally the effect of extracellular fluids at the site of incision in to the tissues 
could be a contributory factor to the variability of the observed impedance. 
These fluids could include blood from the excised tissue, intracellular fluid 
leaking from dead or dying cells and interstitial fluid which surrounds all cells. 
The varying degree to which any or all of these fluids were present at the 
time of the electrical impedance could potentially have had an influence on 
the measurements obtained. This is however a fundamental aspect of 
performing investigations on biological samples and the inter sample 
variation is impossible to overcome.  
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As part of the validation of the silicon probe device it was necessary to 
conduct impedance modulus recordings on freshly excised ex vivo breast 
tissue samples. It was not possible to control all of the potential variables that 
could have an effect on the recorded impedance values including patient 
age, cancer type and grade, time between removal and recording, amount of 
blood present at recording site, intracellular and extracellular fluid volumes 
as well as many other environmental and physiological variables. The design 
of the study protocol aimed to reduce the potential impact of these factors by 
performing the recordings under similar laboratory conditions each time and 
as soon after removal from the patient as feasibly possible (within 1 hour 
post removal). However, this validation study was only suitable for assessing 
the silicon probes ability to record ex vivo tissue. Performing recordings in 
the in vitro environment presents many different variables that need to be 
assessed but also eliminates some of the environmental factors associated 
with ex vivo measurements. This can include recording at body temperature, 
active blood flow, insertion through and into intact tissues, no applied 
pressure and probe placement without macroscopic identification as well as 
many other patient specific variables. The result presented in this chapter 
show that despite the many physiological and environmental variables that 
were present when recording the ex vivo tissue samples it was possible to 
differentiate statistically between 23 pairs of normal and abnormal tissue 
samples. This demonstrated that the silicon probe was able to detect the 
cellular difference between the different tissue types by measuring the 
impedance modulus. 
4.7 Conclusions 
One of the most significant obstacles encountered during the conduct of the 
clinical breast study was patient recruitment. A requirement of the medical 
scientists was to have tumour samples with a diameter of no less than 1.5 
cm but preferably greater than 2 cm, the majority of the breast cancer 
patients undergoing surgery with Mr Martin O’Sullivan were identified through 
the BreastCheck screening service. As breast cancer screening aims to 
detect cancer at very early stages, tumour size can often be less than 15 mm 
[14]. As a result many of the patients presented with non-palpable tumours 
Human Breast Tissue Clinical Trial  Chapter 4 
204 
 
which were only detected radiographically and were too small to be included 
in the study. This meant that the recruitment of patients was extremely slow 
with less than 1 patient per week being consented to the trial. It was also not 
possible to obtain electrical impedance recordings from the majority of wire-
guided wide-local excision specimens. Five of the study participants that 
were lost to follow up underwent US wire-guided wide-local excision 
procedures. The laboratory protocol for histological processing of samples 
with inserted wire-guides prohibits the wire from being displaced prior to 
fixation and x-ray analysis. The point at which the wire-guide is inserted in to 
the lesion significantly inhibited the ability of the medical scientists to cut in to 
the lesion. This meant that it was often not possible to expose the interior 
aspect of the tumour. This additional exclusion criterion further limited the 
patient recruitment process and significantly reduced the total number of 
specimens from which recordings were obtained. 
4.7.1 Future Work 
The future work related to this experimental section involves the continued 
recruitment of suitable patients to provide a larger sample size for the 
analysis of the probes sensitivity and specificity. An increased variety of 
tissues being included for analysis could provide a valuable insight in to the 
ability of the probe to differentiate between normal, benign and cancerous 
tissues of breast origin. Of particular future clinical benefit would be 
differentiation and confirmation of benign breast lesions that could allow to 
patient to avoid undergoing surgery for removal of the tissues [15, 16]. This 
could potentially decrease the total number of patients requiring treatment for 
lesions that have been confirmed as benign.  This could significantly reduce 
the cost to the healthcare system across the country and possibly worldwide.  
Another potential future application of the device could be during surgery for 
the accurate determination of cancer-free margins [17, 18]. There is no 
consensus on what constitutes a cancer-free margin worldwide and this can 
vary from no cancer cells touching the inked-margin to 1 cm of tissue 
between the two [18]. These assessments are only made a number of days 
post-surgery due to the histologic staining process involved. Therefore, an 
impedance tool capable of real-time determination of cancer-free surgical 
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margins could significantly decrease the re-excision rate for patients 
undergoing breast conservation surgery. 
Future clinical trial studies will be required to determine the probes ability to 
screen and detect breast abnormalities including fibroadenoma, DCIS as well 
as invasive breast tumours. The overall sensitivity and specificity of the 
device will have to be assessed across each of the intended tissues of 
interest which may include other organs throughout the body such as the 
prostate which is the most common cancer in men worldwide [19]. The future 
development of these prototype devices will endeavour to produce a device 
that will act as an adjunct technology to the existing state of the art of digital 
x-ray mammography. These devices would provide essential diagnostic 
information which could inform a clinician’s decision in the treatment of a 
patient. 
A number of possible substrate materials will need to be trialled to assess 
the best one to use to increase the overall strength of the probe while 
maintaining the overall biocompatibility of the device. It would also eliminate 
the need to make an incision in to the area of interest in order to obtain the 
electrical impedance recordings. Most importantly the new instrument must 
be commercially viable and be user-friendly to ensure uptake and use by 
clinical and hospital staff. The predicted benefit of this device would be as an 
adjunct to x-ray mammography in the assessment of breast lesions, detected 
either clinically or by screening. It may potentially have a role to play in 
obtaining clear or negative margins during the breast cancer surgery. There 
is a significant potential benefit to using this probe in the determination of 
benign breast lesions. If a lesion could be confirmed as being non-cancerous 
it could potentially avoid the need for a CNB. This would significantly reduce 
the number of procedures being performed and would also reduce the 
number of benign lesions sent for histological analysis. It would also give the 
patient reassurance at the time of sampling that a cancerous lesion was not 
detected as well as having economic benefits to the health service. 
A significant amount of research will be required in order to produce a new 
prototype of the silicon probe. The substrate material which will be chosen to 
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replace the silicon must be highly compatible with semiconductor fabrication 
processes, biocompatible and strong enough to withstand insertion into 
extremely dense cancerous tissues within the breast. An ideal solution to this 
problem would be to deposit the gold electrodes on to an existing CNB 
needle. This would allow for precise needle-tip localisation during sampling 
of breast lesions to ensure accurate tissue capture. It would also provide a 
substrate that is suitable for insertion in to cancerous tissues and is 
completely biocompatible with the human body. The major drawback to the 
use of these needles is the circular shape which is not compatible with 
current deposition processes. Therefore, further research will be required to 
produce a more robust prototype device that would allow for an expansion of 
the ongoing clinical study to investigate more of the probes capabilities.  
  
Human Breast Tissue Clinical Trial  Chapter 4 
207 
 
4.8 References 
1. Srinivasaraghavan, V., J. Strobl, D. Wang, J.R. Heflin, and M. Agah, A 
comparative study of nano-scale coatings on gold electrodes for 
bioimpedance studies of breast cancer cells. Biomedical 
microdevices, 2014. 16(5): p. 689-696. 
2. Posten, H.O., Robustness of the two-sample t-test, in Robustness of 
statistical methods and nonparametric statistics. 1984, Springer. p. 
92-99. 
3. Russo, J. and I.H. Russo, Histological Evaluation of the Normal 
Breast, in Techniques and Methodological Approaches in Breast 
Cancer Research. 2014, Springer. p. 45-73. 
4. Edge, S.B., D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, and A. 
Trotti, AJCC cancer staging manual. Vol. 649. 2010: Springer New 
York. 
5. Tavassoli, F.A. and P. Devilee, Pathology and genetics of tumours of 
the breast and female genital organs. Vol. 4. 2003: Iarc. 
6. Malhotra, G.K., X. Zhao, H. Band, and V. Band, Histological, 
molecular and functional subtypes of breast cancers. Cancer Biol 
Ther, 2010. 10(10): p. 955-60. 
7. Perou, C.M., T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. 
Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. 
Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lonning, A.L. 
Borresen-Dale, P.O. Brown, and D. Botstein, Molecular portraits of 
human breast tumours. Nature, 2000. 406(6797): p. 747-52. 
8. Sorlie, T., C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, 
T. Hastie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, T. Thorsen, H. 
Quist, J.C. Matese, P.O. Brown, D. Botstein, P.E. Lonning, and A.L. 
Borresen-Dale, Gene expression patterns of breast carcinomas 
distinguish tumor subclasses with clinical implications. Proc Natl Acad 
Sci U S A, 2001. 98(19): p. 10869-74. 
9. Coffman, F.D. and S. Cohen, Impedance measurements in the 
biomedical sciences. Stud Health Technol Inform, 2013. 185: p. 185-
205. 
10. Ching, C.T., T.P. Sun, S.H. Huang, C.S. Hsiao, C.H. Chang, S.Y. 
Huang, Y.J. Chen, C.S. Cheng, H.L. Shieh, and C.Y. Chen, A 
preliminary study of the use of bioimpedance in the screening of 
squamous tongue cancer. Int J Nanomedicine, 2010. 5: p. 213-20. 
11. Morimoto, T., Y. Kinouchi, T. Iritani, S. Kimura, Y. Konishi, N. 
Mitsuyama, K. Komaki, and Y. Monden, Measurement of the electrical 
bio-impedance of breast tumors. Eur Surg Res, 1990. 22(2): p. 86-92. 
12. Morimoto, T., S. Kimura, Y. Konishi, K. Komaki, T. Uyama, Y. 
Monden, Y. Kinouchi, and T. Iritani, A study of the electrical bio-
impedance of tumors. J Invest Surg, 1993. 6(1): p. 25-32. 
13. Mishra, V., H. Bouayad, A. Schned, A. Hartov, J. Heaney, and R.J. 
Halter, A real-time electrical impedance sensing biopsy needle. IEEE 
Trans Biomed Eng, 2012. 59(12): p. 3327-36. 
14. BreastCheck, BreastCheck Programme Report 2013/14. 2015. p. 13. 
15. Jossinet, J., Variability of impedivity in normal and pathological breast 
tissue. Med Biol Eng Comput, 1996. 34(5): p. 346-50. 
Human Breast Tissue Clinical Trial  Chapter 4 
208 
 
16. Jossinet, J., The impedivity of freshly excised human breast tissue. 
Physiol Meas, 1998. 19(1): p. 61-75. 
17. Singletary, S.E., Surgical margins in patients with early-stage breast 
cancer treated with breast conservation therapy. The American 
Journal of Surgery, 2002. 184(5): p. 383-393. 
18. Morrow, M., Breast conservation and negative margins: how much is 
enough? The Breast, 2009. 18, Supplement 3: p. S84-S86. 
19. American Cancer Society, Cancer Facts & Figures 2014. 2014, 
American Cancer Society, Inc.: Atlanta. 
 
Summary and Future Work  Chapter 5 
209 
 
 
 
 
 
 
Chapter 5 
 
 
Conclusions 
  
Summary and Future Work  Chapter 5 
210 
 
5. Summary and Future Work 
5.1 Chapter 1 Summary 
Over the last two decades there has been a significant amount of research 
conducted to investigate the use of electrical impedance to detect cancer in 
tissues throughout the body with particular focus on the breast. Prototype 
devices were previously described in the literature which used electrical 
impedance as both an imaging and invasive detection method. From the 
background literature it has been shown that skin surface EIT was not 
effective enough at detecting breast cancer especially in large breasts due to 
a poor depth of penetration. For this reason the technology did not provide a 
reasonable alternative to the gold standard of digital x-ray mammography. 
However, the use of electrical impedance as a detection method 
incorporated on to a minimally invasive needle/probe has the ability to prove 
extremely useful in a number of clinical settings. This includes benign lesion 
testing, biopsy needle localisation and cancer-free margin determination. By 
utilising a novel device in these areas there is a possibility to meet a clinical 
need which is as yet unmet, while also significantly reducing the financial 
burden on the healthcare system. By using a novel device to aid in the 
determination of benign breast lesions in settings such as the BreastCheck 
screening clinics in Ireland there could be a significant reduction in the 
number of patients undergoing core-needle biopsies and full 
histopathological analysis. This would reduce patient discomfort as well as 
reducing the workload on the hospital laboratory system. If successful, it also 
has the potential benefit of being able to re-assure patients immediately, 
which could significantly limit the anxiety associated with being called back 
for assessment following a screening mammogram. 
5.2 Chapter 2 Summary 
In this chapter the fabrication and characterisation of novel electrical 
impedance devices were investigated. Initially, stainless steel was used as 
the substrate material. This was ultimately unsuccessful and was replaced 
with silicon. This material is the most compatible with the fabrication 
processes currently used the Tyndall National Institute as well as the wider 
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semiconductor industry. It was possible to fabricate and package a prototype 
device that showed excellent surface properties when analysed with SEM, 
EDX, FIB and AFM. The probes also showed excellent electrochemical 
properties when tested extensively with CV and electrical impedance. The 
results obtained in this chapter showed that reproducible and reliable devices 
had been created that were capable of detecting electrical impedance 
signals. This formed the basis of the work conducted in chapter three. 
5.2.1 Chapter 2 Future Work 
The future work arising from the research in this chapter will involve the 
fabrication of the next generation of impedance sensors. This will require 
significant research in to the type of material used as the substrate for 
deposition as well as a method for patterning electrodes on to a curved 
surface. On completion of these investigations a new prototype that is more 
robust than the current silicon probe could be produced that would be 
suitable for testing in biological tissues. 
5.3 Chapter 3 Summary 
The research presented in Chapter 3 of this thesis involved the 
biocompatibility testing of the stainless steel and silicon devices and the 
testing of meat samples of bovine, ovine and porcine origin. The 
biocompatibility testing showed that the fabrication techniques and materials 
used in the development of the prototype devices did not adversely affect the 
growth of immortalised cell lines on their surfaces. This was determined 
using a number of techniques including nuclear staining, light, fluorescent 
and SEM and a resazurin cell viability assay. The importance of having a 
biocompatible device is particularly relevant in this project as the long term 
goal was to create a device which could be used to analyse tissues in human 
patients in a clinical setting. Approval for clinical testing of this type of device 
would never be granted without first demonstrating that the device would not 
cause an adverse reaction upon insertion in to a patient. In the second half of 
this chapter a series of experiments were conducted to demonstrate the 
ability of the prototype silicon probes to differentiate between fat and muscle 
tissues in ex vivo meat samples using the modulus of the impedance. The 
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results outlined showed that for all samples tested the probes were capable 
of differentiating between muscle and fat at three amplitudes of recording 
and across all frequencies tested. In addition to this, experiments were 
performed to determine what effect an applied external force and depth of 
recording may have on the electrical impedance signal observed. The results 
demonstrated that there was a negligible difference between the different 
variables measured.   
5.3.1 Chapter 3 Future Work 
The future work resulting from this chapter will mostly be focused on the 
testing of biological tissues. By assessing different healthy tissues it would 
be possible to generate a database of electrical impedance values. This 
could be used as a baseline for a future study of pathological animal tissues 
in both live and slaughtered animals. Any future prototypes developed as 
part of this work would need to be biocompatibility tested in the same 
manner as the probes described in this thesis. 
5.4 Chapter 4 Summary 
The work presented in this chapter details the research conducted as part of 
a first-in-human clinical trial investigating the ability of the silicon probe to 
differentiate between healthy and cancerous breast tissue in human patients. 
This trial was conducted from March 2015 to March  2016 in CUH in 
conjunction with the Departments of Surgery, Anaesthesia and 
Histopathology. A total of 33 patients were consented to the trial and 
recordings were obtained from 23 of these with 10 lost to follow up. The 
results showed that the probe was capable of differentiating the healthy 
tissue margins, benign and cancerous breast lesions. The tumours tested 
during the trial were divided according to the type and grade of the tumour 
present and each of these was confirmed histologically by a consultant 
histopathologist. This work was conducted as part of an ongoing clinical trial 
that will continue to collect and test patient samples obtained during breast 
surgery to provide a proof of concept of the probes ability to differentiate 
between human breast tissues. The results presented in this chapter show 
that the silicon probe prototype device was capable of differentiating between 
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healthy tissue margins, cancerous and benign lesions within the breast. The 
type or grade of tumour does affect the probes ability to determine 
differences between the tissues. 
5.4.1 Chapter 4 Future Work 
In the opening chapter of this thesis a key research questions was posed: 
1) Can we use electrical impedance to differentiate between healthy and 
cancerous tissues of the breast? 
Three additional research questions that will need to be investigated in the 
future are: 
1) Can we provide real-time analysis of minimally invasive needle tip 
localisation during biopsies? 
2) Can we improve margin determination during breast cancer surgery? 
3) Can we provide a diagnostic tool for the determination of benign 
breast lesions? 
It has been shown through the data presented in this thesis that it is possible 
to differentiate healthy, benign and cancerous tissues of the breast using 
electrical impedance. In order to answer the rest of these questions further 
research will be required that will build upon the foundation provided by the 
work presented in this thesis. The future work in this topic will be focused on 
the recruitment of a large patient cohort to enable the sensitivity and 
specificity of the electrical impedance device to be determined. It will also be 
necessary to recruit patients with as many different subtypes of cancer as 
possible to ensure that each one can be reliably differentiated from the 
surrounding healthy tissue.  
5.5 Thesis Conclusion 
The aim of this thesis was to develop a new method for differentiating 
between healthy and cancerous tissue types for the purpose of detecting 
breast cancer. The method by which this was achieved was to use semi-
conductor fabrication techniques to produce a novel microelectrode 
impedance sensor. This was developed based on the work of previous 
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research groups who had demonstrated electrical impedance was effective 
at differentiating between tissue types within the human body. The data 
presented here showed that the techniques employed in the fabrication of a 
novel impedance sensor were suitable and resulted in a device that was 
suitable for use in a first-in-human clinical trial. As part of the study design, 
histological confirmation of probe placement was obtained which had not 
previously been assessed in any of the literature. This allowed the many 
different subtypes of cancer described in Chapter 4 to be identified and 
individually analysed. This was necessary because of the heterogeneous 
nature of breast cancer which means that it cannot be considered one single 
disease. This thesis has successfully provided a detailed description of the 
work undertaken in developing this novel method of tissue determination; 
has successfully achieved many of the research aims outlined in the opening 
chapter and has laid the foundation for research in to this area in the future. 
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6. Appendices 
6.1 Patient Information Leaflet 
Patient Information Leaflet 
(Version:  1.4   Date: 23 Jun. 14) 
Study title: Electrical Impedance Measurement of Healthy and 
Cancerous Breast Tissues ex vivo 
 
Principal investigator’s name: Mr Martin O’ Sullivan 
 
Principal investigator’s title: Consultant Breast 
Surgeon 
 
Telephone of principal investigator:  021 4920337 
 
Co-investigator’s name: Dr Brian O’Donnell 
 
Co-investigator’s title: Consultant Anaesthetist 
 
You are being invited to take part in a research study carried out 
at Cork University Hospital by CUH and Tyndall National Institute. 
Before you decide whether or not you wish to take part, you should read the 
information provided below carefully and, if you wish, discuss it with your 
family, friends or GP (doctor).  Take time to ask questions – do not feel 
rushed or under pressure to make a quick decision. 
You should clearly understand the risks and benefits of taking part in this 
study so that you can make a decision that is right for you. This process is 
known as ‘Informed Consent’.  
You do not have to take part in this study and a decision not to take part will 
not affect your future medical care.  
You can change your mind about taking part in the study any time you 
like.  Even if the study has started, you can still opt out.  You do not have to 
give us a reason.  If you do opt out, it will not affect the quality of treatment 
you get in the future.  
Why is this study being done? 
This study is being conducted to determine if a new medical device 
(produced by researchers at the Tyndall National Institute, and doctors in 
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University College Cork and Cork University Hospital) is capable of 
identifying the difference between healthy and cancerous breast tissue. The 
device will be tested using tissue samples removed during surgery and that 
are undergoing normal processing by the Department of Pathology as part of 
the diagnostic process to confirm the presence or absence of a particular 
disease. 
Who is organising and funding this study? 
The study is being organised as a joint project between Cork University 
Hospital and the Tyndall National Institute as part of a PhD research project 
funded by Molecular Medicine Ireland. The device testing will be conducted 
by Niall Savage who is the PhD researcher involved with this project. 
Why am I being asked to take part? 
You are being asked to partake in this study because you are a patient of Mr 
Martin O’Sullivan and are undergoing surgery to remove an area of breast 
tissue as part of your treatment. 
 
How will the study be carried out? 
This study will be carried out in the Department of Pathology in CUH where 
the sample removed during surgery will be processed for diagnosis. 
Electrical recordings will be performed by Niall Savage in association with 
the biomedical science staff in the department during the initial sample 
processing.  
What will happen to me if I agree to take part? 
Should you agree to participate in this study you will be required to sign a 
consent form that allows your samples to be used as part of the trial 
investigation. Whether you wish to participate in the study or not there will be 
no change to your planned care. If you choose to participate in the study no 
additional tissue will need to be removed beyond what is required as part of 
your clinical treatment. The electrical recordings will not affect the quality of 
the sample being analysed by the Department of Pathology. Information 
regarding your diagnosed condition will be retained as part of the study for 
comparison to the electrical data findings. All information which might identify 
you individually will be removed and any medical information that is retained 
will not be disclosed. 
What other treatments are available to me? 
If you choose not to participate in this study your treatment will remain 
unaffected and your tissue samples will not be used in any aspect of this 
study. 
What are the benefits? 
The benefits of this research project will be in the potential development of a 
new medical device that will improve breast cancer patient care and 
diagnosis in the future. There will be no immediate benefit to you as a 
participant in this study. 
What are the risks? 
There are no foreseeable risks to you as a patient because the testing 
required by this study will be performed after the breast tissue has been 
removed and is sent to the pathology laboratory for processing. No extra 
tissue is required as the study will use samples from the tissue that is 
removed as part of your clinical care. 
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Will it cost me anything to take part? 
There will be no additional costs applied to your treatment as a result of 
participating in this study. 
Is the study confidential? 
As part of the study it will be necessary for the researcher to compare the 
sample data with the diagnostic report produced by the Department of 
Pathology as presented to your consultant. Your individual patient number 
will be recorded along with any necessary information in regards to sample 
and disease diagnosis (e.g. age, sex, location of tumour, type and stage). All 
other biographical details will be recorded only on your medical records as 
part of normal hospital practice and will be accessible only by the medical 
staff of the hospital. All data generated during this study will be stored on 
secure servers maintained by the I.T Department of Tyndall National 
Institute. All tissue samples generated during surgery will be processed by 
the Department of Pathology according to standard operating procedures 
and will be archived accordingly. Data generated by this study may in future 
be published in scientific and/or medical journals but it will not be possible for 
you as a patient to be identified as a result as all relevant information will 
have been removed prior to publication. 
Where can I get further information? 
If you have any further questions about the study or if you want to opt out of 
the study, you can rest assured it won't affect the quality of treatment you get 
in the future.   
If you need any further information now or at any time in the future, please 
contact:  
Name: Niall Savage 
  
Address: Tyndall National Institute, University College Cork, Cork, Ireland. 
  
Phone No: 021 4205607 
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6.2 Patient Consent Form 
PATIENT CONSENT FORM: 
Clinical Research Ethics Committee of the Cork Teaching Hospitals 
(Version 1.4; 09 Mar. 15) 
 
 
CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH PROTOCOL 
Section A 
Patient Name: ____________ MRN:  ______________ DOB: ____/______/____ 
 
Title of Protocol: Protocol for Sampling Fresh Breast Cancer Tissue for Research 
Purposes 
 
Doctor(s) Directing Research: Mr. Martin O’Sullivan    
Phone: (C.I. phone no.) +353 21 4920337 
 
You are being asked to participate in a research study.  The doctors at University 
College Cork study the nature of disease and attempt to develop improved methods 
of diagnosis and treatment.  In order to decide whether or not you want to be a part 
of this research study, you should understand enough about its risks and benefits to 
make an informed judgment.  This process is known as informed consent.  This 
consent form and the associated patient information leaflet give detailed information 
about the research study, which will be discussed with you.  Once you understand 
the study, you will be asked to sign this form if you wish to participate. 
 
Section B 
I. NATURE AND DURATION OF PROCEDURE(S): 
 This research study will use cancerous and healthy breast tissue samples 
removed during surgery to allow testing of a prototype medical device which is 
designed to detect breast cancer using an electrical signal known as 
impedance. Each recording takes approximately 30 seconds and multiple 
recordings will been taken throughout a suspected lesion and in the surrounding 
healthy tissue. 
 
II. POTENTIAL RISKS AND BENEFITS: 
 There is no foreseeable risk to you or your treatment as the procedure will only 
be conducted on tissue after its removal and in conjunction with the department 
of pathology to ensure the standard of care remains unaffected.  
 
III. POSSIBLE ALTERNATIVES: 
 You may choose not to participate in this study as the process is voluntary. 
           
 
Section C                                                                                
 AGREEMENT TO CONSENT 
The research project and the treatment procedures associated with it have 
been fully explained to me.  All experimental procedures have been identified and 
no guarantee has been given about the possible results.  I have had the opportunity 
to ask questions concerning any and all aspects of the project and any procedures 
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involved.  I am aware that participation is voluntary and that I may withdraw my 
consent at any time.  I am aware that my decision not to participate or to withdraw 
will not restrict my access to health care services normally available to me.  
Confidentiality of records concerning my involvement in this project will be 
maintained in an appropriate manner.  When required by law, the records of this 
research may be reviewed by government agencies and sponsors of the research. 
 I understand that the sponsors and investigators have such insurance as is 
required by law in the event of injury resulting from this research. 
 I, the undersigned, hereby consent to participate as a subject in the above 
described project conducted at the Cork Teaching Hospitals.  I have received a 
copy of this consent form for my records.  I understand that if I have any questions 
concerning this research, I can contact the doctor(s) listed above.  If I have further 
queries concerning my rights in connection with the research, I can contact the 
Clinical Research Ethics Committee of the Cork Teaching Hospitals, Lancaster Hall, 
6 Little Hanover Street, Cork. 
 After reading the entire consent form, if you have no further questions about 
giving consent, please sign where indicated. 
 
 
                                                 
Doctor 
 
 
     
Signature of Patient  
 
 
     
Parent or Guardian (If applicable) 
 
 
                                              
Witness     
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6.3 Summary of C.V. for Chief Investigator 
CV Summary Mr Martin O’Sullivan, Consultant Surgeon 
 
Name:    Martin James O’Sullivan 
Date of birth:   19th July 1971 
Nationality:    Irish 
Marital status:   Married 
Work address:   Department of Surgery, 
     Lead Surgeon, 
Cork University Hospital, BreastCheck, 
Wilton,   Infirmary Road, 
Cork    Cork 
Contact address:   See above 
Telephone:    +353 21 4920337  (work) 
     +353 86 8130283  (mobile) 
E-mail address:   martin.osullivan1@hse.ie 
Qualifications:   M.B., B.Ch., B.A.O.     
     F.R.C.S.I.      
     M.A. (Healthcare Administration) 
M.D.     
Irish Medical Council Number:  19307 
Curriculum vitae summary 
Clinical experience 
Consultant (Lead) Surgeon with BreastCheck South since 2007 
Completed the Irish Higher Surgical Training Scheme in General Surgery 
including Fellowship in USA 
Trained in Oncoplastic surgery in USA 
Teaching 
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Extensive experience of undergraduate teaching throughout career 
Experience as examiner and exam organiser of undergraduate examinations 
Senior Lecturer, UCC 
Instructor ALTS courses, 2004 onwards 
Management 
MA (honours) in Healthcare Administration 
Academic record 
Publications 
>26 publications in peer-reviewed journals  
Fifty-five published abstracts 
Presentations 
>100 communications to learned societies / meetings, both national and 
international, including three invited lectures 
Distinctions 
Honours in Surgery, Medicine & Paediatrics (three of the four subjects) in the 
final year medical examinations, 1995 
Poster prize, European Society of Surgery, 4th annual meeting, Poland, 
December 2000 
Inaugural Charles Pannett medal, Society of Academic and Research 
Surgery forum, London, January 2002 
Poster prize, 12th Annual Medical Faculty Research Day, Cork University 
Hospital, June 2004 
6.4 Ethical Approval Application 
Due to the size of the original application it was not possible to attach it as 
part of the thesis. It is available on request. 
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6.5 List of Oral and Poster Presentations 
6.5.1 Conference Proceedings 
1. “Development of a smart needle integrated with a micro-structured 
impedance sensor for the detection of breast cancer”, N.T.P. Savage, B.D. 
O’Donnell, M.J. O’Sullivan, E.J. Moore; World Congress on Medical Physics 
and Biomedical Engineering, June 7-12, 2015, Toronto, Canada.  Volume 
51, July 2015, Pages 1293-1296. 
6.5.2 Oral Presentations 
1. “Micro-structured Electrodes for the in vitro detection of Impedance in 
cancer cell lines”, Niall T.P. Savage; Brian D. O’Donnell; Martin J. 
O’Sullivan; Eric J. Moore; Molecular Medicine Ireland (MMI) Annual Scientific 
Meeting, 12th March 2014. 
2. “Development of a smart needle integrated with a micro-structured 
impedance sensor for the detection of breast cancer”, Niall T.P. Savage; 
Brian D. O’Donnell; Martin J. O’Sullivan; Eric J. Moore; World Congress on 
Medical Physics and Biomedical Engineering, 7-12th June 2015. 
3. “Development of a smart needle integrated with a micro-structured 
impedance sensor for the detection of breast cancer”, Niall T.P. Savage; 
Brian D. O’Donnell; Martin J. O’Sullivan; Eric J. Moore; Chemistry 
Postgraduate Research Day, 21st August 2015 
4. “Development of a smart micro-structured impedance probe for the 
detection of breast cancer”, Niall T.P. Savage; Michelle Fitzgerald; Walter 
Messina; Brian D. O’Donnell; Martin J. O’Sullivan; Eric J. Moore; European 
Platform on Smart Systems (EPoSS) Conference 2015, 12-13th October 
2015 
6.5.3 Poster Presentations 
1. “Development of a smart needle integrated with nanostructured 
impedance sensor for detection of breast cancer”, Savage N.T.P; O’Donnell 
B.D; O’Sullivan M; Moore E.J; Molecular Medicine Ireland (MMI) Annual 
Scientific Meeting, 14th March 2013. 
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2. “Impedance Detection of breast cancer and ductal carcinoma in situ”, 
Savage N.T.P; O’Donnell B.D; O’Sullivan M; Moore E.J; Tyndall National 
Institute Internal Conference, 25th April 2013, 
3. “Breast cancer and ductal carcinoma in situ identification using a dual-
electrode system”, Savage N.T.P; O’Donnell B.D; O’Sullivan M; Moore E.J; 
Royal Academy of Medicine in Ireland (RAMI) Conference, 20th June 2013. 
4. “Breast cancer and ductal carcinoma in situ identification in cell culture 
models and ex vivo human tissue samples” Savage N.T.P; O’Donnell B.D; 
O’Sullivan M; Moore E.J; College of Medicine and Health (CoMH) 
Conference, 13th June 2013. 
5. “Novel detection of breast cancer and ductal carcinoma in situ”, Savage 
N.T.P; O’Donnell B.D; O’Sullivan M; Moore E.J; Conference on Analytical 
Science, Ireland (CASi) Conference, 1st and 2nd July 2013. 
6. “Impedance detection of breast cancer and ductal carcinoma in situ”, Niall 
T.P. Savage; Brian D. O’Donnell; Martin J. O’Sullivan; Eric J. Moore; Tyndall 
National Institute ICT For Health Conference, 16th September 2013.  
7. “Micro-structured Impedance Electrodes for the Detection of Breast 
Cancer and Ductal Carcinoma in situ”, Niall T.P. Savage; Brian D. 
O’Donnell; Martin J. O’Sullivan; Eric J. Moore; Micro-Nano-Bio 
Systems/European Platform on Smart Systems (MNBS/EpoSS) Conference, 
23rd-25th September 2013. Winner of Best Poster Award. 
8. “Micro-structured Impedance Electrodes for the Detection of Breast 
Cancer and Ductal Carcinoma in situ”, Niall T.P. Savage; Brian D. 
O’Donnell; Martin J. O’Sullivan; Eric J. Moore; Smart Systems Integration 
(SSI) Conference, 26-27 March 2014.  
9. “Development of a micro-structured electrode for the detection of breast 
cancer”, Niall Savage; Brian O’Donnell; Martin O’Sullivan; Eric Moore; 
Department of Chemistry Postgraduate Research Day, UCC, 28th August 
2014. 
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10. “Development of a smart needle integrated with a micro-structured 
impedance sensor for detection of breast cancer”, Niall T.P. Savage; Brian 
D. O’Donnell; Martin J. O’Sullivan; Eric J. Moore; Molecular Medicine Ireland 
(MMI) Annual Scientific Meeting, 24th March 2015. 
11. “Gold Micro-Electrodes for the Detection of Breast Cancer in situ”, Niall 
T.P. Savage; Brian D. O’Donnell; Martin J. O’Sullivan; Eric J. Moore; Evolve 
Biomed Conference, 29-30th April 2015. 
12. “Impedance Sensors for Biomedical and Bioassay Applications”, Lisa 
Helen, Walter Messina, Niall Savage, Michelle Fitzgerald, George Shorten, 
Bill Bennett, Martin O’Sullivan, Brian O’Donnell and Eric Moore; NanoMA 
2015, 15-16th July 2015, Tsukuba, Japan. 
13. “Impedance Sensors for biomedical & bioassay applications”, Niall T.P. 
Savage, Walter Messina, Michelle Fitzgerald, Lisa Helen, George Shorten, 
Michael W. Bennett, Martin J. O’Sullivan, Brian D. O’Donnell and Eric J. 
Moore; Micro-Nano-Bio Systems/European Platform on Smart Systems 
(MNBS/EPoSS) Conference, 12th-15th October 2015. 
6.5.4 Demonstrations 
1. “Impedance Sensors for Biomedical & Bioassay Applications”, Niall 
Savage; Michael Bennett; Martin O’Sullivan; Brian O’Donnell; Eric Moore; 
Tyndall National Institute Internal Conference, 7th-8th May 2014. 
2. “Impedance Sensors for Biomedical & Bioassay Applications”, Niall 
Savage; Walter Messina; Michelle Fitzgerald; Lisa Helen; George Shorten; 
Michael Bennett; Martin O’Sullivan; Brian O’Donnell; Eric Moore; Tyndall 
National Institute-Teagasc MOU Signing Event, 3rd Oct 2014. 
3. “Smart Probe”, Niall Savage; Tyndall Technology Days, 18-20th Nov 
2014.  
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6.6 Clinical Trial Images 
6.6.1 Macroscopic Images 
Study Participant 05 - Wide-local Excision – 26mm Metastatic Squamous 
Cell Carcinoma 
 
Study Participant 10 – Mastectomy – 95 mm Invasive Ductal Carcinoma 
Grade 3 
 
Study Participant 11 – Wide-local Excision – 25 mm Invasive Ductal 
Carcinoma Grade 3 
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Study Participant 12 – Mastectomy – 18 mm Invasive Ductal Carcinoma 
Grade 3 
 
Study Participant 17 – Wide-local Excision – 21 mm Mixed Invasive Ductal 
and Lobular Carcinoma Grade 2  
 
Study Participant 18 – Mastectomy – 27 mm Invasive Ductal Carcinoma 
Grade 2 
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Study Participant 19 – Diagnostic Excision Biopsy – 25 mm Fibroadenoma 
 
Study Participant 20 – Wide-local Excision – 34 mm Invasive Mucinous 
Carcinoma Grade 2 
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6.6.2 Microscopic Images 
Study Participant 02 
Gross Pathology:  
Invasive Ductal Carcinoma Grade 2 
Histologic Slide Analysis:  
A) Normal Breast  
B) Invasive Ductal Carcinoma Grade 2 
 
Study Participant 03 
Gross Pathology:  
Invasive Lobular Carcinoma Grade 2 
Histologic Slide Analysis: 
A) Invasive Lobular Carcinoma Grade 2 Area 1  
B) Invasive Lobular Carcinoma Grade 2 Area 2 (x4)  
C) Invasive Lobular Carcinoma Grade 2 Area 2 (x10)  
D) Invasive Lobular Carcinoma Grade 2 Area 3 
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Study Participant 05 
Gross Pathology: 
Metastatic Squamous Cell Carcinoma 
Histologic Slide Analysis: 
A) Normal Breast  
B) Metastatic Squamous Cell Carcinoma 
 
Study Participant 07 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast 01 
B) Normal Breast 02 
C) Invasive Ductal Carcinoma Grade 3 
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Study Participant 08 
Gross Pathology: 
Fibroadenoma 
Histologic Slide Analysis: 
A) Normal Breast  
B) Fibroadenoma 
 
Study Participant 09  
Gross Pathology: 
Invasive Ductal Carcinoma Grade 2 
Histologic Slide Analysis: 
A) Normal Breast  
B) Invasive Ductal Carcinoma Grade 2 
 
Study Participant 10 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast  
B) Invasive Ductal Carcinoma Grade 3 
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Study Participant 11 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast  
B) Invasive Ductal Carcinoma Grade 3 
 
Study Participant 12 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast  
B) Invasive Ductal Carcinoma Grade 3 
 
Study Participant 13 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast  
B) Invasive Ductal Carcinoma Grade 3 
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Study Participant 14 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast  
B) Invasive Ductal Carcinoma Grade 3 
 
Study Participant 15 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast (x4)  
B) Normal Breast (x10) 
C) Invasive Ductal Carcinoma Grade 3 (x4) 
D) Invasive Ductal Carcinoma Grade 3 (x10) 
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Study Participant 17 
Gross Pathology: 
Mixed Invasive Ductal and Lobular Carcinoma Grade 2 
Histologic Slide Analysis: 
A) Normal Breast  
B) Mixed Invasive Ductal and Lobular Carcinoma Grade 2 
 
Study Participant 18 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 2 
Histologic Slide Analysis: 
A) Normal Breast 
B) Invasive Ductal Carcinoma Grade 2 
 
Study Participant 19 
Gross Pathology: 
Atypical Lobular Hyperplasia in Fibroadenoma 
Histologic Slide Analysis: 
A) Normal Breast 
B) Atypical Lobular Hyperplasia in Fibroadenoma 
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Study Participant 20 
Gross Pathology: 
Invasive Mucinous Carcinoma Grade 2 
Histologic Slide Analysis: 
A) Normal Breast 
B) Invasive Ductal Carcinoma Grade 2  
C) Invasive Ductal Carcinoma Grade 2 Area 2 
 
Study Participant 26 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast 
B) Invasive Ductal Carcinoma Grade 3 
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Study Participant 27 
Gross Pathology: 
Mixed Invasive Ductal and Lobular Carcinoma Grade 2 
Histologic Slide Analysis: 
A) Normal Breast  
B) Mixed Invasive Ductal and Lobular Carcinoma Grade 2 
 
 
Study Participant 28 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast 
B) Invasive Ductal Carcinoma Grade 3 
 
 
Study Participant 30 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast 
B) Invasive Ductal Carcinoma Grade 3 
 
 
  
Appendices  Chapter 6 
237 
 
Study Participant 31 
Gross Pathology: 
Mixed Invasive Ductal and Lobular Carcinoma Grade 2 
Histologic Slide Analysis: 
A) Normal Breast  
B) Mixed Invasive Ductal and Lobular Carcinoma Grade 2 
 
 
Study Participant 32 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 3 
Histologic Slide Analysis: 
A) Normal Breast 
B) Invasive Ductal Carcinoma Grade 3 
 
 
Study Participant 33 
Gross Pathology: 
Invasive Ductal Carcinoma Grade 2 
Histologic Slide Analysis: 
A) Normal Breast 
B) Invasive Ductal Carcinoma Grade 2 
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6.7 Dimensions of Cell Culture Holders 
 
Holder Section Dimension Size (mm) 
Top of Holder 
Width 30 
Depth 30 
Height 12 
Media Well 
Diameter 15 
Depth 10 
Bottom Well Opening Diameter 2 
O-ring Recess 
Diameter 5 
Depth 2 
Bottom of Holder 
Width 30 
Depth 30 
Height 12 
Probe Recess 
Width 3 
Depth 16 
Height 0.5 
Screw Holes Diameter 4 
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6.8 Paired-samples T test Outputs 
6.8.1 Beef, Lamb and Pork 
 
 Paired Differences 
t df Sig. (2-tailed) 
Tissue Type Mean S.D S.E.M 
95% C.I 
Lower Upper 
All Tissues 41653 18594 3578 34298 49009 11.640 26 0.000000000008 
Beef 35607 16189 5396 23163 48051 6.598 8 0.000170 
Lamb 58816 9933 3311 51180 66452 17,762 8 0.00000001 
Pork 30537 15854 5284 18350 42724 5,778 8 0.000415 
 
6.8.2 Clinical Trial Samples 
 
Paired Differences 
t df Sig. (2-tailed) 
Lesion Type Mean S.D S.E.M 
95% C.I 
Lower Upper 
All Samples 4340 4122 859 2557 6122 5.049 22 0.000047 
All Cancer 4187 4290 936 2234 6139 4.470 20 0.000233 
Primary Breast 3845 4098 916 1927 5763 4.196 19 0.000490 
All IDC 3661 3748 967 1585 5737 3.783 14 0.002311 
IDC G3 5111 4615 1391 2010 8212 3.673 10 0.004294 
IDC G2 1329 651 325 293 2365 4.083 3 0.026547 
Mixed IDC/ILC G2 2278 3985 2301 -7622 12179 .990 2 0.426417 
Fibroadenoma 5947 383 271 2497 9397 21.906 1 0.029041 
 
